
<html lang="en"     class="pb-page"  data-request-id="396a18c6-740c-44f7-875a-133af6733d35"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-18;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm300967g;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Creator" content="Michele  McTigue" /></meta><meta name="dc.Creator" content="Mitchell  Nambu" /></meta><meta name="dc.Creator" content="Michelle  Tran-Dubé" /></meta><meta name="dc.Creator" content="Mason  Pairish" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Lei  Jia" /></meta><meta name="dc.Creator" content="Hengmiao  Cheng" /></meta><meta name="dc.Creator" content="Jacqui  Hoffman" /></meta><meta name="dc.Creator" content="Phuong  Le" /></meta><meta name="dc.Creator" content="Mehran  Jalaie" /></meta><meta name="dc.Creator" content="Gilles H.  Goetz" /></meta><meta name="dc.Creator" content="Kevin  Ryan" /></meta><meta name="dc.Creator" content="Neil  Grodsky" /></meta><meta name="dc.Creator" content="Ya-li  Deng" /></meta><meta name="dc.Creator" content="Max  Parker" /></meta><meta name="dc.Creator" content="Sergei  Timofeevski" /></meta><meta name="dc.Creator" content="Brion W.  Murray" /></meta><meta name="dc.Creator" content="Shinji  Yamazaki" /></meta><meta name="dc.Creator" content="Shirley  Aguirre" /></meta><meta name="dc.Creator" content="Qiuhua  Li" /></meta><meta name="dc.Creator" content="Helen  Zou" /></meta><meta name="dc.Creator" content="James  Christensen" /></meta><meta name="dc.Description" content="The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-ME..." /></meta><meta name="Description" content="The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-ME..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 10, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300967g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300967g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300967g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300967g" /></link>
        
    
    

<title>Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300967g" /></meta><meta property="og:title" content="Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0013.jpeg" /></meta><meta property="og:description" content="The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-MET HTS campaign and subsequently demonstrated to have an unusual degree of selectivity against a broad array of other kinases. The cocrystal structure of the related oxindole hydrazide c-MET inhibitor 10 with a nonphosphorylated c-MET kinase domain revealed a unique binding mode associated with the exquisite selectivity profile. The chemically labile oxindole hydrazide scaffold was replaced with a chemically and metabolically stable triazolopyrazine scaffold using structure based drug design. Medicinal chemistry lead optimization produced 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (2, PF-04217903), an extremely potent and exquisitely selective c-MET inhibitor. 2 demonstrated effective tumor growth inhibition in c-MET dependent tumor models with good oral PK properties and an acceptable safety profile in preclinical studies. 2 progressed to clinical evaluation in a Phase I oncology setting." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300967g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300967g">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300967g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300967g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300967g&amp;href=/doi/10.1021/jm300967g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8091-8109</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300965a" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301024w" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/jm3014647"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++McTigue">Michele McTigue</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mitchell++Nambu">Mitchell Nambu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Tran-Dub%C3%A9">Michelle Tran-Dubé</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mason++Pairish">Mason Pairish</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Jia">Lei Jia</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hengmiao++Cheng">Hengmiao Cheng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacqui++Hoffman">Jacqui Hoffman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phuong++Le">Phuong Le</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mehran++Jalaie">Mehran Jalaie</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gilles+H.++Goetz">Gilles H. Goetz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Ryan">Kevin Ryan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Grodsky">Neil Grodsky</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-li++Deng">Ya-li Deng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Max++Parker">Max Parker</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sergei++Timofeevski">Sergei Timofeevski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brion+W.++Murray">Brion W. Murray</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shinji++Yamazaki">Shinji Yamazaki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shirley++Aguirre">Shirley Aguirre</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiuhua++Li">Qiuhua Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Zou">Helen Zou</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Christensen">James Christensen</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-638-6333. Fax: 877-481-1783. E-mail: <a href="/cdn-cgi/l/email-protection#acc6c9cdc282cfd9c5ecdccac5d6c9de82cfc3c1"><span class="__cf_email__" data-cfemail="ea808f8b84c4899f83aa9a8c83908f98c4898587">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300967g&amp;href=/doi/10.1021%2Fjm300967g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8091–8109</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 27, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 July 2012</li><li><span class="item_label"><b>Published</b> online</span>10 September 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 September 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300967g" title="DOI URL">https://doi.org/10.1021/jm300967g</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8091%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJ.%2BJean%2BCui%252C%2BMichele%2BMcTigue%252C%2BMitchell%2BNambu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D18%26contentID%3Djm300967g%26title%3DDiscovery%2Bof%2Ba%2BNovel%2BClass%2Bof%2BExquisitely%2BSelective%2BMesenchymal-Epithelial%2BTransition%2BFactor%2B%2528c-MET%2529%2BProtein%2BKinase%2BInhibitors%2Band%2BIdentification%2Bof%2Bthe%2BClinical%2BCandidate%2B2-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2B%2528PF-04217903%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8109%26publicationDate%3DSeptember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300967g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4291</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">67</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300967g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;McTigue&quot;},{&quot;first_name&quot;:&quot;Mitchell&quot;,&quot;last_name&quot;:&quot;Nambu&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Tran-Dubé&quot;},{&quot;first_name&quot;:&quot;Mason&quot;,&quot;last_name&quot;:&quot;Pairish&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Jia&quot;},{&quot;first_name&quot;:&quot;Hengmiao&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Jacqui&quot;,&quot;last_name&quot;:&quot;Hoffman&quot;},{&quot;first_name&quot;:&quot;Phuong&quot;,&quot;last_name&quot;:&quot;Le&quot;},{&quot;first_name&quot;:&quot;Mehran&quot;,&quot;last_name&quot;:&quot;Jalaie&quot;},{&quot;first_name&quot;:&quot;Gilles&quot;,&quot;last_name&quot;:&quot;H. Goetz&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Ryan&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Grodsky&quot;},{&quot;first_name&quot;:&quot;Ya-li&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Max&quot;,&quot;last_name&quot;:&quot;Parker&quot;},{&quot;first_name&quot;:&quot;Sergei&quot;,&quot;last_name&quot;:&quot;Timofeevski&quot;},{&quot;first_name&quot;:&quot;Brion&quot;,&quot;last_name&quot;:&quot;W. Murray&quot;},{&quot;first_name&quot;:&quot;Shinji&quot;,&quot;last_name&quot;:&quot;Yamazaki&quot;},{&quot;first_name&quot;:&quot;Shirley&quot;,&quot;last_name&quot;:&quot;Aguirre&quot;},{&quot;first_name&quot;:&quot;Qiuhua&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Christensen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;8091-8109&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300967g&quot;},&quot;abstract&quot;:&quot;The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-MET HTS campaign and subsequently demonstrated to have an unusual degree of selectivity against a broad array of other kinases. The cocrystal structure of the related oxindole hydrazide c-MET inhibitor 10 with a nonphosphorylated c-MET kinase domain revealed a unique binding mode associated with the exquisite selectivity profile. The chemically labile oxindole hydrazide scaffold was replaced with a chemically and metabolically stable triazolopyrazine scaffold using structure based drug design. Medicinal chemistry lead optimization produced 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (2, PF-04217903), an extremely potent and exquisitely selective c-MET inhibitor. 2 demonstrated effective tumor growth inhibition in c-MET dependent tumor models with good oral PK properties&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300967g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300967g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300967g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300967g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300967g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300967g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300967g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300967g&amp;href=/doi/10.1021/jm300967g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300967g" /></input><a href="/doi/pdf/10.1021/jm300967g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26pmid%3D22924734%26genre%3Darticle%26aulast%3DCui%26date%3D2012%26atitle%3DDiscovery%2Bof%2Ba%2BNovel%2BClass%2Bof%2BExquisitely%2BSelective%2BMesenchymal-Epithelial%2BTransition%2BFactor%2B%2528c-MET%2529%2BProtein%2BKinase%2BInhibitors%2Band%2BIdentification%2Bof%2Bthe%2BClinical%2BCandidate%2B2-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2B%2528PF-04217903%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D18%26spage%3D8091%26epage%3D8109%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291567" title="Oxindoles">Oxindoles</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jmcmar.2012.55.issue-18/production/jmcmar.2012.55.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit <b>6</b> was identified during a c-MET HTS campaign and subsequently demonstrated to have an unusual degree of selectivity against a broad array of other kinases. The cocrystal structure of the related oxindole hydrazide c-MET inhibitor <b>10</b> with a nonphosphorylated c-MET kinase domain revealed a unique binding mode associated with the exquisite selectivity profile. The chemically labile oxindole hydrazide scaffold was replaced with a chemically and metabolically stable triazolopyrazine scaffold using structure based drug design. Medicinal chemistry lead optimization produced 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (<b>2</b>, <b>PF-04217903</b>), an extremely potent and exquisitely selective c-MET inhibitor. <b>2</b> demonstrated effective tumor growth inhibition in c-MET dependent tumor models with good oral PK properties and an acceptable safety profile in preclinical studies. <b>2</b> progressed to clinical evaluation in a Phase I oncology setting.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">c-MET, also called hepatocyte growth factor receptor (HGFR), belongs to a structurally unique subfamily of receptor tyrosine kinase (RTK), along with RON protein kinase. The natural ligand for c-MET is hepatocyte growth factor (HGF), also known as scatter factor. The c-MET/HGF signaling pathway plays important roles during normal development, organogenesis, and homeostasis. After activation by HGF, c-MET induces an invasive program consisting of cell proliferation, migration, invasion, and survival that is essential during normal processes, such as morphogenesis and wound healing.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Aberrant c-MET/HGF signaling through constitutive activation, gene amplification, mutations, and activation of an autocrine loop occurs in virtually all types of solid tumors, and as such is implicated in multiple tumor oncogenic processes, such as mitogenesis, survival, angiogenesis, and invasive growth, and especially in the metastatic process.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Furthermore, overexpression of c-MET and HGF was demonstrated to correlate with poor prognosis or metastatic progression in a number of major human cancers.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> For these reasons, c-MET and its ligand HGF are emerging as attractive targets for targeted cancer therapies.</div><div class="NLM_p">The strategies to regulate the c-MET/HGF pathway include HGF antagonists (NK2 and NK4),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> anti-HGF antibodies,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> anti-c-MET monoclonal antibodies,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and c-MET small molecule inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The anti-HGF antibody AMG 102 (rilotumumab), when combined with the anti-EGFR antibody panitumumab, showed a higher overall response rate for colorectal cancer patients than patients treated with panitumumab plus placebo in a randomized phase II study.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> A durable, complete response of metastatic gastric cancer with high c-MET gene polysomy and evidence for an autocrine production of hepatocyte growth factor was achieved with c-MET monoclonal antibody MetMab.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Overexpression of c-MET in non-small-cell lung cancer (NSCLC) represents more than half of the population and is associated with a worse outcome. MetMab, in combination with erlotinib, significantly improved PFS and OS, resulting in a near 3-fold reduction in the risk of death.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The first crystal structures of c-MET were published in 2002<a onclick="showRef(event, 'cit11a'); return false;" href="javascript:void(0);" class="ref cit11a">(11a)</a> and 2003,<a onclick="showRef(event, 'cit11b'); return false;" href="javascript:void(0);" class="ref cit11b">(11b)</a> which facilitate small molecule c-MET inhibitor development. Several classes of small molecule c-MET inhibitors with different binding modes and selectivity profiles progressed to clinical trials (Chart<a class="ref internalNav" href="#cht1" aria-label="1">1</a>). Foretinib, a type II inhibitor bound into the deep hydrophobic back pocket, is a multitargeted c-MET/VEGFR2 inhibitor<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and demonstrated partial regression or stable disease in patients with papillary renal carcinoma<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and poorly differentiated gastric cancer.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> MK-2461 (<b>1</b>) is a potent c-MET inhibitor that is selective for the inhibition of the phosphorylated c-MET enzyme.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>1</b> is currently in phase I/II clinic trials for cancer treatments. Crizotinib is a potent c-MET/ALK dual inhibitor<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which demonstrated marked efficacy for a subset of NSCLC patients with an EML4-ALK fusion gene, leading to a fast track FDA approval.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, crizotinib demonstrated a rapid and durable response for a NSCLC patient with <i>de novo</i><i>MET</i> amplification, but without ALK rearrangement.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Patients with <i>MET</i>-amplified esophagogastric adenocarcinoma and glioblastoma achieved dramatic clinical improvement and radiographic regression upon treatment with crizotinib.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> Tivantinib (ARQ-197) is reported as a non-ATP-competitive small molecule c-MET inhibitor;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> albeit, it is bound at the ATP binding site. When given with the EGFR inhibitor erlotinib in patients with NSCLC who have had prior chemotherapy but are EGFR TKI naïve, tivantinib may prolong PFS, extend OS, and delay metastases compared with treatment with erlotinib alone.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Strong interest in targets that inhibit the HGF/c-MET pathway is fueled by the continually emerging evidence of clinical benefit in a variety of cancers.</div><div class="NLM_p">2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (<b>2</b>, <b>PF-04217903</b>) is a potent and exquisitely selective ATP competitive c-MET inhibitor.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>2</b> demonstrated low nanomolar potency against c-MET in both <i>in vitro</i> cell assays and <i>in vivo</i> target modulation studies, and it showed effective tumor growth inhibition with good oral PK properties. <b>2</b> progressed to human clinical studies for oncology. Herein, we report the discovery of a unique c-MET autoinhibitory conformation and the medicinal chemistry effort which led to the discovery of the potent and exquisitely selective c-MET inhibitor <b>2</b>.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative c-MET Inhibitors in Clinical Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structural Elucidation of an HTS Hit</h3><div class="NLM_p">High throughput screening (HTS) is a powerful method for the identification of novel chemical series for a new target. The screening results for novel and efficient hits are highly dependent on the quality and diversification of the compound collection. Hundreds of thousands of compounds with diversified structural features were screened using an enzymatic assay that assessed c-MET inhibition. Compound <b>3</b> from the HTS campaign was an attractive hit with a <i>K</i><sub>i</sub> of 101 nM as an ATP competitive c-MET inhibitor. The structure of <b>3</b> was drawn according to the original compound database record (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>). As a standard procedure for an HTS triage, attractive hits were subjected to analytical tests including LC-MS and NMR spectroscopy methods to confirm the compound identity. The active samples were also subjected to a process referred to as LC-MS-BA (liquid chromatography–mass spectrometry–bioassay), which simultaneously allowed for the assessments of sample purity and structure confirmation through generation of UV and mass spectra. The fraction from the chromatographic step in this process was collected for bioassay, and the comparisons between the chromatographic and bioassay profiles were made to determine whether the activity corresponded to the desired chromatographic peak. Using the LC-MS-BA method, it was discovered that the molecular weight of the active component of <b>3</b> (>90%) was 309.32, which was consistent with the structure of <b>4</b>. <sup>1</sup>H NMR of the active component indicated the absence of the azepan-1-ylmethylene group, which further supported the proposal of the structure of <b>4</b>. A small molecule X-ray structure revealed that the real structure of <b>3</b> was actually the structure of <b>5</b>, a starting material used for the preparation of compound <b>3</b> with the same molecular formula and weight. As a result, the real structure of the active component was deduced to be the structure of <b>6</b>. <b>6</b> was synthesized and confirmed to have the same <sup>1</sup>H NMR and biological activity against c-MET as the active ingredient from the HTS. Thus, the highly efficient c-MET hit of <b>6</b> was successfully identified through careful structural elucidation of an HTS hit.</div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Structural Elucidation of an HTS Hit</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Discovery of an Exquisitely Selective c-MET Binding Mode</h3><div class="NLM_p"><b>6</b> is an attractive hit with high biochemical ligand efficiency (LE = −<i>RT </i>log <i>K</i><sub>i</sub>/the number of heavy atoms = 0.42) and lipophilic efficiency (lipE = −log <i>K</i><sub>i</sub> – cLogD = 4.80) against c-MET. In addition, <b>6</b> was highly selective for c-MET, showing an IC<sub>50</sub> of >20 μM against a panel of other tyrosine and serine/threonine kinases (VEGFR2, EGFR, SRC, DDR, PDGFR, ZC1, PAK4, LCK, and LYN). Although the chemical instability of the hydrazide linkage has a potential safety liability associated with a possible release of the toxic hydrazine, the intriguing selectivity profile prompted further exploration of this hit. Oxindole-based chemical scaffolds have been broadly used as protein kinase inhibitors, with the oxindole generally making hydrogen bonds to the backbone of the kinase hinge segment in the active site of the kinase catalytic domain. Examples include sunitinib (<b>7</b>), a potent split kinase inhibitor,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and 3-hydrazono-1,3-dihydro-indol-2-one <b>8</b> as CDK2 inhibitor<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (Chart<a class="ref internalNav" href="#cht3" aria-label="3">3</a>). Based on the cocrystal structure of <b>8</b> with CDK2 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a), it was rationalized that <b>6</b> should bind to c-MET with the oxindole hydrogen bonding to the kinase hinge, as occurs for most studied oxindole kinase inhibitors, and with the hydrazide extending out to the protein solvent area (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b).</div><figure id="cht3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Structures of Oxindole-Based Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0004.jpeg" id="GRAPHIC-d1592e596-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Compound <b>8</b> bound in CDK2 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FVT">1FVT</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (b) Overlay of <b>8</b> with the proposed binding orientation of <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Even though <b>7</b> is a potent inhibitor against split kinases including VEGFRs, PDGFR, and c-KIT, it is a relatively weak inhibitor against c-MET with an enzymatic IC<sub>50</sub> of 5 μM. A dramatic increase in c-MET inhibitory potency was achieved with the introduction of a 5-benzylsulfonyl group on the 3-[1-(1<i>H</i>-pyrrol-2-yl)meth-(<i>Z</i>)-ylidene]-1,3-dihydroindol-2-one scaffold, as illustrated with PHA-665752 (<b>9</b>), a potent and selective c-MET inhibitor with a <i>K</i><sub>i</sub> of 9 nM.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The cocrystal structure of <b>9</b> with c-MET revealed a strong interaction of the 2,6-dichlorophenyl group with Tyr-1230,<a onclick="showRef(event, 'ref16 ref27'); return false;" href="javascript:void(0);" class="ref ref16 ref27">(16, 27)</a> which is critical for c-MET inhibition. A structural analysis was used to generate hypotheses for the molecular underpinnings of the inhibitory potency and kinase selectivity of <b>6</b>. The solvent exposure area is not expected to provide a high degree of kinase selectivity due to the flexibility and common structural features in this area. Moreover, the traditional oxindole binding mode would hardly rationalize the high ligand efficiency and selectivity of <b>6</b> against c-MET (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). It was therefore predicated that <b>6</b> have a unique binding mode to c-MET for a profile with high ligand efficiency and selectivity. Chemistry optimization of <b>6</b> was carried out to gain further insight on the potential of the series. Demethylation of <b>6</b> improved potency dramatically, and the optimization of the substituents on the oxindole ring afforded analogs with improved enzymatic and cellular potencies, as illustrated with compound <b>10</b> having an enzymatic <i>K</i><sub>i</sub> of 1.3 nM and an IC<sub>50</sub> of 7 nM for the inhibition of c-MET autophosphorylation in the A549 cell line.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Inhibition of phosphorylated c-MET KD in purified enzyme biochemical assays confirmed that the inhibitors can inhibit the active c-MET, and the cell-based activity of the inhibitors prevented RTK autophosphorylation, consistent with inhibitory interaction with the nonphosphorylated form in cells. The minor divergence between the enzyme and cell activities of <b>10</b> implied the inhibition of both active and unactive c-MET.</div><div class="NLM_p">A kinase domain (KD) construct of c-MET, in its nonphosphorylated form, was prepared for utilization in cocrystallization experiments. Indeed, the cocrystal structure of <b>10</b> with nonphosphorylated c-MET protein demonstrated a unique binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Surprisingly, the oxindole ring is not interacting with the hinge as for <b>8</b> bound with CDK2. Instead, the phenolic moiety of <b>10</b> functions as the hinge binder, with the phenol oxygen bound with the N–H of the hinge Met-1160. Also, a water network links the phenol hydroxyl and Met-1160 carbonyl group. As the molecule makes a turn at the methylene linker, the large coplanar structure of the hydrazide–oxindole allows for strong interactions with the protein backbone. The oxygen of the hydrazide carbonyl group hydrogen bonds with the N–H of Asp-1222, and the N–H of oxindole hydrogen bonds with the carbonyl oxygen of Arg-1208. The intramolecular hydrogen bond between hydrazide and oxindole secures the large coplanar structure and induces strong π–π interaction with Tyr-1230 of the A-loop. The protein crystal structure of nonphosphorylated c-MET with <b>10</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) reveals a similar conformation as the nonphosphorylated c-MET with <b>9</b> (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm">2wkm</a>). A unique β-turn at the beginning of the A-loop is formed, and the c-MET protein adopts an autoinhibitory conformation with the A-loop occupying the binding site for the triphosphate of ATP. This unique c-MET autoinhibitory conformation is consistent with the unphosphorlated apo-c-MET<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and other c-MET–inhibitor cocrystal structures.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Although these c-MET cocrystal structures have the same overall protein fold, the relative position of the A-loop is varied. The A-loop and G-loop (glycine-rich loop) of the c-MET protein in the cocrystal structure of <b>10</b> are closer to the inhibitor, and the binding pocket is smaller at the adenine binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) in comparison with <b>9</b>. With the structural overlay of <b>10</b> with <b>9</b> illustrating the changes (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), <b>10</b> has much reduced molecular weight at the common hinge binding area (phenol group in <b>10</b> vs 3-[1-(1<i>H</i>-pyrrol-2-yl)meth-(<i>Z</i>)-ylidene]-1,3-dihydroindol-2-one) in <b>9</b>; however, it has increased molecular weight at the noncommon area, enabling a stronger interaction with the A-loop and the catalytic loop. Because of the strong interaction with the A-loop and reduced interactions at the common kinase inhibitor binding areas, the chemical series of <b>6</b> represents a unique scaffold for the c-MET target with high ligand efficiency and selectivity.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>10</b> with the nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of c-MET protein structures from cocrystal structures with <b>10</b> (gray) and <b>9</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Replacement of the Chemically Unstable Oxindole Hydrazide Scaffold</h3><div class="NLM_p">Although the oxindole hydrazide series of <b>6</b> is a highly efficient and selective scaffold for c-MET, it was necessary to replace the chemically labile hydrazide linkage with a stable structure. Based on the novel c-MET cocrystal structures with oxindole hydrazide compounds, Vojkovsky et al. fused the hydrazide with oxindole together to form a tetracyclic aromatic scaffold as represented with <b>11</b> (Chart<a class="ref internalNav" href="#cht4" aria-label="4">4</a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The electron deficient tetracyclic fused ring retained the strong π–π stacking interaction with electron rich Tyr-1230 and could form hydrogen bonds with N—H of Asp-1226 and C═O of Arg-1208. As expected, <b>11</b> demonstrated equal potency against c-MET. Although the tetracyclic scaffold solved the chemical stability issue associated with the oxindole hydrazide series, the druggability of the tetracyclic scaffold posed a concern. Zhang et al. chopped the tetracyclic scaffold to the bicyclic triazolotriazine scaffold as represented with <b>12</b> (Chart <a class="ref internalNav" href="#cht4" aria-label="4">4</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Surprisingly, <b>12</b> revealed a better ligand efficiency against c-MET than the tetracyclic scaffold even though with the loss of the hydrogen bond with C═O of Arg-1208. The bicyclic triazolopyrazine scaffold prepared by Cui et al. was slightly less potent than the triazolotriazine scaffold, as demonstrated with compound <b>13</b> (Chart<a class="ref internalNav" href="#cht4" aria-label="4">4</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Efforts in the Replacement of the Chemically Unstable Oxindole Hydrazide Scaffold</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using insight from the cocrystal structure of an oxindole hydrazide compound with c-MET, the chemically unstable oxindole hydrazide scaffold was successfully replaced with chemically stable triazolotriazine and triazolopyrazine scaffolds that maintained ligand efficacy (Chart<a class="ref internalNav" href="#cht4" aria-label="4">4</a>). Kinase selectivity screening of <b>12</b> against a total of 98 protein kinases revealed an exquisite selectivity for c-MET (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> available). The unique binding mode results in unprecedented selectivity; albeit, <b>12</b> is bound at the ATP binding site. The cocrystal structure of <b>12</b> bound with nonphosphorylated c-MET confirmed the same binding mode as <b>10</b>, however, with a significant movement of A-loop toward the inhibitor for a better π–π stacking interaction between electron rich Tyr-1230 and the electron deficient triazolotriazine ring (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). In comparison of the cocrystal structure of <b>12</b> with <b>10</b>, there is a significant change in the relative position of phenols. In the cocrystal structure of <b>10</b> with c-MET, the carbonyl group from hydrazide forms a good hydrogen bond with N–H of Asp-1226, and the carbonyl group of oxindole does not have a direct interaction with the protein backbone; however, the oxindole carbonyl forms an intramolecular hydrogen bond with hydrazide to generate a coplanar structure for a π–π stacking interaction with Tyr-1230. For compound <b>12</b>, it is the N-1 of triazolotriazine that forms a hydrogen bond with Asp-1226 from a different angle compared to that of the carbonyl group of the hydrazide in <b>10</b>, which places the triazolotriazine ring in a better position for the π–π stacking interaction with Tyr-1230, and the phenol group closer to the hinge for a better hydrophobic interaction with Met-1226 and hydrogen bond interaction with the hinge Met-1160 in a slightly different position in comparison with the phenol in <b>10</b>. Without the restriction from the interaction with the C═O of Arg-1208, the 5-phenyl group in <b>12</b> orients in a different angle as compared with the oxindole in <b>10</b>. Thus, the improved ligand efficiency of the triazolotriazine series is likely due to better π–π stacking interaction from electron rich Tyr-1230 with the electron deficient triazolotriazine ring.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of cocrystal structures of <b>10</b> (gray) and <b>12</b> (purple) bound with the nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Replacement of the Hinge Binder Phenol</h3><div class="NLM_p">Phenols are well-known to undergo phase II glucuronidation metabolism. Therefore, the next design was focused on the replacement of the phenol hinge binder to optimize the chemical scaffold into a more druggable chemical series. A variety of aromatic groups with heteroatoms as potential hydrogen bond donors and acceptors for the interaction with hinge amino acid residues were explored (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Although the interaction with the A-loop residue Tyr-1230 is important for overall potency and selectivity, it is necessary to use the hinge binder to anchor the molecule into the binding pocket. When the phenol group was removed, <b>14</b> was not active against c-MET with a <i>K</i><sub>i</sub> > 10 μM. The phenol hydroxyl group in concert with a water molecule formed a hydrogen bond network with hinge residue Met-1160. The replacement of the hydroxyl group with the methoxy group in <b>15</b> interrupted the hydrogen bound network, and the activity dropped more than 10-fold in the c-MET cellular assay. <b>16</b> with a fluoro group dropped more than 300-fold of activity in the c-MET enzymatic assay. <b>17</b> with an ortho-chloro group reduced the potency significantly. <b>18</b> with the <i>N</i>-substituted pyridin-4(1<i>H</i>)-one hinge binder showed a significant reduced potency (6.51 μM), likely because of desolvation penalty from the polar carbonyl group. More exploratory approaches including <b>19</b>–<b>22</b> with an extended two-atom linker were carried out. <b>22</b> demonstrated potent inhibition against c-MET in both enzymatic and cellular assays. <b>23</b> and <b>24</b>, with the conventional protein kinase hinge binders quinoline and azaindole, were potent c-MET inhibitors. In summary, the phenol hinge binder could be replaced by other kinase hinge binders that retained potency against c-MET. Not surprisingly, the cocrystal structure of <b>24</b> with c-MET showed good overlay with the cocrystal structure of <b>12</b> with c-MET (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>24</b> and <b>12</b> with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure Activity Relationship of Phenol Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Human liver microsomal intrinsic clearance (μL/min/mg).</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Human hepatocyte intrinsic clearance (μL/min/million). ND, not determined.</p></div></div><div></div></div><div class="NLM_p">In parallel with the efforts to replace the phenol hinge binder, the ADME properties were optimized. In general, the triazolotriazine chemical series had good caco-2 permeability (data not shown). The metabolic stability in the human microsome varied according to the overall lipophilicity and chemical structures (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a). However, the series demonstrated high clearance in human hepatocyte even at very low lipophilicity (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b). The stable compounds in the human hepatocyte assay have <i>O</i>- or <i>N</i>-substituents at the 7-position of the triazolotriazine core, which indicated that the highly electron deficient triazolotriazine core is subject to non-p450 enzymatic oxidation. From the analyses of cLogD and human metabolic stability (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), it was concluded that there would be no druggable chemistry space for the triazolotriazine chemical series, and the series was deprioritized.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0029.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Human liver microsomal clearance (HLM: CLint., app) vs cLogD; (b) Human hepatocyte clearance (HHEP: CLint., app) vs cLogD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Optimization to the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (<b>2</b>)</h3><div class="NLM_p">Alternatively, the less potent triazolopyrazine series of <b>13</b> was explored for potential acceptable ADME properties. The SAR for the phenol replacement of <b>13</b> was similar with the triazolotriazine series of <b>12</b>, as exemplified with <b>25</b>–<b>27</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The 6-substituted quinoline hinge binder in <b>27</b> provided good potency against c-MET and is about 10-fold less potent in the c-MET cellular autophosphorylation assay than the triazolotriazine analogue <b>23</b>. However, the metabolic stabilities in both human liver microsomes and the hepatocyte cell were improved even though the lipophilicity of <b>27</b> was about 0.71 unit higher than that of <b>23</b>, which implies that the triazolopyrazine scaffold was metabolically more stable than triazolotriazine. To further evaluate the potential of the triazolopyrazine series, the analogues <b>28</b>–<b>32</b> with a 6-pyrazol-4-yl substitute were synthesized and demonstrated improved LipE and metabolic stabilities. <b>28</b> is 57-fold more potent than <b>25</b> (0.051 μM over 2.92 μM) in the c-MET cellular assay even though the biochemical potencies (<i>K</i><sub>i</sub>) are similar. The enzymatic assay used the active, autophosphorylated c-MET protein with biochemical potency (<i>K</i><sub>i</sub>) based on the ability of the inhibitor to prevent the phosphorylation of a substrate. The cocrystal structure of <b>12</b> with nonphosphorylated c-MET revealed an autoinhibitory conformation of the c-MET protein with the activation loop occupying the ATP triphosphate binding site. <b>12</b> stabilized the nonphosphorylated c-MET in an inactive conformation and resulted in the potent inhibition of c-MET autophosphorylation in the cell. The <i>N</i>-methylpyrazol-4-yl group in <b>28</b>–<b>32</b> allows a better coplanar structure with the triazolopyrazine core than the phenyl group in <b>25</b>–<b>27</b>. The large coplanar structure facilitates the π–π stacking interaction with Tyr-1230 in the A-loop and led to improved cellular potency. The <i>N</i>-methylpyrazolyl group lowers the LogD by more than two units and results in a significant improvement of LipE, as exemplified with <b>31</b>, which has a LipE of 8.32 in comparison of 4.61 for the close analogue <b>27</b>. With dramatically lowered lipophilicity, <b>31</b> is metabolically stable in both human microsome and hepatocyte. <b>32</b> with a quinazoline hinge binder was 7-fold less potent than <b>31</b>, as expected with the reduced hydrophobic interaction, reduced hydrogen bond strength, and increased desolvation penalty. In summary, a new druggable chemical series of 6-((1<i>H</i>-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline was successfully identified to replace the 6-((1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline series with good chemical and metabolic stabilities, and c-MET cellular potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure Activity Relationship of the Triazolopyrazine Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0018.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). The A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min mg)).</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Human hepatocyte intrinsic clearance (μL/(min million)). ND, not determined.</p></div></div><div></div></div><div class="NLM_p"><b>31</b> demonstrated good cellular potency against c-MET (IC<sub>50</sub> = 1 nM), high cellular lipE (8.32), and good human microsome stability and permeability. However, the low solubility of <b>31</b> would impact the oral absorption potentially. The cocrystal structure of <b>12</b> with c-MET suggested an open space at the 6-pyrazol-yl binding position between the G-loop and the A-loop with a potential interaction with Asp-1164. A variety of polar groups were introduced on the pyrazole to improve the aqueous solubility (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The unsubstituted pyrazole <b>33</b> showed similar potency as <b>31</b>, however with even lower solubility and worse metabolic stability. <b>2</b> with an ethanolic group showed a comparable potency and ADME properties as <b>31</b>. <b>35</b> with a carboxyl ethyl group had a similar <i>K</i><sub>i</sub>; however, it was less active in the cell because of low permeability. The introduction of the more lipophilic group 1,1-dimethyl-1-hydroxyethyl in <b>36</b> reduced the potency and decreased the metabolic stability. The basic compounds <b>37</b> and <b>38</b> showed much improved solubility with good potency, metabolic stability, and permeability. <b>39</b>, with a 1-ethylpyrrolidin-2-one group, showed reduced potency. <b>40</b> and <b>41</b>, with secondary basic groups, showed good potency and reduced permeability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure Activity Relationship of Substituted 6-Pyrazol-4-yl Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0016.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Kinetic apparent solubility at pH 6.5.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min mg)).</p></div><div class="footnote" id="t3fn6"><sup>Table e</sup><p class="last">Caco-2 permeability (10<sup>–6</sup> cm/s). ND, not determined.</p></div></div><div></div></div><div class="NLM_p">To further define the SAR of the 6-((1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline series, a variety of different substituents, in addition to the aryl and heteroaryl groups at the 6-position of the triazolopyrazine core, were investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The essential core <b>42</b> with R = H showed a c-MET cellular potency of 253 nM with a LipE of 6.27. <b>42</b> has the desired ADME properties (good solubility, metabolic stability, and permeability) for further optimization. <b>43</b> with a lipophilic methyl group improved c-MET cellular potency by 3-fold with a similar LipE value (of 6.30) to that for <b>42</b>. The amino function in <b>44</b> enhanced c-MET cell potency (34 nM), with a much improved LipE of 8.42, and lowered the aqueous solubility to 70.6 μM. <b>45</b>, with a lipophilic ethylamino group, further improved c-MET cell potency (6 nM), however with a lower LipE of 8.06, and had a low solubility of 6.57 μM. <b>46</b>, with the hydroxyethylamino group, showed a reduced permeability. <b>47</b>, with the dimethylaminoethyl amino group, had reduced c-MET cell potency even though the solubility is good. <b>51</b>, with the dimethylaminoethyloxy group, showed similar properties as <b>47</b>, except better permeability. The cyclic amino substituents at the 6-position showed good potency and ADME properties, as demonstrated with <b>48</b>–<b>50</b>. In summary, a variety of substituents at the 6-position of the triazolopyrazine core are tolerated, which provides a good opportunity to optimize potency and pharmaceutical properties.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure Activity Relationship of 6-Substituents on ((1<i>H</i>-[1,2,3]Triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0014.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). The A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-MET.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Kinetic apparent solubility at pH 6.5.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min mg)).</p></div><div class="footnote" id="t4fn6"><sup>Table f</sup><p class="last">Caco-2 permeability (10<sup>–6</sup> cm/s). ND, not determined.</p></div></div><div></div></div><div class="NLM_p">After comprehensive multiparameter lead optimization, a number of compounds were selected for <i>in vivo</i> rat PK studies based on potent inhibition of c-MET at both enzymatic and cellular assays and good <i>in vitro</i> ADME properties (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The basic compounds <b>41</b> and <b>48</b> showed unexpected high <i>in vivo</i> rat plasma clearance. Additional compounds with a basic substituent at the 6-position were studied in <i>in vivo</i> rat PK and showed similar results to those for <b>41</b> and <b>48</b> (data not shown). It was suspected that non-p450 related metabolic mechanisms may be linked with the disconnection between the <i>in vitro</i> clearance prediction from rat microsomal stability and <i>in vivo</i> PK results. <b>31</b>, <b>2</b>, and <b>44</b> showed low to moderate <i>in vivo</i> rat clearance, low volume distribution, and good oral bioavailability. <b>2</b> showed a better half-life and volume distribution profile and was chosen for further evaluations.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vivo</i> Rat Pharmacokinetic Properties</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">p<i>K</i><sub>a</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cLogD<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">eLogD<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>plasma</sub>(mL/(min kg))</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub>(L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i><sub>oral</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">342</td><td class="colsep0 rowsep0" align="char" char=".">4.66</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="left">1.29</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">372</td><td class="colsep0 rowsep0" align="char" char=".">4.66</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="left">1.38</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">411</td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="char" char=".">–1.45</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">81.7</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="left">BQL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">277</td><td class="colsep0 rowsep0" align="char" char=".">4.66</td><td class="colsep0 rowsep0" align="char" char=".">–0.95</td><td class="colsep0 rowsep0" align="left">1.23</td><td class="colsep0 rowsep0" align="char" char=".">26.7</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="left">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="char" char=".">346</td><td class="colsep0 rowsep0" align="char" char=".">8.52</td><td class="colsep0 rowsep0" align="char" char=".">–1.73</td><td class="colsep0 rowsep0" align="left">0.86</td><td class="colsep0 rowsep0" align="char" char=".">83.4</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="left">BQL</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Calculated ionization constant of a molecule using ACD pchbat version 9.3.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Experimentally measured bilayer participating coefficient at pH 7.4. BQL: below quantification level.</p></div></div></div><div class="NLM_p">The cocrystal structure of <b>2</b> with a nonphosphorylated c-MET kinase domain showed a similar binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) to that of the complexes of <b>12</b> and <b>23</b> with c-MET. The A-loop adopts an autoinhibitory conformation and possesses a strong interaction with <b>2</b> via a c-MET characteristic π–π interaction of Tyr-1230 with a triazolopyrazine ring. The quinoline group in <b>2</b> is docked into the hinge through a hydrogen bond with Met-1160 and hydrophobic interactions with Ile-1084, Val-1092, Ala-1108, and Met-1211. N-3 on the triazolopyrazine ring forms a hydrogen bond with the N–H of the DFG Asp-1222 residue. Triazolopyrazine is anchored with Tyr-1230 and Met-1211, and the pyrazole moiety forms a hydrogen bond network with a water molecule which interacts with C═O of Tyr-1230 and N–H of Arg-1086. The hydroxyl group from the ethanolic group on the pyrazole forms hydrogen bonds with Asp-1231 and a water molecule.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0028.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of <b>2</b> with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As expected, <b>2</b> demonstrates an exquisite c-MET kinase selectivity (>1000 selectivity to 208 protein kinases).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Despite having a similar overall protein conformation in the cocrystal structures of <b>2</b> and crizotinib (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj">2wgj</a>) with nonphosphorylated c-MET (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>), crizotinib is less selective, being a c-MET/ALK/ROS/RON inhibitor at the cellular level.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Stronger interactions with A-loop Tyr-1230 and also a hydrogen bond to the amide of Asp-1222 may be the basis for the exquisite kinase selectivity of <b>2</b>. This hypothesis is supported by the dramatic decrease in potency of <b>2</b> against c-MET when Tyr-1230 is mutated. For example, <b>2</b> is almost 1000-fold less active against the c-MET activation loop mutants Y1230C (<i>K</i><sub>i</sub>, 9,400 nM) and Y1235H (<i>K</i><sub>i</sub>, 3,900 nM).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, crizotinib is only 10-fold less potent against Y1230C c-MET.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0027.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Overlay of cocrystal structures of <b>2</b> (gray) and crizotinib (green) with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The different selectivity profiles of <b>2</b> and crizotinib indicate the relatively important roles of the Tyr-1230 interaction with the inhibitors. To further explore the nature and the contributions of the Tyr-1230 interaction with <b>10</b>–<b>13</b> and crizotinib, the corresponding interaction fragments <b>A</b>–<b>E</b> were optimized at the B3LYP/6-31G** level of theory with PBF solvation, and the electronic property calculations were completed on the fragments (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The electron density of only the relevant portion of each fragment was revealed for clarity. All the corresponding bond lengths (distances) and bond angles of optimized geometries were in good agreement. The strength of the π–π stacking interaction of the electron rich Tyr-1230 residue should depend on the electron deficiency of the interacting aromatic system in the kinase inhibitors. Three-dimensional-average local ionization energy (ALIE) superimposed onto a surface of constant electron density (0.01 e/au<sup>3</sup>) showing the most positive potential region (deepest blue color for the most electron deficient area) and the most negative potential region (deepest red color for the most electron rich area). The large conjugated coplanar fragment <b>A</b> in the initial HTS hit chemical series interacted with Tyr-1230 efficiently and served as a basis for comparison. In addition to the π–π stacking interaction with Tyr-1230, fragment <b>A</b> formed two pairs of strong hydrogen bonds with the protein backbone, oxindole N—H with the C═O of Arg-1208 and C═O of hydrazide with the N—H of Asp-1222, as shown in the complex of <b>10</b> with c-MET (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). While fragment <b>B</b> retained similar interactions as fragment <b>A</b> with c-MET protein, fragment <b>C</b> showed more blue color (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), indicating more electron deficiency in the aromatic system for a stronger π–π stacking interaction with Tyr-1230. Indeed, <b>12</b> was equally potent as <b>11</b>, however, with a reduced molecular weight, which led to improved ligand efficiency. The stronger interaction with Tyr-1230 of <b>12</b> compensated the weaker C—H hydrogen bond with C═O of Arg-1208. <b>D</b> had a higher electron density for a weaker π–π stacking interaction as compared with <b>C</b>, which was responsible for a decreased activity of <b>13</b> relative to <b>12</b> against c-MET. The substituted phenyl fragment <b>E</b> in crizotinib showed a significantly different electron potential as compared with fragments <b>A–D</b>. The relatively high electron density in <b>E</b> led to a weaker interaction with Tyr-1230, and crizotinib lost only 10-fold potency against Y1230C mutant c-MET as compared with <b>2</b> (>1000 fold). Crizotinib had additional hydrophobic interactions which were common for other kinases and led to lower selectivity in enzymatic assays. Distinguishing from crizotinib, <b>2</b> mainly benefited from the π–π stacking interaction with Tyr-1230. The unique autoinhibitory conformation of c-MET determined the exquisite selectivity profile of <b>2</b>.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0026.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Electronic property calculations of fragments <b>A</b>–<b>E</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antitumor efficacy (TGI) and relationship with the inhibition of c-MET autophosphorylation of <b>2</b> were evaluated in the c-MET amplified GTL-16 xenograft tumor model (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). Near complete inhibition of c-MET activity for 24 h is consistent with maximal inhibition of tumor growth (30 and 10 mg/kg, 100–90% TGI), and potent inhibition of c-MET activity for only a portion of the schedule is consistent with significant but submaximal efficacy (3 and 1 mg/kg, 74–64% TGI). These results suggest that near-complete inhibition of c-MET autophosphorylation (>90% inhibition) for the duration of the administration schedule is necessary to maximize therapeutic benefit. The antitumor efficacies in other tumor models and the mechanisms of antitumor efficacy are published elsewhere.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(32)</a></div><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0025.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Tumor growth inhibition of <b>2</b> in the GTL-16 xenograft tumor model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>2</b> was a weak base with a p<i>K</i><sub>a</sub> value of 4.6, resulting in a pH dependent aqueous solubility. The solubility of the crystal mesylate salt of <b>2</b> at 25 °C in simulated gastric fluid (SGF, pH 1.2) was >2.0 mg/mL. In sodium phosphate buffer (pH 6.5, 0.05 M), the solubility was significantly lower, at 0.6 μg/mL. <b>2</b> showed high metabolic stability in human liver microsomes, moderate human plasma protein binding (84%), and high permeability in the Caco-2 cell assay. Biotransformation mediated by CYP3A4 was likely to be the major clearance mechanism for <b>2</b>. <b>2</b> was not an inhibitor of CYP1A2, 2C8, 2C19, 2D6, and 3A4 (IC<sub>50</sub> >30 μM) in human liver microsomes; however, it moderately inhibited CYP2C9 (IC<sub>50</sub> ∼ 5 μM). <b>2</b> was well absorbed in animals with a projected fraction absorbed of >90% in humans. The CL<sub>blood</sub> and <i>V</i><sub>ss</sub> values in humans were predicted to be 4–8 mL/(min kg) and 2.2 L/kg, respectively.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(33)</a> The human PK profile was evaluated in phase I clinical studies. After a single oral administration at the dose of 30 mg to healthy volunteers, <b>2</b> was rapidly and extensively absorbed with a mean <i>C</i><sub>max</sub> of 0.24 μg/mL at 1.2 h postdose. Thereafter, <b>2</b> declined multiexponentially, with an apparent mean <i>t</i><sub>1/2</sub> of 6.6 h. The mean area under the plasma concentration–time curve was 0.81 (μg  h)/mL, which corresponded to an oral clearance of 9 mL/(min kg).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(33)</a></div><div class="NLM_p"><b>2</b> was negative in the Biolume Ames assay in the presence or absence of rat liver S9 metabolic activation. In the CHO cell micronucleus assay, <b>2</b> was also negative in the absence and presence of S9. <b>2</b> had a low risk of QT prolongation based on the hERG patch clamp studies (IC<sub>50</sub> > 30 μM). <b>2</b> also displayed an acceptable safety profile in exploratory toxicity studies.</div><div class="NLM_p last">Taken on the whole, <b>2</b> was a potent and highly selective c-MET inhibitor <i>in vitro</i> and <i>in vivo</i>. On the basis of the pharmacologic and pharmacokinetic properties, a good safety margin in preclinical animal studies, and a low risk for clinically relevant drug–drug interaction, <b>2</b> was selected for human clinic studies for cancer patients with abnormal c-MET activation.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><b>12</b> and <b>14</b>–<b>24</b> were prepared according to Scheme <a class="ref internalNav" href="#schI" aria-label="1">1</a>. <b>52a</b>–<b>b</b> were prepared according to the literature procedure<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(34)</a> and were coupled with a carboxylic acid in the presence of the coupling reagents hydroxybenzotriazole (HOBT) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) in <i>N</i>-methylpyrrolidone (NMP) at ambient temperature. After the completion of the coupling reaction, the reaction mixture was microwaved at 170 °C until the formation of the triazolotriazine core was completed.<figure id="schI" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0024.jpeg" id="GRAPHIC-d1592e1966-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HOBT, EDC, NMP, ambient temperature, 1–2 h; (b) microwave at 170 °C, 0.5 h or longer.</p></p></figure></div><div class="NLM_p"><b>13</b> and <b>25</b>–<b>33</b> were prepared according the general three-step procedure in Scheme <a class="ref internalNav" href="#schII" aria-label="2">2</a>. The substituted amine replaced the 3-bromo group of 3,5-dibromopyrazin-2-amine in <i>n</i>-butanol with the presence of diisopropylethylamine (DIPEA) under reflux to provide <i>N</i><sup>2</sup>-substituted 6-bromo-pyrazine-2,3-diamine <b>54</b>. The Sandmeyer reaction using isoamyl nitrite in dimethylformamide (DMF) closed the ring to provided the key intermediate <b>55</b>. <b>13</b> and <b>25</b>–<b>33</b> were obtained with conventional Suzuki coupling conditions.<figure id="schII" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0023.jpeg" id="GRAPHIC-d1592e2017-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-butanol, DIPEA, reflux, 48 h; (b) isoamyl nitrite, DMF, ambient temperature, overnight, 70 °C to the completion; (c) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 3.5 h.</p></p></figure></div><div class="NLM_p">The synthesis of <b>2</b> was summarized in Scheme <a class="ref internalNav" href="#schIII" aria-label="3">3</a>. <b>58</b> was prepared under conventional alkylation conditions with Cs<sub>2</sub>CO<sub>3</sub> as a base in DMF solvent at 70 °C. The boronic ester was introduced via metalation with <i>i</i>-PrMgCl and then quenched with the boronic ester reagent. <b>2</b> was prepared via conventional Suzuki coupling conditions followed by deprotection under hydrogen chloride acidic conditions.<figure id="schIII" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0022.jpeg" id="GRAPHIC-d1592e2075-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schIII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 16 h; (b) <i>i</i>-PrMgCl, THF, 0 °C to RT, 1 h; (c) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 16 h; (d) 4 N HCl/dioxane, CH<sub>2</sub>Cl<sub>2</sub>, RT.</p></p></figure></div><div class="NLM_p">The general alkylation condition was used to introduce various substituted groups on the pyrazole ring of <b>33</b>, as illustrated in Scheme <a class="ref internalNav" href="#schIV" aria-label="4">4</a>.</div><figure id="schIV" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0021.jpeg" id="GRAPHIC-d1592e2129-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schIV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, overnight.</p></p></figure><div class="NLM_p last">The preparation of <b>42</b>–<b>51</b> was summarized in Scheme <a class="ref internalNav" href="#schV" aria-label="5">5</a>. Hydrogenation of <b>55d</b> gave <b>42</b>. The methyl group was introduced from <b>55d</b> under palladium catalyst to provide <b>43</b>. <b>44</b> was prepared with ammonia under microwave thermal conditions. A variety of substituted amino groups were introduced with potassium carbonate as a base under microwave thermal conditions to provide <b>45</b>–<b>50</b>. The alkoxy compound <b>51</b> was prepared with triethylamine as a base under microwave thermal conditions.<figure id="schV" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0020.jpeg" id="GRAPHIC-d1592e2184-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>, Pd/C, MeOH/AcOH/EtOAc, 18 h; (b) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 16 h; (c) concentrated ammonia–water solution, microwave at 100 °C, 1 h; (d) K<sub>2</sub>CO<sub>3</sub>, <i>i</i>-PrOH, microwave at 80 °C, 20 min; (e) Et<sub>3</sub>N, <i>n</i>-BuOH, microwave at 120 °C, 20 min.</p></p></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47336" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47336" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Oxindole hydrazide <b>6</b> with an unusual kinase selectivity profile was a hit in a c-MET receptor tyrosine kinase HTS campaign. The selectivity profile could not be rationalized with the conventional oxindole kinase inhibitor binding mode in which the oxindole bound to the hinge region of the ATP binding site. A cocrystal structure of the related oxindole hydrazide compound <b>10</b> with the nonphosphorylated c-MET kinase domain confirmed a unique binding mode with a phenol group bound to the hinge region and the oxindole hydrazide portion having a strong interaction with the activation loop. Based on insight from the cocrystal structure, a tetracyclic mimic, represented with <b>11</b>, was designed, and it demonstrated increased potency and the same selectivity profile. Further optimization of druglike properties resulted in a triazolotriazine series, as represented with <b>12</b>. The quinoline group was designed to replace the phenol group as a hinge binder, and the triazolopyrazine ring was used to replace the metabolically labile triazolotriazine ring to generate a new chemically and metabolically stable scaffold, as illustrated with compound <b>23</b>. Medicinal chemistry optimization of the triazolopyrazine series led to the discovery of <b>2</b>, which demonstrated potent inhibition of c-MET in both <i>in vitro</i> cell assays and <i>in vivo</i> target modulation studies. In preclinical studies, <b>2</b> had significant tumor growth inhibition, good oral PK properties, and an acceptable safety margin. <b>2</b> is an ATP competitive inhibitor and bound at the adenine binding pocket. However, the kinase selectivity screens against 208 different protein kinases indicated an exquisite selectivity profile associated with <b>2</b>, which could be explained with the unique binding topography of the c-MET kinase domain. <b>2</b> was advanced into phase I clinical studies for oncology indications.</div><div class="NLM_p last">The successes of imatinib for chronic myeloid leukemia patients having BCR-ABL abnormal gene, erlotinib for advanced nonsmall cell lung cancer patients having EGFR mutations, and crizotinib for lung cancer patients having EML4-ALK fusion gene illustrate the importance to identify the disease-driven oncogene for the effective treatment of cancers. However, genetic intratumor heterogeneity presents major challenges to personalized medicine and can lead to tumor adaptation and resistance to treatment.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(35)</a> Frequently, there are more than one abnormal genes associated with a particular cancer. The design of a kinase inhibitor targeting a specific subset of kinases may not be practical because of the diversified kinase structures and intrinsic kinase activities. The combination of drugs targeting specific mechanisms associated with the disease may represent the future of cancer treatment. Highly selective kinase inhibitors should provide good opportunities to combine together for maximum efficacy and minimum toxicity. <b>2</b>, distinguished from multitargeted c-MET inhibitors currently in clinical trials, will provide opportunities to validate the role of the c-MET target in tumor development, and it could be used as a single agent or combined effectively with other agents for the treatment of cancers.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Methods for Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as purchased from commercial sources. Reactions were carried out under nitrogen atmosphere unless otherwise indicated. Silica gel chromatography was done using the appropriate size Biotage prepacked silica filled cartridges. NMR spectra were generated on a Bruker 300 or 400 MHz instrument and obtained as CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> or MeOH-<i>d</i><sub>4</sub> solutions (reported in ppm), using CDCl<sub>3</sub> as the reference standard (7.27 ppm), DMSO-<i>d</i><sub>6</sub> (2.50 ppm), and MeOH-<i>d</i><sub>4</sub> (3.31 ppm). Multiplicities were given as s (singlet), br s (broad singlet), d (doublet), t (triplet), dt (double of triplets), and m (multiplet). Mass spectral data (APCI) was gathered on an Agilent 1100 LC with MSD (Agilent model G1946B upgraded to D model) single-quadrupole mass spectrometric detectors running with an atmospheric pressure chemical ionization source. The LC instrument includes a binary pump (Agilent model G1312A) with an upper pressure limit of 400 bar attached to an autosampler (Agilent model G1313A) which uses an external tray for sample submission. The column compartment (Agilent model G1316A) is attached to a diode array (Agilent model G1315A). The instrument acquisition and data handling were done with ChemStation rev B.02.01. The purity measurements were done by measuring peak area at 254 nm, 224 nm, and total ion chromatogram. To evaluate the purity of each peak, the UV–vis spectrum from 190 to 700 nm at a step size of 2 nm and mass spectrum scan from 150 to 850 amu with a cycle time of 0.29 cycle/s was performed. Retention times (RT) were in minutes, and purity was calculated as percentage of total area. Two HPLC methods were utilized for purity. Method A: Waters Acquity UPLC BEH C18 column, 1.7 μm, 2.1 mm × 100 mm, column temperature 80 °C; solvent A: water (0.1% formic acid and 0.05% ammonium formate); solvent B: methanol (0.1% formic acid and 0.05% ammonium formate); gradient: 5–95%B in 10 min, 95%B 10–12 min; flow rate 0.6 mL/min. Method B: EclipsXDB C8 column, 3.5 μm, 4.6 mm × 50 mm, column temperature 40 °C; solvent A: water (5% ACN, 2 mM ammonium acetate, 0.1% acetic acid); solvent B: ACN (5% H<sub>2</sub>O, 2 mM ammonium acetate, 0.1% acetic acid); gradient: 20–85%B (0.0–2.5 min), 85–95%B (2.5–3.5 min), 95%B (5 min); flow rate = 0.8 mL/min. Compound purity was determined by combustion analysis (Atlantic Microlabs, Inc.) or high pressure liquid chromatography (HPLC) with a confirming purity of ≥95% for all final biological testing compounds.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure A for the Preparation of Triazolotriazine Compounds</h3><div class="NLM_p last">To a solution of substituted acetic acid (1 molar equiv), HOBT (1 molar equiv), and EDC (1.1 molar equiv) in NMP (0.25 M) in a microwave reaction vessel was added <b>52a</b> or <b>52b</b> (1.0 molar equiv). The suspension was stirred at ambient temperature until a clear solution was obtained and a complete conversion to the intermediate <b>53</b> was observed by LC-MS (it took 1–2 h). The reaction vessel was then microwaved at 170 °C for 30 min or longer until over 90% conversion to the final product was observed in LC-MS. The reaction solution was diluted with ethyl acetate, washed with water 5 times to remove the reaction solvent, and washed with brine. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified on a silica gel column, eluting with EtOAc–hexane (50% to 100% EtOAc), or purified on a reversed phase preparative HPLC, eluting with 10–40% (30 min) acetonitrile in water (containing 0.1% acetic acid). A highly crystalline solid product was obtained.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 3-(4-Fluorobenzyl)-6-(4-fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>16</b>)</h3><div class="NLM_p">To a solution of (4-fluorophenyl)acetic acid (154.1 mg, 1.0 mmol), HOBT (1 molar equiv), and EDC (1.1 molar equiv) in NMP (4.0 mL) in a microwave reaction vessel was added [6-(4-fluorophenyl)[1,2,4]triazin-3-yl]hydrazine (205.2 mg, 1.0 mmol). The suspension was stirred at ambient temperature for overnight. LC-MS showed a complete conversion to the hydrazide intermediate. The reaction vessel was then microwaved at 170 °C for 30 min and LC-MS showed about 30% product was formed, at 170 °C for an additional 30 min and 60% product, and at 170 °C for another 30 min and >90% product was formed from LC-MS. The reaction solution was diluted with ethyl acetate, washed with water for 5 times to remove the reaction solvent, and washed with brine. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified on a silica gel column eluting with EtOAc–hexane (50% to 100% EtOAc) to provide a yellow crystalline solid product (110 mg, 34% yield); LC-MS <i>m</i>/<i>z</i> 324 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 1H), 8.25 (dd, <i>J</i> = 5.43, 8.97 Hz, 2H), 7.41–7.56 (m, 4H), 7.16 (t, <i>J</i> = 8.97 Hz, 2H), 4.57 (s, 2H); HPLC purity (method A): RT 11.78, >99%.</div><div class="NLM_p last">Compounds <b>12</b> and <b>14</b>–<b>24</b> were prepared according to the general procedure A.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-((6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-3-yl)methyl)phenol (<b>12</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 322 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 9.30 (s, 1H), 8.25 (dd, <i>J</i> = 5.31, 8.84 Hz, 2H), 7.50 (t, <i>J</i> = 8.84 Hz, 2H), 7.19 (d, <i>J</i> = 8.34 Hz, 2H), 6.70 (s, 2H), 4.43 (s, 2H); HPLC purity (method A): RT 11.22, >99%.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-(4-Fluorophenyl)-3-methyl[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>14</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 230 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.23–8.30 (m, 2H), 7.46–7.53 (m, 2H), 2.75 (s, 3H); HPLC purity (method A): RT 10.96, >99%.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-(4-Fluorophenyl)-3-(4-methoxybenzyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>15</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 336 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.25 (dd, <i>J</i> = 5.43, 8.97 Hz, 2H), 7.50 (t, <i>J</i> = 8.97 Hz, 2H), 7.33 (d, <i>J</i> = 8.84 Hz, 2H), 6.84–6.93 (m, 2H), 4.49 (s, 2H), 3.71 (s, 3H); HPLC purity (method A): RT 11.71, >99%.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2-Chloro-4-((6-(4-fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-3-yl)methyl)phenol (<b>17</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 356 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 9.35 (s, 1H), 8.18–8.31 (m, 2H), 7.44–7.53 (m, 2H), 7.41 (d, <i>J</i> = 2.02 Hz, 1H), 7.16 (dd, <i>J</i> = 2.02, 8.34 Hz, 1H), 6.90 (d, <i>J</i> = 8.34 Hz, 1H), 4.46 (s, 2H); HPLC purity (method A): RT 11.45, >95%.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-((6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-3-yl)methyl)pyridin-4(1<i>H</i>)-one (<b>18</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 323 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.44 (s, 1H), 8.31 (dd, <i>J</i> = 5.43, 8.97 Hz, 2H), 7.78–7.86 (m, 2H), 7.52 (t, <i>J</i> = 8.84 Hz, 2H), 6.08–6.18 (m, 2H), 5.76 (s, 2H); HPLC purity (method A): RT 9.13, >95%.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 6-(4-Fluorophenyl)-3-((pyridin-3-yloxy)methyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>19</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 323 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.08 (s, 1H), 8.49 (br s, 1H), 8.31 (br s, 1H), 7.99–8.12 (m, 2H), 7.55 (dd, <i>J</i> = 8.46, 1.89 Hz, 1H), 7.29–7.37 (m, 3H), 5.75 (s, 2H); HPLC purity (method B): RT 2.71, >95%.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 6-(4-Fluorophenyl)-3-((thieno[3,2-<i>b</i>]pyridin-7-yloxy)methyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>20</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 379 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.41 (s, 1H), 8.23–8.35 (m, 2H), 8.18 (d, <i>J</i> = 7.58 Hz, 1H), 8.05 (d, <i>J</i> = 5.56 Hz, 1H), 7.67 (d, <i>J</i> = 5.56 Hz, 1H), 7.49–7.55 (m, 2H), 6.16 (d, <i>J</i> = 7.58 Hz, 1H), 6.13 (s, 2H); HPLC purity (method B): RT 2.08, >95%.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 6-(4-Fluorophenyl)-3-((1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylthio)methyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazine (<b>21</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 380 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.19 (br s, 1H), 9.39 (s, 1H), 8.81 (s, 1H), 8.36 (s, 1H), 8.11–8.17 (m, 2H), 7.39–7.48 (m, 2H), 5.34 (s, 2H); HPLC purity (method A): RT 11.23, >95%.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(((6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-3-yl)methyl)thio)-5-(methylamino)isothiazole-4-carboxamide (<b>22</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 417 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.39 (s, 1H), 8.19–8.27 (m, 2H), 8.02 (br s, 1H), 7.44–7.55 (m, 2H), 7.09 (br s, 2H), 4.99 (s, 2H), 2.83 (s, 3H); HPLC purity (method B): RT 2.71, >95%.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 6-((6-(4-Fluorophenyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-3-yl)methyl)quinoline (<b>23</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 357 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.37 (s, 1H), 8.93 (d, <i>J</i> = 4.04 Hz, 1H), 8.44 (d, <i>J</i> = 8.59 Hz, 1H), 8.22–8.29 (m, 2H), 8.01–8.06 (m, 2H), 7.88 (d, <i>J</i> = 9.09 Hz, 1H), 7.60 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 7.46–7.51 (m, 2H), 4.81 (s, 2H); HPLC purity (method B): RT 2.83, >95%</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-(3-((1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)methyl)[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazin-6-yl)benzonitrile (<b>24</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 353.0 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (br s, 1H), 9.39 (s, 1H), 8.37 (d, <i>J</i> = 8.59 Hz, 2H), 8.20 (dd, <i>J</i> = 1.52, 4.55 Hz, 1H), 8.12 (d, <i>J</i> = 8.84 Hz, 2H), 8.04–8.08 (m, 1H), 7.49 (d, <i>J</i> = 2.27 Hz, 1H), 7.06 (dd, <i>J</i> = 4.67, 7.96 Hz, 1H), 4.69 (s, 2H); HPLC purity (method A): RT 10.84, >95%.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure B for the Preparation of Triazolopyrazine Compounds <b>13</b> and <b>25</b>–<b>33</b></h3></div><div id="sec5_15_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Step 1: 6-Bromo-<i>N</i><sup>2</sup>-(quinolin-6-ylmethyl)pyrazine-2,3-diamine (<b>54d</b>)</h3><div class="NLM_p last">3,5-Dibromopyrazin-2-amine (21.8 g, 0.086 mol), quinolin-6-ylmethaneamine (13.6 g, 0.086 mol), and diisopropylethylamine (16.5 mL, 0.0946 mol) were dissolved in <i>n</i>-BuOH (150 mL). The reaction mixture was refluxed for 2 days and evaporated. The residue was treated with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and water (200 mL). The obtained mixture was vigorously stirred for 20 min. The formed precipitate was separated by filtration, washed with water, and dried to afford <b>54d</b> (21 g, 74%) as a colorless solid; LC-MS <i>m</i>/<i>z</i> 330 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (dd, <i>J</i> = 1.52, 4.04 Hz, 1H), 8.35 (d, <i>J</i> = 7.83 Hz, 1H), 8.01 (d, <i>J</i> = 8.59 Hz, 1H), 7.90 (s, 1H), 7.75 (dd, <i>J</i> = 1.89, 8.72 Hz, 1H), 7.52 (dd, <i>J</i> = 4.17, 8.21 Hz, 1H), 7.22 (s, 1H), 7.17 (t, <i>J</i> = 5.43 Hz, 1H), 6.25 (s, 2H), 4.71 (d, <i>J</i> = 5.56 Hz, 2H).</div></div><div id="sec5_15_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Step 2. 6-((6-Bromo-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>55d</b>)</h3><div class="NLM_p last"><b>54d</b> (77 g, 0.233 mol) was dissolved in DMF (2 L). The solution was cooled to 0 °C. A solution of isoamyl nitrite (32.76 g, 0.28 mol) in DMF (500 mL) was added dropwise for 90 min. The reaction mixture was stirred at room temperature overnight and then heated to 70 °C until the reaction was complete. The reaction mixture was cooled to room temperature and concentrated in high vacuum. The residue was crystallized from THF to afford <b>55d</b> (55.7 g, 70%) as brown crystals; LC-MS <i>m</i>/<i>z</i> 341 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.01 (s, 1H), 8.91 (dd, <i>J</i> = 1.77, 4.29 Hz, 1H), 8.35 (d, <i>J</i> = 7.58 Hz, 1H), 8.03 (d, <i>J</i> = 8.59 Hz, 1H), 7.94 (d, <i>J</i> = 1.26 Hz, 1H), 7.78 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 7.54 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 6.19 (s, 2H); Anal. Calcd for C<sub>14</sub>H<sub>9</sub>N<sub>6</sub>Br: C, 49.29; H, 2.66; N, 24.63. Found: C, 49.37; H, 2.79; N, 24.41.</div></div><div id="sec5_15_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Step 3: 6-((6-(4-Fluorophenyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>27</b>)</h3><div class="NLM_p">A mixture of DME (3.0 mL) and aqueous Na<sub>2</sub>CO<sub>3</sub> (1.0 M, 0.88 mL) was degassed by bubbling in argon for 10 min. The mixture was transferred via syringe to a vial containing <b>55d</b> (100 mg, 0.29 mmol), 4-fluorophenylboronic acid (45 mg, 0.32 mmol), and Pd(dppf)C1<sub>2</sub>·CH<sub>2</sub>C1<sub>2</sub> (6.2 mg, 0.01 mmol). The vial was capped and heated to 80 °C for 3.5 h. The crude reaction mixture was diluted with dichloromethane and then washed with water. The dichloromethane solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified via column chromatography, eluting with ethyl acetate and dichloromethane to provide <b>27</b> (77 mg, 74%). LC-MS <i>m</i>/<i>z</i> 357 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19–9.24 (m, 1H), 8.98 (dd, <i>J</i> = 4.29, 1.52 Hz, 1H), 8.64 (s, 1H), 8.52 (d, <i>J</i> = 7.83 Hz, 1H), 8.30 (s, 1H), 8.04–8.10 (m, 2H), 7.91 (dd, <i>J</i> = 8.72, 1.89 Hz, 1H), 7.64 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 6.17 (s, 2H), 3.94 (s, 3H); HPLC purity (method B): RT 3.41, >95%.</div><div class="NLM_p last">Compounds <b>13</b>, <b>25</b>–<b>26</b>, and <b>28</b>–<b>33</b> were prepared according to general procedure B.</div></div><div id="sec5_15_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-((6-(4-Fluorophenyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)phenol (<b>13</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 322 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.5–9.57 (m, 1H), 9.48 (s, 1H), 8.36–8.44 (m, 2H), 7.47 (t, <i>J</i> = 8.72 Hz, 2H), 7.32 (d, <i>J</i> = 8.34 Hz, 2H), 6.74 (d, <i>J</i> = 8.34 Hz, 2H), 5.88 (s, 2H); HPLC purity (method B): RT 3.24, >95%.</div></div><div id="sec5_15_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 6-(4-Fluorophenyl)-1-(4-methoxybenzyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (<b>25</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 336 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (s, 1H), 8.40 (dd, <i>J</i> = 5.43, 8.97 Hz, 2H), 7.39–7.51 (m, 4H), 6.93 (d, <i>J</i> = 8.59 Hz, 2H), 5.95 (s, 2H), 3.31 (s, 3H); HPLC purity (method A): RT 11.99, >99%.</div></div><div id="sec5_15_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(4-Fluorobenzyl)-6-(4-fluorophenyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (<b>26</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 324 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.49 (s, 1H), 8.38 (dd, <i>J</i> = 5.43, 8.97 Hz, 2H), 7.54 (dd, <i>J</i> = 5.56, 8.59 Hz, 2H), 7.46 (t, <i>J</i> = 8.84 Hz, 2H), 7.21 (t, <i>J</i> = 8.84 Hz, 2H), 6.02 (s, 2H); HPLC purity (method A): RT 11.59, >99%.</div></div><div id="sec5_15_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-(4-Methoxybenzyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (<b>28</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 322 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.65 (s, 1H), 8.31 (s, 1H), 7.42 (d, <i>J</i> = 8.84 Hz, 2H), 6.93 (d, <i>J</i> = 8.84 Hz, 2H), 5.85 (s, 2H), 3.96 (s, 3H), 3.72 (s, 3H); HPLC purity (method A): RT 11.37, >99%.</div></div><div id="sec5_15_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-((2,3-Dihydrobenzofuran-5-yl)methyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (<b>29</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 334 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (s, 1H), 8.62–8.69 (m, 1H), 8.33 (s, 1H), 7.33 (s, 1H), 7.25 (d, <i>J</i> = 8.34 Hz, 1H), 6.75 (d, <i>J</i> = 8.08 Hz, 1H), 5.83 (s, 2H), 4.49 (t, <i>J</i> = 8.72 Hz, 2H), 3.97 (s, 3H), 3.13 (t, <i>J</i> = 8.72 Hz, 2H); HPLC purity (method B): RT 2.94, >95%.</div></div><div id="sec5_15_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-((2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)methyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (<b>30</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 350 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.17 (s, 1H), 8.63 (s, 1H), 8.29 (s, 1H), 6.96 (d, 1H), 6.89–6.92 (dd, 1H), 6.81–6.83 (d, 1H), 5.78 (s, 2H), 4.18 (s, 4H), 3.94 (s, 3H); HPLC purity (method A): RT 11.27, >99%.</div></div><div id="sec5_15_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 6-((6-(1-Methyl-1H-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>31</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 343 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 8.90 (dd, <i>J</i> = 1.77, 4.29 Hz, 1H), 8.65 (s, 1H), 8.38 (dd, <i>J</i> = 1.01, 8.34 Hz, 1H), 8.31 (d, <i>J</i> = 0.51 Hz, 1H), 7.97–8.07 (m, 2H), 7.84 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 7.54 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 6.16 (s, 2H), 3.95 (s, 3H); HPLC purity (method A): RT 10.90, >99%.</div></div><div id="sec5_15_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 6-((6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinazoline (<b>32</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 344 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1H), 9.28 (s, 1H), 9.21 (s, 1H), 8.62 (s, 1H), 8.29 (s, 1H), 8.08–8.15 (m, 2H), 8.00–8.06 (m, 1H), 6.19 (s, 2H), 3.93 (s, 3H); HPLC purity (method A): RT 10.58, >95%.</div></div><div id="sec5_15_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 6-((6-(1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>33</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 329 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.47 (br s, 1H), 9.26 (s, 1H), 8.89 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.55 (br s, 2H), 8.38 (d, <i>J</i> = 8.59 Hz, 1H), 7.99–8.07 (m, 2H), 7.84 (dd, <i>J</i> = 8.97, 1.64 Hz, 1H), 7.53 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 6.15 (s, 2H); HPLC purity (method B): RT 2.38, >95%.</div></div><div id="sec5_15_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) (<b>34</b>)</h3></div><div id="sec5_15_13_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Step 1: 4-Iodo-1-(2-(tetrahydro-2<i>H</i>-pyran-2-yloxy)ethyl)-1<i>H</i>-pyrazole (<b>58</b>)</h3><div class="NLM_p last">In a round-bottom flask was added 4-iodopyrazole (10.22 g, 52.70 mmol), Cs<sub>2</sub>CO<sub>3</sub> (20.6 g, 63.2 mmol), and anhydrous DMF (100 mL). The suspension was stirred at 23 °C for 5 min. 2-(2-Bromoethoxy)tetrahydro-2<i>H</i>-pyran (9.95 mL, 63.2 mmol) was added, and the reaction mixture was stirred at 70 °C for 16 h. After the reaction mixture was cooled down, EtOAc (100 mL) and water (100 mL) were added. The organic layer was collected, and the aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with water (3 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford a dark brown oil. The crude product was purified on a silica gel column, eluting with ethyl acetate and hexanes to provide <b>58</b> as a yellow oil (14.78 g, 87% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.89 (s, 1H), 7.52 (s, 1H), 4.47–4.56 (m, 1H), 4.25–4.35 (m, 2H), 3.81–3.96 (m, 1H), 3.66–3.75 (m, 1H), 3.45–3.57 (m, 1H), 3.32–3.40 (m, 1H), 1.34–1.71 (m, 6H).</div></div><div id="sec5_15_13_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Step 2: 1-(2-(Tetrahydro-2<i>H</i>-pyran-2-yloxy)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>60</b>)</h3><div class="NLM_p last">To a solution of <b>57</b> (1.0 g, 3.1 mmol) in anhydrous THF (8 mL) was added <i>i</i>-PrMgCl (2 M in THF, 3.10 mL, 6.21 mmol) at 0 °C dropwise under nitrogen. The reaction was stirred for 1 h at 0 °C under nitrogen. To the solution was added 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.736 g, 4.66 mmol) at 0 °C, and the resulting yellow solution was allowed to stir for 1 h at ambient temperature under nitrogen. The reaction was quenched with a saturated aqueous solution of NH<sub>4</sub>Cl (10 mL). EtOAc (50 mL) and saturated aqueous NH<sub>4</sub>Cl solution (10 mL) were added. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product as a yellow oil. The oil was purified in a silica gel column, eluting with EtOAc and hexanes to provide <b>60</b> as clear oil (800 mg, 80% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91 (s, 1H), 4.48–4.54 (m, 1H), 4.26–4.33 (m, 2H), 3.86–3.90 (m, 1H), 3.66–3.76 (m, 1H), 3.45–3.57 (m, 1H), 3.33–3.39 (m, 1H), 1.33–1.70 (m, 6H), 1.24 (s, 12H).</div></div><div id="sec5_15_13_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Step 3: 6-((6-(1-(2-(Tetrahydro-2<i>H</i>-pyran-2-yloxy)ethyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>61</b>)</h3><div class="NLM_p">To a solution of <b>55d</b> (845 mg, 2.48 mmol) in DME (16 mL) was added <b>60</b> (800 mg, 2.48 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (2.42 g, 7.43 mmol) in H<sub>2</sub>O (4 mL). The reaction mixture was degassed and charged with nitrogen three times. The palladium catalyst Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (101 mg, 0.124 mmol) was added, and the reaction mixture was degassed and charged with nitrogen three times, and stirred for 16 h at 80 °C under nitrogen. The reaction mixture was then filtered over a pad of Celite and washed with EtOAc (50 mL) and water (25 mL). The filtrate was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified via Biotage silica gel column chromatography, eluting with hexane/EtOAc (0–100%) to provide <b>61</b> (910 mg, 81% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.82–8.95 (m, 1H), 8.67 (s, 1H), 8.28–8.45 (m, 2H), 7.92–8.08 (m, 2H), 7.77–7.90 (m, 1H), 7.53 (dd, <i>J</i> = 8.29, 4.14 Hz, 1H), 6.15 (s, 2H), 4.49–4.62 (m, 2H), 4.30–4.47 (m, 2H), 3.91–4.00 (m, 1H), 3.67–3.87 (m, <i>J</i> = 5.46 Hz, 1H), 3.47–3.60 (m, 1H), 3.35–3.42 (m, 1H), 1.48–1.66 (m, 2H), 1.32–1.45 (m, 3H).</div><div class="NLM_p last">Step 4: To a solution of <b>61</b> (780 mg, 1.71 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added the anhydrous HCl/dioxane solution dropwise (4 N, 1.07 mL, 4.27 mmol). A white solid precipitated out. The reaction mixture was stirred for 1 h, and the LCMS showed the completion of the reaction. The reaction mixture was concentrated, and the residue was dissolved in distilled water (15 mL). The solution was adjusted to pH 7 with Na<sub>2</sub>CO<sub>3</sub>. An off-white solid crashed out, which was filtered, washed with water, and dried on a high vacuum for 1 h. The solid was recrystallized from EtOH (50 mL) to provide <b>2</b> (400 mg, 63% yield) as a white crystalline solid: mp 222 °C; LC-MS <i>m</i>/<i>z</i> 373 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.94 (dd, <i>J</i> = 1.52, 4.29 Hz, 1H), 8.64 (s, 1H), 8.46 (d, <i>J</i> = 8.59 Hz, 1H), 8.33 (s, 1H), 8.02–8.08 (m, 2H), 7.88 (dd, <i>J</i> = 1.89, 8.72 Hz, 1H), 7.59 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 6.17 (s, 2H), 4.25 (t, <i>J</i> = 5.43 Hz, 2H), 3.79 (t, <i>J</i> = 5.43 Hz, 2H); HPLC purity (method A): RT 10.679, 99.6%; Anal. Calcd for C<sub>19</sub>H<sub>16</sub>N<sub>8</sub>O<b>·</b>1.0H<sub>2</sub>O: C, 58.45; H, 4.65; N, 28.70. Found: C, 58.45; H, 4.57; N, 28.50.</div></div><div id="sec5_15_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2-Methyl-1-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)propan-2-ol (<b>36</b>)</h3><div class="NLM_p last">To a suspension of <b>33</b> (50 mg, 0.15 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (50 mg, 0.15 mmol) in DMF (2 mL) was added 2,2-dimethyl-oxirane (21.6 mg, 0.30 mmol). The reaction was stirred at 80 °C for 16 h. The reaction was then purified with a reverse-phased preparative HPLC eluting with acetonitrile/water having 0.1% acetic acid to yield <b>36</b> as a white amorphous solid after lyophilization (13 mg, 22% yield); LC-MS <i>m</i>/<i>z</i> 401 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (s, 1H), 8.90 (dd, <i>J</i> = 1.64, 4.17 Hz, 1H), 8.58 (s, 1H), 8.34–8.41 (m, 1H), 8.32 (s, 1H), 7.98–8.06 (m, 2H), 7.83 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 7.54 (dd, <i>J</i> = 4.17, 8.21 Hz, 1H), 6.16 (s, 2H), 4.81 (s, 1H), 4.12 (s, 2H), 1.11 (s, 6H); HPLC purity (method A): RT 11.10, >99%.</div></div><div id="sec5_15_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>,<i>N</i>-Dimethyl-2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanamine (<b>37</b>)</h3><div class="NLM_p">To a solution of <b>33</b> (50 mg, 0.152 mmol) in anhydrous DMF (1.52 mL, 0.1 M) was added cesium carbonate (100 mg, 0.304 mmol). The 1-(2-chloroethyl)pyrrolidine-HCl salt (26 mg, 0.152 mmol) was added, and the reaction mixture was allowed to stir under nitrogen for 3 h at 80 °C. The reaction mixture was purified directly by preparative HPLC using acetonitrile and H<sub>2</sub>O with 0.1% HOAc to give <b>37</b> (15 mg, 23% yield); LC-MS <i>m</i>/<i>z</i> 400 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.51 (br s, 1H), 9.27 (s, 1H), 8.93 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.75–8.79 (m, 1H), 8.45–8.52 (m, 1H), 8.43 (d, <i>J</i> = 8.34 Hz, 1H), 8.05 (d, <i>J</i> = 8.59 Hz, 1H), 8.00 (d, <i>J</i> = 1.26 Hz, 1H), 7.85 (dd, <i>J</i> = 8.72, 1.89 Hz, 1H), 7.58 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 6.17 (s, 2H), 4.64 (t, <i>J</i> = 6.19 Hz, 2H), 3.63 (br s, 2H), 2.83 (br s, 6H); HPLC purity (method A): RT 9.64, 95.30%.</div><div class="NLM_p last"><b>38</b> and <b>39</b> were prepared with a similar procedure as that used for  <b>37</b>.</div></div><div id="sec5_15_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 6-((6-(1-(2-(Pyrrolidin-1-yl)ethyl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>38</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 426.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (s, 1H), 8.88 (dd, <i>J</i> = 1.77, 4.29 Hz, 1H), 8.67 (s, 1H), 8.35–8.39 (m, 1H), 8.30 (s, 1H), 7.96–8.05 (m, 2H), 7.82 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 7.51 (s, 1H), 6.14 (s, 2H), 4.30 (t, <i>J</i> = 6.44 Hz, 2H), 3.35–3.42 (m, 4H), 2.86 (t, <i>J</i> = 6.44 Hz, 2H), 2.44–2.48 (m, 4H), 1.63 (td, <i>J</i> = 3.22, 6.69 Hz, 4H); HPLC purity (method A): RT 9.86, >99%.</div></div><div id="sec5_15_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 1-(2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1H-pyrazol-1-yl)ethyl)pyrrolidin-2-one (<b>39</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 440.0 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.90 (dd, <i>J</i> = 1.77, 4.04 Hz, 1H), 8.69 (s, 1H), 8.38 (d, <i>J</i> = 7.33 Hz, 1H), 8.34 (s, 1H), 7.99–8.06 (m, 2H), 7.84 (dd, <i>J</i> = 2.02, 8.84 Hz, 1H), 7.54 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 6.16 (s, 2H), 4.34 (t, <i>J</i> = 5.94 Hz, 2H), 3.62 (t, <i>J</i> = 5.94 Hz, 2H), 3.10–3.20 (m, 2H), 2.07–2.17 (m, 2H), 1.82 (t, <i>J</i> = 7.45 Hz, 2H); HPLC purity (method A): RT 10.79, >99%.</div></div><div id="sec5_15_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)acetic acid (<b>35</b>)</h3><div class="NLM_p last">The methyl ester of <b>35</b> was prepared with a similar procedure as that used for <b>37</b>. To a solution of 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)acetic acid methyl ester (242 mg, 0.60 mmol) in MeOH (4 mL) was added a freshly prepared solution of LiOH (72 mg, 3.02 mmol) in water (1 mL). The reaction was stirred for 16 h at ambient temperature. The white suspension was then neutralized to pH 7 with 1 N HC1, and a white solid precipitated out. The solid was filtered, washed with water, and dried under a high vacuum for 16 h to provide <b>35</b> (131 mgs, 56% yield); LC-MS <i>m</i>/<i>z</i> 387 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.15 (s, 1H), 8.82 (d, <i>J</i> = 2.78 Hz, 1H), 8.52 (s, 1H), 8.31 (d, <i>J</i> = 7.58 Hz, 1H), 8.19 (s, 1H), 7.90–8.00 (m, 2H), 7.78 (s, 1H), 7.42–7.50 (m, 1H), 6.09 (s, 2H), 4.54–4.69 (m, 2H); HPLC purity (method A): RT 10.21, 96.19%.</div></div><div id="sec5_15_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>R</i>)-6-((6-(1-(Pyrrolidin-3-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>40</b>)</h3><div class="NLM_p last">The <i>N</i>-Boc analogue of <b>40</b> was prepared according to a similar procedure as that used for <b>37</b>. The Boc-protecting group was removed with 4 N HCl in dioxane in methanol solvent; LC-MS <i>m</i>/<i>z</i> 398 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 9.16 (br s, 2H), 8.94 (dd, <i>J</i> = 2.78, 1.52 Hz, 1H), 8.82 (s, 1H), 8.44 (s, 2H), 8.00–8.10 (m, 2H), 7.86 (d, <i>J</i> = 8.84 Hz, 1H), 7.59 (ddd, <i>J</i> = 6.19, 4.17, 2.02 Hz, 1H), 6.17 (s, 2H), 5.26–5.38 (m, <i>J</i> = 7.14, 7.14, 4.04, 3.66 Hz, 1H), 3.65–3.74 (m, 1H), 3.57–3.65 (m, 1H), 3.44 (d, <i>J</i> = 16.67 Hz, 2H), 2.41–2.48 (m, 1H), 2.29–2.40 (m, 1H); HPLC purity (method A): RT 9.90, 99%.</div></div><div id="sec5_15_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 6-((6-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>41</b>)</h3><div class="NLM_p last">The <i>N</i>-Boc analogue of <b>41</b> was prepared according to a similar procedure as that used for <b>37</b>. The Boc-protecting group was removed with 4 N HCl in dioxane in methanol solvent; LC-MS <i>m</i>/<i>z</i> 412 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 2 equiv HCl-salt) δ 9.27 (s, 1H), 8.84–8.98 (m, 2H), 8.62–8.76 (m, 2H), 8.48 (d, <i>J</i> = 7.58 Hz, 1H), 8.37 (s, 1H), 8.01–8.10 (m, 2H), 7.88 (d, <i>J</i> = 8.59 Hz, 1H), 7.61 (dd, <i>J</i> = 4.29, 8.08 Hz, 1H), 6.17 (s, 2H), 4.61 (t, <i>J</i> = 10.74 Hz, 1H), 3.36–3.46 (m, <i>J</i> = 12.60 Hz, 2H), 3.01–3.19 (m, 2H), 2.10–2.29 (m, 4H); HPLC purity (method A): RT 10.00, >99%.</div></div><div id="sec5_15_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 6-((1<i>H</i>-[1,2,3]Triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>42</b>)</h3><div class="NLM_p last">A solution of <b>55d</b> (200 mg, 0.586 mmol) in MeOH (10 mL)/AcOH (1 mL)/EtOAc (1 mL) was degassed 3 times with nitrogen. To this solution was added Pd/C (20 mg). A balloon containing hydrogen was added via syringe, and the reaction was allowed to stir for 18 h at room temperature. The reaction did not complete, and more Pd/C was added (20 mg) and stirred for 18 h at room temperature. The reaction was stopped when LCMS showed a ratio of 1:1 (product/starting material). The reaction was filtered over Celite and washed with EtOAc (50 mL). The filtered solution was concentrated and purified by Biotage silica gel column chromatography with hexane/EtOAc to give <b>42</b> as a white solid (30 mg, 20% yield); LC-MS <i>m</i>/<i>z</i> 263.0 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85–8.92 (m, 3H), 8.31–8.39 (m, 1H), 8.00 (d, <i>J</i> = 8.59 Hz, 1H), 7.96 (d, <i>J</i> = 1.52 Hz, 1H), 7.77 (dd, <i>J</i> = 2.15, 8.72 Hz, 1H), 7.52 (dd, <i>J</i> = 4.17, 8.21 Hz, 1H), 6.22 (s, 2H); HPLC purity (method A): RT 10.11, 97.2%.</div></div><div id="sec5_15_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 6-((6-Methyl-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>43</b>)</h3><div class="NLM_p last">To a solution of <b>55d</b> (100 mg, 0.29 mmol) and methyl boronic acid (20 mg, 0.32 mmol) in DME/H<sub>2</sub>O (4:1, 0.1 M) was added sodium carbonate (92 mg, 0.87 mmol). The mixture was degassed with nitrogen three times. Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (10 mg, 0.015 mmol) was added, and the reaction was degassed again three times. After it was heated to 80 °C for 16 h, the reaction mixture was filtered through a pad of Celite and washed with EtOAc. The aqueous layer was extracted with EtOAc (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The crude material was purified directly by preparative HPLC using ACN/H<sub>2</sub>O with 0.1% HOAc to afford <b>43</b> (13 mg, 16%); LC-MS <i>m</i>/<i>z</i> 277.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (dd, <i>J</i> = 1.77, 4.29 Hz, 1H), 8.79 (s, 1H), 8.36 (d, <i>J</i> = 7.58 Hz, 1H), 8.01 (d, <i>J</i> = 8.84 Hz, 1H), 7.91 (s, 1H), 7.75 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 7.53 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 6.17 (s, 2H), 2.74 (s, 3H); HPLC purity (method B): RT 2.60, 95%.</div></div><div id="sec5_15_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-amine (<b>44</b>)</h3><div class="NLM_p last">To a microwave vessel were added <b>55d</b> (300 mg, 0.88 mmol) and NH<sub>4</sub>OH (3 mL). The reaction was irradiated in a microwave at 100 °C for 1 h. The solid was filtered and washed with water and then recrystallized in MeOH, filtered, and dried to give <b>44</b> as a white crystal solid (100 mg, 41%); mp 266 °C; LC-MS <i>m</i>/<i>z</i> 278 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (dd, <i>J</i> = 1.64, 4.17 Hz, 1H), 8.35 (dd, <i>J</i> = 1.01, 8.34 Hz, 1H), 8.04 (s, 1H), 7.99–8.03 (m, 1H), 7.80 (d, <i>J</i> = 1.52 Hz, 1H), 7.68 (dd, <i>J</i> = 2.02, 8.84 Hz, 1H), 7.49–7.56 (m, 3H), 5.88 (s, 2H); HPLC purity (method A): RT 9.33, >99%.</div></div><div id="sec5_15_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>R</i>)-1-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)pyrrolidin-3-amine (<b>48</b>)</h3><div class="NLM_p">Step 1. A mixture of <b>55d</b> (200 mg, 0.59 mmol), potassium carbonate (243 mg, 1. 76 mmol), and (<i>R</i>)-tertbutylpyrrolidin-3-ylcarbamate (218 mg, 1.17 mmol) in 2-propanol (6 mL) was heated in the microwave at 80 °C for 20 min. The mixture was allowed to cool, and the solids were collected by filtration and then purified by flash chromatography, eluting with chloroform/ethyl acetate (25–75%) to afford the <i>N</i>-Boc protected <b>48</b> (239 mg, 91%).</div><div class="NLM_p">Step 2. To a solution of (<i>R</i>)-<i>tert</i>-butyl 1-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)pyrrolidin-3-ylcarbamate (100 mg, 0.224 mmol) in dichloromethane (2.2 mL) was added hydrochloric acid (4 N in dioxane 0.56 mL, 2.24 mmol). After stirring at room temperature for 6 h, the reaction was diluted with dichloromethane and quenched with saturated sodium bicarbonate (5 mL). The organic layer was separated and concentrated to afford the desired product <b>48</b> (65 mg, 84%); LC-MS <i>m</i>/<i>z</i> 347 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.85 (dd, <i>J</i> = 1.5, 4.3 Hz, 1H), 8.36 (d, <i>J</i> = 8.3 Hz, 1H), 8.15 (s, 1H), 8.01 (d, <i>J</i> = 8.6 Hz, 1H), 7.95 (d, <i>J</i> = 1.0 Hz, 1H), 7.85 (dd, <i>J</i> = 2.0, 8.8 Hz, 1H), 7.55 (dd, <i>J</i> = 4.4, 8.5 Hz, 1H), 5.95 (s, 2H), 3.88–3.78 (m, 2H), 3.75–3.66 (m, 2H), 3.48–3.40 (m, 1H), 2.35–2.22 (m, 1H), 2.03–1.86 (m, 1H); HPLC purity (method A): RT 8.96, >99%.</div><div class="NLM_p last">Compounds <b>45</b>–<b>47</b> and <b>49</b>–<b>50</b> were prepared with similar procedures as that for <b>48</b>.</div></div><div id="sec5_15_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-Ethyl-1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-amine (<b>45</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 306 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (dd, <i>J</i> = 1.64, 4.17 Hz, 1H), 8.32–8.38 (m, 1H), 8.19 (br s, 1H), 7.96–8.04 (m, 2H), 7.89–7.94 (m, 1H), 7.74 (dd, <i>J</i> = 2.02, 8.84 Hz, 1H), 7.53 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 5.87 (s, 2H), 3.34–3.39 (m, 2H), 1.16 (t, <i>J</i> = 7.20 Hz, 3H); HPLC purity (method A): RT 11.13, >99%.</div></div><div id="sec5_15_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 2-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-ylamino)ethanol (<b>46</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 322 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (dd, <i>J</i> = 1.6, 4.2 Hz, 1H), 8.36 (d, <i>J</i> = 8.3 Hz, 1H), 8.26 (t, <i>J</i> = 5.8 Hz, 1H), 8.10 (s, 1H), 8.00 (d, <i>J</i> = 8.6 Hz, 1H), 7.93 (d, <i>J</i> = 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 2.0, 8.6 Hz, 1H), 7.53 (dd, <i>J</i> = 4.3, 8.3 Hz, 1H), 5.87 (s, 2H), 4.82 (t, <i>J</i> = 5.3 Hz, 1H), 3.58 (q, <i>J</i> = 5.6 Hz, 2H), 3.44 (q, <i>J</i> = 5.7 Hz, 2H); HPLC purity (method A): RT 10.20, >99%.</div></div><div id="sec5_15_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-Dimethyl-<i>N</i><sup>2</sup>-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)ethane-1,2-diamine (<b>47</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 349 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (dd, <i>J</i> = 1.52, 4.29 Hz, 1H), 8.34 (d, <i>J</i> = 8.08 Hz, 1H), 7.96–8.05 (m, 2H), 7.92 (s, 1H), 7.79 (dd, <i>J</i> = 2.02, 8.84 Hz, 1H), 7.53 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 5.93 (s, 2H), 3.59 (t, <i>J</i> = 6.57 Hz, 2H), 2.59 (t, <i>J</i> = 6.57 Hz, 2H), 2.24 (s, 6H); HPLC purity (method A): RT 8.34, >99%.</div></div><div id="sec5_15_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 1-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)pyrrolidin-3-ol (<b>49</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 348 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (dd, <i>J</i> = 1.77, 4.04 Hz, 1H), 8.36 (d, <i>J</i> = 7.58 Hz, 1H), 8.22 (s, 1H), 8.00 (d, <i>J</i> = 8.59 Hz, 1H), 7.90–7.96 (m, 1H), 7.76 (dd, <i>J</i> = 1.89, 8.72 Hz, 1H), 7.53 (dd, <i>J</i> = 4.17, 8.21 Hz, 1H), 5.90 (s, 2H), 5.10 (br s, 1H), 4.43 (br s, 1H), 3.56–3.80 (m, 3H), 3.48–3.55 (m, 1H), 1.84–2.08 (m, 2H); HPLC purity (method A): RT 10.01, >99%.</div></div><div id="sec5_15_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 6-((6-(4-Methylpiperazin-1-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)methyl)quinoline (<b>50</b>)</h3><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 361 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.92 (br s, 1H), 8.30 (s, 1 H), 8.12 (d, <i>J</i> = 8.3 Hz, 1H), 8.08 (d, <i>J</i> = 8.8 Hz, 1H), 7.82 (s, 1 H), 7.77 (dd, <i>J</i> = 1.9, 8.7 Hz, 1H), 7.41 (dd, <i>J</i> = 4.3, 8.3 Hz, 1H), 5.88 (s, 2H), 3.86–3.78 (m, 4H), 2.59 (br s, 4H), 2.39 (s, 3H); HPLC purity (method A): RT 8.45, >99%.</div></div><div id="sec5_15_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>,<i>N</i>-Dimethyl-2-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yloxy)ethanamine (<b>51</b>)</h3><div class="NLM_p last">A mixture of <b>55d</b> (100 mg, 0.293 mmol), triethylamine (0.123 mL, 0.879 mmol), and <i>N</i>,<i>N</i>-dimethylethanolamine (0.959 mL, 0.586 mmol) in <i>n</i>-butanol (3.0 mL) was heated in the microwave at 120 °C for 20 min and then concentrated. The crude product was purified by flash chromatography using a Horizon purification system on a 25S column eluting with chloroform/7 N ammonia in methanol (0.1–5%) to afford <b>49</b> (75 mg, 74%); LC-MS <i>m</i>/<i>z</i> 350 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (dd, <i>J</i> = 1.6, 4.2 Hz, 1H), 8.42 (s, 1H), 8.36 (d, <i>J</i> = 7.6 Hz, 1H), 8.01 (d, <i>J</i> = 8.6 Hz, 1H), 7.97 (d, <i>J</i> = 1.5 Hz, 1H), 7.78 (dd, <i>J</i> = 2.0, 8.8 Hz, 1H), 7.53 (dd, <i>J</i> = 4.3, 8.3 Hz, 1H), 6.06 (s, 2H), 4.50 (t, <i>J</i> = 5.7 Hz, 2H), 2.61 (t, <i>J</i> = 5.7 Hz, 2H), 2.13 (s, 6H); HPLC purity (method A): RT 8.09, 99%.</div></div><div id="sec5_15_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Biochemical Kinase Assays</h3><div class="NLM_p last">c-MET enzyme inhibition was measured by a continuous coupled spectrophotometric assay as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The assay monitored ATP consumption coupled to oxidation of NADH (measured at 340 nm) while regenerating ATP in the presence of phosphoenol pyruvate (PEP) and coupling enzymes, pyruvate kinase (PK), and lactic dehydrogenase (LDH). Assay reactions contained 0.30 mM ATP (4<i>K</i><sub>m</sub>), 0.5 mM Met2 peptide (Ac-ARDMYDKEYYSVHNK), 20 mM MgCl<sub>2</sub>, 1 mM PEP, 330 μM NADH, 2 mM DTT, 15 units/mL LDH, 15 units/mL PK, test compound (1% DMSO final) in 100 mM HEPES, pH 7.5, 37 °C, and the reactions were initiated by adding 50 nM c-Met N-terminal His6-tagged recombinant human enzyme, aa residues 974–1390 (Millipore Corp./Upstate Ltd., Billerica, MA). The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies, and the dose–response data were fit to the equation for competitive inhibition by the method of nonlinear least-squares (GraphPad Prism, GraphPad Software, San Diego, CA).</div></div><div id="sec5_15_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Cellular Kinase Phosphorylation ELISA Assays<a onclick="showRef(event, 'ref34 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref36">(36, 32)</a></h3><div class="NLM_p last">All experiments were done under standard conditions (37 °C and 5% CO<sub>2</sub>). IC50 values were calculated by concentration–response curve fitting using a Microsoft Excel-based four-parameter method. Cells were seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors were added for up to 20 min. After incubation of cells with an inhibitor for 1 h and/or appropriate ligands for the designated times, cells were washed once with HBSS supplemented with 1 mmol/L Na<sub>3</sub>VO<sub>4</sub>, and protein lysates were generated from cells. Subsequently, phosphorylation of selected protein kinases was assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates were (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase-conjugated anti-total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethylbenzidine peroxidase substrate (Bio-Rad) to initiate a colorimetric reaction that was stopped by adding 0.09 N H<sub>2</sub>SO<sub>4</sub>; and (f) measured for absorbance in 450 nm using a spectrophotometer. The A549 cell line was used for the c-MET cellular kinase phosphorylation ELISA assay.</div></div><div id="sec5_15_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Human Microsomal Stability Studies</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for 30 min in a final volume of 200 μL of 100 mM potassium phosphate buffer (pH 7.4) containing pooled human liver microsomes (0.8 mg/mL protein) and 2 mM NADPH. Reactions were initiated with the addition of NADPH following a 10-min preincubation. Aliquots of incubation samples were protein precipitated with cold methanol containing 0.1 μM buspirone (internal standard) and centrifuged, and supernatants were analyzed by LC-MS/MS. All incubations were performed in triplicate, and the percent remaining of parent drug at the end of incubation was determined by LC-MS/MS peak area ratio.</div></div><div id="sec5_15_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Cocrystal Structures</h3><div class="NLM_p last">c-MET cocrystals were obtained at 13 °C by the hanging drop vapor diffusion method by mixing 1.2 μL of protein solution (containing 7–13 mg/mL c-MET KD (residues 1051–1348) with a 5-fold molar excess of selected c-MET inhibitor) with 1.2 μL of solution containing 0.05 M citrate-phosphate pH 4.6, 0–0.275 M NaCl, and 21% polyethylene glycol MW = 3350. Details of the crystal structure determinations can be accessed from the PDB database.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75"><a href="/doi/suppl/10.1021/jm300967g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Kinase selectivity screening data for <b>12</b> against a total of 98 protein kinases. This material is available free of charge via the internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300967g/suppl_file/jm300967g_si_001.pdf">jm300967g_si_001.pdf (170.3 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates of the c-MET crystal structures have been deposited in the Protein Data Bank for compounds <b>2</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>), <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze">3zze</a>), <b>12</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ap7">4ap7</a>), and <b>24</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4aoi">4aoi</a>).</p><div class="testing" data-doi="10.1021/jm300967g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97fdf2f6f9b9f4e2fed7e7f1feedf2e5b9f4f8fa"><span class="__cf_email__" data-cfemail="264c4347480845534f6656404f5c43540845494b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele McTigue</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitchell Nambu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Tran-Dubé</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mason Pairish</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Jia</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengmiao Cheng</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacqui Hoffman</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phuong Le</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mehran Jalaie</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gilles H. Goetz</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Ryan</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Grodsky</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-li Deng</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Max Parker</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sergei Timofeevski</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brion W. Murray</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shinji Yamazaki</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shirley Aguirre</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuhua Li</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Zou</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Christensen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer
Worldwide
Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1592e4794-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Muhammad Alimuddin for analytical support, to the Pfizer PDM department for <i>in vitro</i> ADME and <i>in vivo</i> pharmacokinetic studies, and to the Pfizer DSRD department for <i>in vitro</i> exploratory toxicity studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> Abbreviations</h2><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">c-MET</td><td class="NLM_def"><p class="first last">mesenchymal-epithelial transition factor</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccaccio, C.</span><span> </span><span class="NLM_article-title">Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1006%2Fexcr.1999.4684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=10579914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADyaK1MXnsF2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1999&pages=88-99&author=P.+M.+Comoglioauthor=L.+Tamagnoneauthor=C.+Boccaccio&title=Plasminogen-related+growth+factor+and+semaphorin+receptors%3A+a+gene+superfamily+controlling+invasive+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen-Related Growth Factor and Semaphorin Receptors: A Gene Superfamily Controlling Invasive Growth</span></div><div class="casAuthors">Comoglio, Paolo M.; Tamagnone, Luca; Boccaccio, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review, with 131 refs.  Plasminogen-related growth factors (PRGFs), also known as "scatter factors", trigger a unique biol. program leading to "invasive growth".  This is a result of the integration of apparently independent biol. responses including cell proliferation, cell survival, cell motility, invasion of extracellular matrixes, and induction of cell polarity.  Under physiol. conditions, the coordinated execution of the underlying genetic programs leads to the formation of tubular structures by epithelial organs (the so-called branching morphogenesis).  PRGF receptors are tyrosine kinases, encoded by a family of oncogenes: MET and RON.  They feature unique signal transduction properties as their cytoplasmic tails contain a two-tyrosine multifunctional docking site that binds multiple SH2-contg. intracellular signal transducers.  Invasive growth results from the concomitant activation of Ras (growth), phosphatidylinositol 3-kinase ("scattering"), and signal transducer and activator of transcription (cell polarity and morphogenesis).  We recently identified a new human gene family, encoding large transmembrane proteins, sex/plexins, sharing homologies with Met.  These mols. are receptors for semaphorins, involved in axon guidance and cell-cell repulsion, a process reminiscent of scattering and invasive growth.  Deregulated activation of PRGF or semaphorin ligands or receptors, by mutation or overexpression, confers to cancer cells invasive and metastatic properties.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoexoQs4NR1hrVg90H21EOLACvtfcHk0lhudljQp7gwzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnsF2it74%253D&md5=c177cf4d120afa68c3c9e108306b4a14</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1999.4684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1999.4684%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DBoccaccio%26aufirst%3DC.%26atitle%3DPlasminogen-related%2520growth%2520factor%2520and%2520semaphorin%2520receptors%253A%2520a%2520gene%2520superfamily%2520controlling%2520invasive%2520growth%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1999%26volume%3D253%26spage%3D88%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Invasive growth: from development to metastasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=857-862&author=P.+M.+Comoglioauthor=L.+Trusolino&title=Invasive+growth%3A+from+development+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInvasive%2520growth%253A%2520from%2520development%2520to%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D857%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0lhh8phDFbVW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET: structure, functions and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-MET%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0lhh8phDFbVW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET as a target in human cancer and characterization of inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Cancer Lett. (Amsterdam, Neth.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">225</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2Fj.canlet.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=15922853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2005&pages=1-26&author=J.+Christensenauthor=J.+Burrowsauthor=R.+Salgia&title=c-MET+as+a+target+in+human+cancer+and+characterization+of+inhibitors+for+therapeutic+intervention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention</span></div><div class="casAuthors">Christensen, James G.; Burrows, Jon; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, Imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.  A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clin. setting.  The proto-oncogene, c-Met, encodes the high-affinity receptor for hepatocyte growth factor (HGF) or scatter factor (SF).  C-Met and HGF are each required for normal mammalian development and have been shown to be particularly important in cell migration, morphogenic differentiation, and organization of three-dimensional tubular structures (e.g. renal tubular cells, gland formation, etc.) as well as cell growth and angiogenesis.  Both c-Met and HGF have been shown to be deregulated in and to correlate with poor prognosis in a no. of major human cancers.  New data describing the constitutive phosphorylation of c-Met in a no. of human tumors is presented here along with a variety of mechanisms by which c-Met can become activated, including mutation and gene amplification.  In support of the clin. data implicating c-Met activation in the pathogenesis of human cancers, introduction of c-Met and HGF (or mutant c-Met) into cells conferred the properties of motility, invasiveness, and tumorigenicity to the transformed cells.  Conversely, the inhibition of c-Met with a variety of receptor antagonists inhibited the motility, invasiveness, and tumorigenicity of human tumor cell lines.  Consistent with this observation, small-mol. inhibitors of c-Met were developed that antagonized c-Met/HGF-dependent phenotypes and tumor growth in mouse models.  This review will address the potential for development of c-Met inhibitors for treatment of human cancers with particular emphasis on recent findings with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTbSn0ouMILVg90H21EOLACvtfcHk0lhh8phDFbVW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D&md5=106b145cbf442e9fec9667817697658d</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%2520as%2520a%2520target%2520in%2520human%2520cancer%2520and%2520characterization%2520of%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DCancer%2520Lett.%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D2005%26volume%3D225%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The met receptor tyrosine kinase in invasion and metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+met+receptor+tyrosine+kinase+in+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0lgEkOkQeedmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520met%2520receptor%2520tyrosine%2520kinase%2520in%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lgEkOkQeedmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1200%2FJCO.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.-L.+Chengauthor=B.+Trinkauthor=T.-S.+Tzaiauthor=H.-S.+Liuauthor=S.-H.+Chanauthor=C.-L.+Hoauthor=D.+Sidranskyauthor=N.-H.+Chow&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0lgEkOkQeedmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DChan%26aufirst%3DS.-H.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lengyel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resau, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harneck, N.</span><span> </span><span class="NLM_article-title">c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1002%2Fijc.20598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=15455388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Km" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=678-682&author=E.+Lengyelauthor=D.+Prechtelauthor=J.+H.+Resauauthor=K.+Gaugerauthor=A.+Welkauthor=K.+Lindemannauthor=G.+Alantiauthor=T.+Richterauthor=B.+Knudsenauthor=G.+F.+Vande+Woudeauthor=N.+Harneck&title=c-MET+overexpression+in+node-positive+breast+cancer+identifies+patients+with+poor+clinical+outcome+independent+of+Her2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span></div><div class="casAuthors">Lengyel, Ernst; Prechtel, Dieter; Resau, James H.; Gauger, Katja; Welk, Anita; Lindemann, Kristina; Salanti, Georgia; Richter, Thomas; Knudsen, Beatrice; Vande Woude, George F.; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-682</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis.  In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochem. and confocal immunofluorescence.  Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade.  Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression.  Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addn. to Her2/neu.  Median disease-free survival in patients with c-Met overexpressing tumors was 8 mo compared to 53 mo when c-Met expression was low (p = 0.037; RR = 3.0).  This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate anal.  In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further anal. in a larger cohort of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-vk_XMTZ6LVg90H21EOLACvtfcHk0lhEhyZUgsxwHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Km&md5=d1d709a602edbff17ee9240e05cb8412</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1002%2Fijc.20598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20598%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DE.%26aulast%3DPrechtel%26aufirst%3DD.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DGauger%26aufirst%3DK.%26aulast%3DWelk%26aufirst%3DA.%26aulast%3DLindemann%26aufirst%3DK.%26aulast%3DAlanti%26aufirst%3DG.%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DHarneck%26aufirst%3DN.%26atitle%3Dc-MET%2520overexpression%2520in%2520node-positive%2520breast%2520cancer%2520identifies%2520patients%2520with%2520poor%2520clinical%2520outcome%2520independent%2520of%2520Her2%252Fneu%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D113%26spage%3D678%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lo Muzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coccia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capogreco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campisi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carinci, F.</span><span> </span><span class="NLM_article-title">Effect of c-MET expression on survival in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1159%2F000092716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=116-121&author=L.+Lo+Muzioauthor=A.+Farinaauthor=C.+Rubiniauthor=E.+Cocciaauthor=M.+Capogrecoauthor=G.+Colellaauthor=R.+Leonardiauthor=G.+Campisiauthor=F.+Carinci&title=Effect+of+c-MET+expression+on+survival+in+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1159%2F000092716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000092716%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26aulast%3DFarina%26aufirst%3DA.%26aulast%3DRubini%26aufirst%3DC.%26aulast%3DCoccia%26aufirst%3DE.%26aulast%3DCapogreco%26aufirst%3DM.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DLeonardi%26aufirst%3DR.%26aulast%3DCampisi%26aufirst%3DG.%26aulast%3DCarinci%26aufirst%3DF.%26atitle%3DEffect%2520of%2520c-MET%2520expression%2520on%2520survival%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2006%26volume%3D27%26spage%3D116%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radjabi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kistner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkyilmaz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">–</span> <span class="NLM_lpage">1679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1670-1679&author=K.+Sawadaauthor=A.+E.+Radjabiauthor=N.+Shinomiyaauthor=E.+Kistnerauthor=H.+Kennyauthor=A.+R.+Beckerauthor=M.+A.+Turkyilmazauthor=R.+Salgiaauthor=S.+D.+Yamadaauthor=G.+F.+Vande+Woudeauthor=M.+S.+Tretiakovaauthor=E.+Lengyel&title=c-MET+overexpression+is+a+prognostic+factor+in+ovarian+cancer+and+an+effective+target+for+inhibition+of+peritoneal+dissemination+and+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DRadjabi%26aufirst%3DA.%2BE.%26aulast%3DShinomiya%26aufirst%3DN.%26aulast%3DKistner%26aufirst%3DE.%26aulast%3DKenny%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DA.%2BR.%26aulast%3DTurkyilmaz%26aufirst%3DM.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3Dc-MET%2520overexpression%2520is%2520a%2520prognostic%2520factor%2520in%2520ovarian%2520cancer%2520and%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520peritoneal%2520dissemination%2520and%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1670%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Drebber, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollschweiler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienes, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hölscher, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mönig, S. P.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=18497953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1477-1483&author=U.+Drebberauthor=S.+E.+Baldusauthor=B.+Noldenauthor=G.+Grassauthor=E.+Bollschweilerauthor=H.+P.+Dienesauthor=A.+H.+H%C3%B6lscherauthor=S.+P.+M%C3%B6nig&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+gastric+carcinoma+compared+to+p53+and+p21+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3e</span><div class="casTitle"><span class="NLM_cas:atitle">The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span></div><div class="casAuthors">Drebber Uta; Baldus Stephan E; Nolden Britt; Grass Guido; Bollschweiler Elfriede; Dienes Hans P; Holscher Arnulf H; Monig Stefan P</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-83</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas.  We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy.  Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Lauren, Ming and Goseki classifications.  Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21.  The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters.  The c-met staining pattern was positive in 73.7%.  P53 and p21 were positive in 86.8 and 67.5%, respectively.  No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen.  A significant increase of p53 expression was observed in stage pT3 and -4.  The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis.  In the multivariate analysis this impact was maintained for c-met.  P21 proved to be a significant prognostic factor in the multivariate analysis.  Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcwNSw0zEj49-cVm4E2RlLfW6udTcc2eaNjGbf2p_3kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D&md5=5f503921226de1902468d1526a7322e7</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrebber%26aufirst%3DU.%26aulast%3DBaldus%26aufirst%3DS.%2BE.%26aulast%3DNolden%26aufirst%3DB.%26aulast%3DGrass%26aufirst%3DG.%26aulast%3DBollschweiler%26aufirst%3DE.%26aulast%3DDienes%26aufirst%3DH.%2BP.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DA.%2BH.%26aulast%3DM%25C3%25B6nig%26aufirst%3DS.%2BP.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520gastric%2520carcinoma%2520compared%2520to%2520p53%2520and%2520p21%2520nuclear%2520accumulation%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D1477%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Mechanism and significance of bifunctional NK4 in cancer treatment</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2005&pages=316-327&author=K.+Matsumotoauthor=T.+Nakamura&title=Mechanism+and+significance+of+bifunctional+NK4+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DMechanism%2520and%2520significance%2520of%2520bifunctional%2520NK4%2520in%2520cancer%2520treatment%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2005%26volume%3D333%26spage%3D316%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Otsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubczak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breckenridge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larochelle, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, G.</span><span> </span><span class="NLM_article-title">Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2055</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1128%2FMCB.20.6.2055-2065.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=10688652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVKmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2055-2065&author=T.+Otsukaauthor=J.+Jakubczakauthor=W.+Vieiraauthor=D.+P.+Bottaroauthor=D.+Breckenridgeauthor=W.+J.+Larochelleauthor=G.+Merlino&title=Disassociation+of+met-mediated+biological+responses+in+vivo%3A+the+natural+hepatocyte+growth+factor%2Fscatter+factor+splice+variant+NK2+antagonizes+growth+but+facilitates+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis</span></div><div class="casAuthors">Otsuka, Toshiyuki; Jakubczak, John; Vieira, Wilfred; Bottaro, Donald P.; Breckenridge, Diane; Larochelle, William J.; Merlino, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2055-2065</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) stimulates numerous cellular activities capable of contributing to the metastatic phenotype, including growth, motility, invasiveness, and morphogenetic transformation.  When inappropriately expressed in vivo, an HGF/SF transgene induces numerous hyperplastic and neoplastic lesions.  NK1 and NK2 are natural splice variants of HGF/SF; all interact with a common receptor, Met.  Although both agonistic and antagonistic properties have been ascribed to each isoform in vitro, NK1 retains the full spectrum of HGF/SF-like activities when expressed as a transgene in vivo.  Here the authors report that transgenic mice broadly expressing NK2 exhibit none of the phenotypes characteristic of HGF/SF or NK1 transgenic mice.  Instead, when coexpressed in NK2-HGF/SF bitransgenic mice, NK2 antagonizes the pathol. consequences of HGF/SF and discourages the s.c. growth of transplanted Met-contg. melanoma cells.  Remarkably, the metastatic efficiency of these same melanoma cells is dramatically enhanced in NK2 transgenic host mice relative to wild-type recipients, rivaling levels achieved in HGF/SF and NK1 transgenic hosts.  Considered in conjunction with reports that in vitro NK2 induces scatter, but not other activities, these data strongly suggest that cellular motility is a crit. determinant of metastasis.  Moreover, the authors' results demonstrate how alternatively structured ligands can be exploited in vivo to functionally dissoc. Met-mediated activities and their downstream pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp01dLjR6oTS7Vg90H21EOLACvtfcHk0lhCkNvHE_uDug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVKmsb0%253D&md5=9313466d62905b39955631301907861d</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.6.2055-2065.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.6.2055-2065.2000%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DT.%26aulast%3DJakubczak%26aufirst%3DJ.%26aulast%3DVieira%26aufirst%3DW.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DBreckenridge%26aufirst%3DD.%26aulast%3DLarochelle%26aufirst%3DW.%2BJ.%26aulast%3DMerlino%26aufirst%3DG.%26atitle%3DDisassociation%2520of%2520met-mediated%2520biological%2520responses%2520in%2520vivo%253A%2520the%2520natural%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520splice%2520variant%2520NK2%2520antagonizes%2520growth%2520but%2520facilitates%2520metastasis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2055%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Matsumoto, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor and Met in tumor biology and therapeutic applications with NK4</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3360</span><span class="NLM_x">–</span> <span class="NLM_lpage">3370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=3360-3370&author=K+Matsumotoauthor=T.+Nakamuraauthor=K.+Sakaiauthor=T.+Nakamura&title=Hepatocyte+growth+factor+and+Met+in+tumor+biology+and+therapeutic+applications+with+NK4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DHepatocyte%2520growth%2520factor%2520and%2520Met%2520in%2520tumor%2520biology%2520and%2520therapeutic%2520applications%2520with%2520NK4%26jtitle%3DProteomics%26date%3D2008%26volume%3D8%26spage%3D3360%26epage%3D3370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Burgess, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, X.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1721-1729&author=T.+Burgessauthor=A.+Coxonauthor=S.+Meyerauthor=J.+Sunauthor=K.+Rexauthor=T.+Tsurudaauthor=Q.+Chenauthor=S.-Y.+Hoauthor=L.+Liauthor=S.+Kaufmanauthor=K.+McDormanauthor=R.+C.+Cattleyauthor=J.+Sunauthor=G.+Elliottauthor=K.+Zhangauthor=X.+Fengauthor=X.-C.+Jiaauthor=L.+Greenauthor=R.+Radinskyauthor=R.+Kendall&title=Fully+human+monoclonal+antibodies+to+hepatocyte+growth+factor+with+therapeutic+potential+against+hepatocyte+growth+factor%2Fc-Met-dependent+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DHo%26aufirst%3DS.-Y.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DCattley%26aufirst%3DR.%2BC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DX.-C.%26aulast%3DGreen%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DFully%2520human%2520monoclonal%2520antibodies%2520to%2520hepatocyte%2520growth%2520factor%2520with%2520therapeutic%2520potential%2520against%2520hepatocyte%2520growth%2520factor%252Fc-Met-dependent%2520human%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1721%26epage%3D1729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Reslan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span> </span><span class="NLM_article-title">MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4360</span><span class="NLM_x">–</span> <span class="NLM_lpage">4368</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4360-4368&author=H.+Jinauthor=R.+Yangauthor=Z.+Zhengauthor=M.+Romeroauthor=J.+Rossauthor=H.+Bou-Reslanauthor=R.+A.D.+Caranoauthor=I.+Kasmanauthor=E.+Maiauthor=J.+Youngauthor=J.+Zhaauthor=Z.+Zhangauthor=S.+Rossauthor=R.+Schwallauthor=G.+Colbernauthor=M.+Merchant&title=MetMAb%2C+the+one-armed+5D5+anti-c-Met+antibody%2C+inhibits+orthotopic+pancreatic+tumor+growth+and+improves+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DRomero%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DBou-Reslan%26aufirst%3DH.%26aulast%3DCarano%26aufirst%3DR.%2BA.D.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSchwall%26aufirst%3DR.%26aulast%3DColbern%26aufirst%3DG.%26aulast%3DMerchant%26aufirst%3DM.%26atitle%3DMetMAb%252C%2520the%2520one-armed%25205D5%2520anti-c-Met%2520antibody%252C%2520inhibits%2520orthotopic%2520pancreatic%2520tumor%2520growth%2520and%2520improves%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4360%26epage%3D4368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van der Horst, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velilla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madrona, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, A. K.</span><span> </span><span class="NLM_article-title">Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models <i>in vivo</i></span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=355-364&author=E.+H.+van+der+Horstauthor=L.+Chinnauthor=M.+Wangauthor=T.+Velillaauthor=H.+Tranauthor=Y.+Madronaauthor=A.+Lamauthor=M.+Jiauthor=T.+C.+Hoeyauthor=A.+K.+Sato&title=Discovery+of+fully+human+anti-MET+monoclonal+antibodies+with+antitumor+activity+against+colon+cancer+tumor+models+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DE.%2BH.%26aulast%3DChinn%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DVelilla%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DMadrona%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DHoey%26aufirst%3DT.%2BC.%26aulast%3DSato%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%2520fully%2520human%2520anti-MET%2520monoclonal%2520antibodies%2520with%2520antitumor%2520activity%2520against%2520colon%2520cancer%2520tumor%2520models%2520in%2520vivo%26jtitle%3DNeoplasia%26date%3D2009%26volume%3D11%26spage%3D355%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">Development of c-MET pathway inhibitors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1225</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1225-1241&author=X.+Liuauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=Development+of+c-MET+pathway+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520c-MET%2520pathway%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1225%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">Novel antibody, rilotumumab (AMG 102) shows activity in metastatic colorectal cancer patients</span> <span class="citation_source-journal">Oncology Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=22-23&author=R.+S.+Tuma&title=Novel+antibody%2C+rilotumumab+%28AMG+102%29+shows+activity+in+metastatic+colorectal+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DNovel%2520antibody%252C%2520rilotumumab%2520%2528AMG%2520102%2529%2520shows%2520activity%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%26jtitle%3DOncology%2520Times%26date%3D2011%26volume%3D33%26spage%3D22%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Catenacci, D. V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=573-579&author=D.+V.+T.+Catenacciauthor=L.+Hendersonauthor=S.-Y.+Xiaoauthor=P.+Patelauthor=R.+L.+Yauchauthor=P.+Hegdeauthor=J.+Zhaauthor=A.+Panditaauthor=A.+Petersonauthor=R.+Salgia&title=Durable+complete+response+of+metastatic+gastric+cancer+with+anti-Met+therapy+followed+by+resistance+at+recurrence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%2BT.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DS.-Y.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDurable%2520complete%2520response%2520of%2520metastatic%2520gastric%2520cancer%2520with%2520anti-Met%2520therapy%2520followed%2520by%2520resistance%2520at%2520recurrence%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D573%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Surati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1517%2F14712598.2011.626762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22047509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1655-1662&author=M.+Suratiauthor=P.+Patelauthor=A.+Petersonauthor=R.+Salgia&title=Role+of+MetMAb+%28OA-5D5%29+in+c-MET+active+lung+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span></div><div class="casAuthors">Surati, Mosmi; Patel, Premal; Peterson, Amy; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase.  Though only in early clin. testing, this agent holds great promise in diseases thought to be driven by c-MET activation, as evidenced by the Phase II results in NSCLC where a benefit in overall survival was obsd. in patients with MET-diagnostic-pos. disease.  Thus far, both alone and in combination with other targeted agents, this drug has been well tolerated and no new significant safety signals have been identified.  Areas covered: This review summarizes the structure and function of the c-MET receptor and its ligand hepatic growth factor (HGF), provides an overview of select targeted monotherapies developed to interfere in the MET-HGF signaling pathway, discusses pre-clin. and clin. data surrounding MetMAb, and concludes with an expert opinion regarding this novel agent.  Expert opinion: MetMAb has been well tolerated and based on Phase II data testing it, in combination with erlotinib in advanced NSCLC, may have a role in improving survival in patients with disease driven by c-MET activation.  However, Phase III validation is underway and the results of these studies will help elucidate which patients will benefit most from this novel agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNaynTSW2ErVg90H21EOLACvtfcHk0lhJY0TNYsWxFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN&md5=78a25ac9a8b03aa9e3113776d40854e2</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.626762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.626762%26sid%3Dliteratum%253Aachs%26aulast%3DSurati%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520MetMAb%2520%2528OA-5D5%2529%2520in%2520c-MET%2520active%2520lung%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 7505.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Spigel%2C+D.+R.%3B+Ervin%2C+T.+J.%3B+Ramlau%2C+R.%3B+Daniel%2C+D.+B.%3B+Goldschmidt%2C+J.+H.%3B+Blumenschein%2C+G.+R.%3B+Krzakowski%2C+M.+J.%3B+Robinet%2C+G.%3B+Clement-Duchene%2C+C.%3B+Barlesi%2C+F.%3B+Govindan%2C+R.%3B+Patel%2C+T.%3B+Orlov%2C+S.+V.%3B+Wertheim%2C+M.+S.%3B+Zha%2C+J.%3B+Pandita%2C+A.%3B+Yu%2C+W.%3B+Yauch%2C+R.+L.%3B+Patel%2C+P.+H.%3B+Peterson%2C+A.+C.+Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+7505."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mroczkowski, B.; McTigue, M. A..; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu., J.</span><span> </span><span class="NLM_article-title">Catalytic domains of the human hepatocyte growth factor receptor kinase and material and methods for identification thereof</span>. USP 277968, EP1243596A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Mroczkowski&author=M.+A..+McTigue&author=J.+Sarup&author=B.+W.+Murray&author=M.+Hickey&author=H.+Parge&author=J.+Zhu.&title=Catalytic+domains+of+the+human+hepatocyte+growth+factor+receptor+kinase+and+material+and+methods+for+identification+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMroczkowski%26aufirst%3DB.%26atitle%3DCatalytic%2520domains%2520of%2520the%2520human%2520hepatocyte%2520growth%2520factor%2520receptor%2520kinase%2520and%2520material%2520and%2520methods%2520for%2520identification%2520thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0lhtQU-k2UWNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Tracy+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DTracy%2BLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Srinivasan, R.; Choueiri, T. K.; Vaishampayan, U.; Rosenberg, J. E.; Stein, M. N.; Logan, T.; Bukowski, R. M.; Mueller, T.; Keer, H. N.; Linehan, W. M.</span><span> </span><span class="NLM_article-title">A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)</span>. Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30–June 3, 2008; Abstr. 5103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Srinivasan%2C+R.%3B+Choueiri%2C+T.+K.%3B+Vaishampayan%2C+U.%3B+Rosenberg%2C+J.+E.%3B+Stein%2C+M.+N.%3B+Logan%2C+T.%3B+Bukowski%2C+R.+M.%3B+Mueller%2C+T.%3B+Keer%2C+H.+N.%3B+Linehan%2C+W.+M.+A+phase+II+study+of+the+dual+MET%2FVEGFR2+inhibitor+XL880+in+patients+%28pts%29+with+papillary+renal+carcinoma+%28PRC%29.+Presented+at+ASCO+2008+Annual+Meeting%2C+Chicago%2C+IL%2C+May+30%E2%80%93June+3%2C+2008%3B+Abstr.+5103."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DR.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520dual%2520MET%252FVEGFR2%2520inhibitor%2520XL880%2520in%2520patients%2520%2528pts%2529%2520with%2520papillary%2520renal%2520carcinoma%2520%2528PRC%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Jhawer, M. P.; Kindler, H. L.; Wainberg, Z. A.; Hecht, J. R.; Kerr, R. O.; Ford, J. M.; Henderson, C.; Mueller, T.; Keer, H. N.; Shah, M. A.</span><span> </span><span class="NLM_article-title">Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study</span>. Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30–June 3, 2008; Abstr. 4572.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jhawer%2C+M.+P.%3B+Kindler%2C+H.+L.%3B+Wainberg%2C+Z.+A.%3B+Hecht%2C+J.+R.%3B+Kerr%2C+R.+O.%3B+Ford%2C+J.+M.%3B+Henderson%2C+C.%3B+Mueller%2C+T.%3B+Keer%2C+H.+N.%3B+Shah%2C+M.+A.+Preliminary+activity+of+XL880%2C+a+dual+MET%2FVEGFR2+inhibitor%2C+in+MET+amplified+poorly+differentiated+gastric+cancer+%28PDGC%29%3A+Interim+results+of+a+multicenter+phase+II+study.+Presented+at+ASCO+2008+Annual+Meeting%2C+Chicago%2C+IL%2C+May+30%E2%80%93June+3%2C+2008%3B+Abstr.+4572."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJhawer%26aufirst%3DM.%2BP.%26atitle%3DPreliminary%2520activity%2520of%2520XL880%252C%2520a%2520dual%2520MET%252FVEGFR2%2520inhibitor%252C%2520in%2520MET%2520amplified%2520poorly%2520differentiated%2520gastric%2520cancer%2520%2528PDGC%2529%253A%2520Interim%2520results%2520of%2520a%2520multicenter%2520phase%2520II%2520study" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span> </span><span class="NLM_article-title">Structural basis for selective small molecule kinase inhibition of activated c-Met</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">11218</span><span class="NLM_x">–</span> <span class="NLM_lpage">11225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=11218-11225&author=K.+W.+Rickertauthor=S.+B.+Patelauthor=T.+J.+Allisonauthor=N.+J.+Byrneauthor=P.+L.+Darkeauthor=R.+E.+Fordauthor=D.+J.+Guerinauthor=D.+L.+Hallauthor=M.+Kornienkoauthor=J.+Luauthor=S.+K.+Munshiauthor=J.+C.+Reidauthor=J.+M.+Shipmanauthor=E.+F.+Stantonauthor=K.+J.+Wilsonauthor=J.+R.+Youngauthor=S.+M.+Soissonauthor=K.+J.+Lumb&title=Structural+basis+for+selective+small+molecule+kinase+inhibition+of+activated+c-Met"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAllison%26aufirst%3DT.%2BJ.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DStanton%26aufirst%3DE.%2BF.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520selective%2520small%2520molecule%2520kinase%2520inhibition%2520of%2520activated%2520c-Met%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D11218%26epage%3D11225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgGo16k_7Cp7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell-lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.-J.+Bangauthor=R.+Camidgeauthor=A.+T.+Shawauthor=B+Solomonauthor=R.+G.+Makiauthor=S.-H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.-H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell-lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lgGo16k_7Cp7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DCamidge%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.-H.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell-lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eZ7h30dfJzYQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Chi, A. S.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T.</span><span> </span><span class="NLM_article-title">Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 2072.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chi%2C+A.+S.%3B+Kwak%2C+E.+L.%3B+Clark%2C+J.+W.%3B+Wang%2C+D.+L.%3B+Louis%2C+D.+N.%3B+Iafrate%2C+A.+J.%3B+Batchelor%2C+T.+Clinical+improvement+and+rapid+radiographic+regression+induced+by+a+MET+inhibitor+in+a+patient+with+MET-amplified+glioblastoma.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+2072."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26atitle%3DClinical%2520improvement%2520and%2520rapid%2520radiographic%2520regression%2520induced%2520by%2520a%2520MET%2520inhibitor%2520in%2520a%2520patient%2520with%2520MET-amplified%2520glioblastoma" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lennerz, J. K.; Kwak, E. L.; Michael, M.; Fox, S. B.; Ackerman, A.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y.; Clark, J. W.; Solomon, B. J.; Iafrate, A., J.</span><span> </span><span class="NLM_article-title">Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 4130.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lennerz%2C+J.+K.%3B+Kwak%2C+E.+L.%3B+Michael%2C+M.%3B+Fox%2C+S.+B.%3B+Ackerman%2C+A.%3B+Bergethon%2C+K.%3B+Lauwers%2C+G.+Y.%3B+Christensen%2C+J.+G.%3B+Wilner%2C+K.+D.%3B+Haber%2C+D.+A.%3B+Salgia%2C+R.%3B+Bang%2C+Y.%3B+Clark%2C+J.+W.%3B+Solomon%2C+B.+J.%3B+Iafrate%2C+A.%2C+J.+Identification+of+a+small+and+lethal+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib+by+MET+amplification.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+4130."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26atitle%3DIdentification%2520of%2520a%2520small%2520and%2520lethal%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%2520by%2520MET%2520amplification" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0liIbLHH5i7XQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garmey, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramlau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbachevsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span> </span><span class="NLM_article-title">Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3307</span><span class="NLM_x">–</span> <span class="NLM_lpage">3315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1200%2FJCO.2010.34.0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=21768463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3307-3315&author=L.+V.+Sequistauthor=J.+von+Pawelauthor=E.+G.+Garmeyauthor=W.+L.+Akerleyauthor=W.+Bruggerauthor=D.+Ferrariauthor=Y.+Chenauthor=D.+B.+Costaauthor=D.+E.+Gerberauthor=S.+Orlovauthor=R.+Ramlauauthor=S.+Arthurauthor=I.+Gorbachevskyauthor=B.+Schwartzauthor=J.+H.+Schiller&title=Randomized+phase+II+study+of+erlotinib+plus+tivantinib+versus+erlotinib+plus+placebo+in+previously+treated+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ramdomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; von Pawel, Joachim; Garmey, Edward G.; Akerley, Wallace L.; Brugger, Wolfram; Ferrari, Dora; Chen, Yinpu; Costa, Daniel B.; Gerber, David E.; Orlov, Sergey; Ramlau, Rodryg; Arthur, Susan; Gorbachevsky, Igor; Schwartz, Brian; Schiller, Joan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3307-3315</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: c-MET (MET) receptor activation is assocd. with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell lung cancer (NSCLC).  This global, randomized phase II trial examd. erlotinib plus tivantinib (ARQ 197; ArQule, Woburn, MA), a novel MET inhibitor.  Methods: Previously treated patients with EGFR TKI-naive advanced NSCLC were randomly assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or erlotinib plus placebo (EP).  The primary end point was progression-free survival (PFS).  At the time of progression, cross-over from EP to erlotinib plus tivantinib (ET) was permitted.  Archival tumor tissue specimens were required.  Results: One hundred sixty-seven patients were randomly assigned to ET (n = 84) and to EP (n = 83).  Median PFS was 3.8 mo for ET and 2.3 mo for EP (hazard ratio [HR], 0.81; 95% CI, 0.57 to 1.16; P = .24).  Exploratory anal. revealed that the small cohort with KRAS mutations achieved a PFS HR of 0.18 (95% CI, 0.05 to 0.70; interaction P = .006).  Objective responses were seen in 10% of patients on ET, 7% of patients on EP, and in two patients who crossed over from EP to ET, including one with EGFR mutation and MET gene copy no. greater than 5.  There were no significant differences in adverse events between study arms.  Conclusion: The combination of the MET inhibitor tivantinib and erlotinib is well-tolerated.  Although the study did not meet its primary end point, evidence of activity was demonstrated, esp. among patients with KRAS mutations.  Addnl. study of tivantinib and erlotinib in patients with NSCLC is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9Ba8OADqqrVg90H21EOLACvtfcHk0liIbLHH5i7XQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsrnL&md5=a74b99021191c96e18b79ba11ac5075c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.34.0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.34.0570%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGarmey%26aufirst%3DE.%2BG.%26aulast%3DAkerley%26aufirst%3DW.%2BL.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DArthur%26aufirst%3DS.%26aulast%3DGorbachevsky%26aufirst%3DI.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520erlotinib%2520plus%2520tivantinib%2520versus%2520erlotinib%2520plus%2520placebo%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3307%26epage%3D3315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span> </span><span class="NLM_article-title">Cho, Tang. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Wei&title=Cho%2C+Tang.+Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26atitle%3DCho%252C%2520Tang.%2520Discovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bramson, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corona, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gampe, R. T.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montana, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuyper, L. F.</span><span> </span><span class="NLM_article-title">Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and x-ray crystallographic analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4339</span><span class="NLM_x">–</span> <span class="NLM_lpage">4358</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010117d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4339-4358&author=H.+N.+Bramsonauthor=J.+Coronaauthor=S.+T.+Davisauthor=S.+H.+Dickersonauthor=M.+Edelsteinauthor=S.+V.+Fryeauthor=R.+T.+Gampeauthor=P.+A.+Harrisauthor=A.+Hassellauthor=W.+D.+Holmesauthor=R.+N.+Hunterauthor=K.+E.+Lackeyauthor=B.+Lovejoyauthor=M.+J.+Luzzioauthor=V.+Montanaauthor=W.+J.+Rocqueauthor=D.+Rusnakauthor=L.+Shewchukauthor=J.+M.+Vealauthor=D.+H.+Walkerauthor=L.+F.+Kuyper&title=Oxindole-based+inhibitors+of+cyclin-dependent+kinase+2+%28CDK2%29%3A+design%2C+synthesis%2C+enzymatic+activities%2C+and+x-ray+crystallographic+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span></div><div class="casAuthors">Bramson, H. Neal; Corona, John; Davis, Stephen T.; Dickerson, Scott H.; Edelstein, Mark; Frye, Stephen V.; Gampe, Robert T., Jr.; Harris, Phil A.; Hassell, Anne; Holmes, William D.; Hunter, Robert N.; Lackey, Karen E.; Lovejoy, Brett; Luzzio, Michael J.; Montana, Val; Rocque, Warren J.; Rusnak, David; Shewchuk, Lisa; Veal, James M.; Walker, Duncan H.; Kuyper, Lee F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4339-4358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related classes of oxindole-based compds., 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).  The initial lead compd. was prepd. as a homolog of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor.  Crystallog. anal. of the lead compd. bound to CDK2 provided the basis for analog design.  A semiautomated method of ligand docking was used to select compds. for synthesis, and a no. of compds. with low nanomolar inhibitory activity vs. CDK2 were identified.  Enzyme binding determinants for several analogs were evaluated by X-ray crystallog.  Compds. in this series inhibited CDK2 with a potency ∼10-fold greater than that for CDK1.  Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOmtXxUWKlrVg90H21EOLACvtfcHk0ljdK-xgXduBsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D&md5=d628549913ca46f9edf6b4692c82419d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm010117d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010117d%26sid%3Dliteratum%253Aachs%26aulast%3DBramson%26aufirst%3DH.%2BN.%26aulast%3DCorona%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DS.%2BT.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DLovejoy%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMontana%26aufirst%3DV.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DKuyper%26aufirst%3DL.%2BF.%26atitle%3DOxindole-based%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202%2520%2528CDK2%2529%253A%2520design%252C%2520synthesis%252C%2520enzymatic%2520activities%252C%2520and%2520x-ray%2520crystallographic%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4339%26epage%3D4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET kinase inhibits c-MET-dependent phenotypes <i>in vitro</i> and exhibits cytoreductive antimutor activity <i>in vivo</i></span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">–</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+c-MET+kinase+inhibits+c-MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%2520kinase%2520inhibits%2520c-MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm">2wkm</a> for the PHA-665752/c-MET complex.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone hydrazides as c-met inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+hydrazides+as+c-met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520hydrazides%2520as%2520c-met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic compounds as c-Met inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+compounds+as+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520compounds%2520as%2520c-Met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of triazolotriazines as c-Met modulators for treating cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+triazolotriazines+as+c-Met+modulators+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520triazolotriazines%2520as%2520c-Met%2520modulators%2520for%2520treating%2520cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl triazolo and imidazopyrazines as c-MET inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+triazolo+and+imidazopyrazines+as+c-MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520triazolo%2520and%2520imidazopyrazines%2520as%2520c-MET%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F1535-7163.MCT-11-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22389468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1036-1047&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=K.+Burgessauthor=M.+Qiuauthor=L.+Engstromauthor=S.+Yamazakiauthor=M.+Parkerauthor=S.+Timofeevskiauthor=J.+J.+Cuiauthor=M.+McTigueauthor=M.+G.+Losauthor=S.+Benderauthor=T.+Smealauthor=J.+G.+Christensen&title=Sensitivity+of+Selected+Human+Tumor+Models+to+PF-04217903%2C+a+Novel+Selective+c-Met+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; Burgess, Kristina; Qiu, Ming; Engstrom, Lars D.; Yamazaki, Shinji; Parker, Max; Timofeevski, Sergei; Cui, Jingrong Jean; McTigue, Michele; Los, Gerrit; Bender, Steven L.; Smeal, Tod; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1036-1047</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met pathway has been implicated in a variety of human cancers for its crit. role in tumor growth, invasion, and metastasis.  PF-04217903 is a novel ATP-competitive small-mol. inhibitor of c-Met kinase.  PF-04217903 showed more than 1,000-fold selectivity for c-Met compared with more than 150 kinases, making it one of the most selective c-Met inhibitors described to date.  PF-04217903 inhibited tumor cell proliferation, survival, migration/invasion in MET-amplified cell lines in vitro, and showed marked antitumor activity in tumor models harboring either MET gene amplification or a hepatocyte growth factor (HGF)/c-Met autocrine loop at well-tolerated dose levels in vivo.  Antitumor efficacy of PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and tumor cell proliferation/survival.  In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by PF-04217903 only led to partial tumor growth inhibition (38%-46%) in vivo.  The combination of PF-04217903 with Recepteur d'origine nantais (RON) short hairpin RNA (shRNA) knockdown in the HT29 model that also expresses activated RON kinase-induced tumor cell apoptosis and resulted in enhanced antitumor efficacy (77%) compared with either PF-04217903 (38%) or RON shRNA alone (56%).  PF-04217903 also showed potent antiangiogenic properties in vitro and in vivo.  Furthermore, PF-04217903 strongly induced phospho-PDGFRβ (platelet-derived growth factor receptor) levels in U87MG xenograft tumors, indicating a possible oncogene switching mechanism in tumor cell signaling as a potential resistance mechanism that might compromise tumor responses to c-Met inhibitors.  Collectively, these results show the use of highly selective inhibition of c-Met and provide insight toward targeting tumors exhibiting different mechanisms of c-Met dysregulation.  Mol Cancer Ther; 11(4); 1036-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrrZdx_x0SrVg90H21EOLACvtfcHk0ljvNmNCcKEEpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D&md5=bd5d2896768e7ae6a65b9c5e2ec3ce15</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0839%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DBurgess%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DEngstrom%26aufirst%3DL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DM.%2BG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DSensitivity%2520of%2520Selected%2520Human%2520Tumor%2520Models%2520to%2520PF-04217903%252C%2520a%2520Novel%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1036%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically-based pharmacokinetic modeling versus traditional one-compartment model</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=383-393&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=S.+Vekichauthor=H.+M.+Jonesauthor=W.+Tanauthor=K.+Wilnerauthor=T.+Koudriakova&title=Prediction+of+oral+pharmacokinetics+of+cMet+kinase+inhibitors+in+humans%3A+physiologically-based+pharmacokinetic+modeling+versus+traditional+one-compartment+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DVekich%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520oral%2520pharmacokinetics%2520of%2520cMet%2520kinase%2520inhibitors%2520in%2520humans%253A%2520physiologically-based%2520pharmacokinetic%2520modeling%2520versus%2520traditional%2520one-compartment%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D383%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Trust, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albright, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">N. A. Perkinson, N. A.</span><span> </span><span class="NLM_article-title">6- and 7-aryl-1,2,4-triazolo[4,3-<i>b</i>]-1,2,4-triazines. Synthesis and characterization</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1979&pages=1393-1403&author=R.+I.+Trustauthor=J.+D.+Albrightauthor=F.+M.+Lovellauthor=N.+A.+N.+A.+Perkinson&title=6-+and+7-aryl-1%2C2%2C4-triazolo%5B4%2C3-b%5D-1%2C2%2C4-triazines.+Synthesis+and+characterization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrust%26aufirst%3DR.%2BI.%26aulast%3DAlbright%26aufirst%3DJ.%2BD.%26aulast%3DLovell%26aufirst%3DF.%2BM.%26aulast%3DN.%2BA.%2BPerkinson%26aufirst%3DN.%2BA.%26atitle%3D6-%2520and%25207-aryl-1%252C2%252C4-triazolo%255B4%252C3-b%255D-1%252C2%252C4-triazines.%2520Synthesis%2520and%2520characterization%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1979%26volume%3D16%26spage%3D1393%26epage%3D1403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marusyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanessa Almendro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">Intra-tumour heterogeneity: a looking glass for cancer? </span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=323-334&author=A.+Marusykauthor=V.+Vanessa+Almendroauthor=K.+Polyak&title=Intra-tumour+heterogeneity%3A+a+looking+glass+for+cancer%3F+"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarusyk%26aufirst%3DA.%26aulast%3DVanessa%2BAlmendro%26aufirst%3DV.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DIntra-tumour%2520heterogeneity%253A%2520a%2520looking%2520glass%2520for%2520cancer%253F%2520%26jtitle%3DCancer%26date%3D2012%26volume%3D12%26spage%3D323%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Szerlipa, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazab, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravartyb, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuirec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fangd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollande, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hused, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanward, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levershac, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikkelseni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C. W.</span><span> </span><span class="NLM_article-title">Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3041-3046&author=N.+J.+Szerlipaauthor=A.+Pedrazabauthor=D.+Chakravartybauthor=M.+Azimcauthor=J.+McGuirecauthor=Y.+Fangdauthor=T.+Ozawaeauthor=E.+C.+Hollandeauthor=J.+T.+Husedauthor=S.+Jhanwardauthor=M.+A.+Levershacauthor=T.+Mikkelseniauthor=C.+W.+Brennan&title=Intratumoral+heterogeneity+of+receptor+tyrosine+kinases+EGFR+and+PDGFRA+amplification+in+glioblastoma+defines+subpopulations+with+distinct+growth+factor+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzerlipa%26aufirst%3DN.%2BJ.%26aulast%3DPedrazab%26aufirst%3DA.%26aulast%3DChakravartyb%26aufirst%3DD.%26aulast%3DAzimc%26aufirst%3DM.%26aulast%3DMcGuirec%26aufirst%3DJ.%26aulast%3DFangd%26aufirst%3DY.%26aulast%3DOzawae%26aufirst%3DT.%26aulast%3DHollande%26aufirst%3DE.%2BC.%26aulast%3DHused%26aufirst%3DJ.%2BT.%26aulast%3DJhanward%26aufirst%3DS.%26aulast%3DLevershac%26aufirst%3DM.%2BA.%26aulast%3DMikkelseni%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26atitle%3DIntratumoral%2520heterogeneity%2520of%2520receptor%2520tyrosine%2520kinases%2520EGFR%2520and%2520PDGFRA%2520amplification%2520in%2520glioblastoma%2520defines%2520subpopulations%2520with%2520distinct%2520growth%2520factor%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2012%26volume%3D109%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gerlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David Endesfelder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronroos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillimore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nohadani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eklund, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Dene, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szallasi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1056%2FNEJMoa1113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22397650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=883-892&author=M.+Gerlingerauthor=A.+J.+Rowanauthor=S.+Horswellauthor=J.+Larkinauthor=D.+David+Endesfelderauthor=E.+Gronroosauthor=P.+Martinezauthor=N.+Matthewsauthor=A.+Stewartauthor=P.+Tarpeyauthor=I.+Varelaauthor=B.+Phillimoreauthor=S.+Begumauthor=N.+Q.+McDonaldauthor=A.+Butlerauthor=D.+Jonesauthor=K.+Raineauthor=C.+Latimerauthor=C.+R.+Santosauthor=M.+Nohadaniauthor=A.+C.+Eklundauthor=B.+Spencer-Deneauthor=G+Clarkauthor=L.+Pickeringauthor=G.+Stampauthor=M.+Goreauthor=Z.+Szallasiauthor=J.+Downwardauthor=P.+A.+Futrealauthor=C.+Swanton&title=Intratumor+heterogeneity+and+branched+evolution+revealed+by+multiregion+sequencing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span></div><div class="casAuthors">Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Donward, Julian; Futreal, P. Andrew; Swanton, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.  Methods: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration anal., and ploidy profiling on multiple spatially sepd. samples obtained from primary renal carcinomas and assocd. metastatic sites.  We characterized the consequences of intratumor heterogeneity using immunohistochem. anal., mutation functional anal., and profiling of mRNA expression.  Results: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region.  Intratumor heterogeneity was obsd. for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro.  Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially sepd. inactivating mutations within a single tumor, suggesting convergent phenotypic evolution.  Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor.  Allelic compn. and ploidy profiling anal. revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors.  Conclusions: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.  Intratumor heterogeneity, assocd. with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5FKqZ_4ThTLVg90H21EOLACvtfcHk0ljnMDiQgxLKyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D&md5=2ab2e658d1218935e12cc934b09e1b95</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113205%26sid%3Dliteratum%253Aachs%26aulast%3DGerlinger%26aufirst%3DM.%26aulast%3DRowan%26aufirst%3DA.%2BJ.%26aulast%3DHorswell%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDavid%2BEndesfelder%26aufirst%3DD.%26aulast%3DGronroos%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DTarpey%26aufirst%3DP.%26aulast%3DVarela%26aufirst%3DI.%26aulast%3DPhillimore%26aufirst%3DB.%26aulast%3DBegum%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DButler%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DLatimer%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DNohadani%26aufirst%3DM.%26aulast%3DEklund%26aufirst%3DA.%2BC.%26aulast%3DSpencer-Dene%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DG%26aulast%3DPickering%26aufirst%3DL.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DSzallasi%26aufirst%3DZ.%26aulast%3DDownward%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DIntratumor%2520heterogeneity%2520and%2520branched%2520evolution%2520revealed%2520by%2520multiregion%2520sequencing%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D883%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatiana B. Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Tatiana+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lg7nP_t2fzzOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DTatiana%2BB.%2BKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e'],'ref3':['cit3a','cit3b','cit3c','cit3d','cit3e'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b','cit39c'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 67 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yu Zhou, Yan Fu, Wanchao Yin, Jian Li, Wei Wang, Fang Bai, Shengtao Xu, Qi Gong, Tao Peng, Yu Hong, Dong Zhang, Dan Zhang, Qiufeng Liu, Yechun Xu, H. Eric Xu, Haiyan Zhang, Hualiang Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 1844-1855. <a href="https://doi.org/10.1021/acs.jmedchem.0c01863" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01863%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinetics-Driven%252BDrug%252BDesign%252BStrategy%252Bfor%252BNext-Generation%252BAcetylcholinesterase%252BInhibitors%252Bto%252BClinical%252BCandidate%26aulast%3DZhou%26aufirst%3DYu%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27102020%26date%3D11022021%26volume%3D64%26issue%3D4%26spage%3D1844%26epage%3D1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Samy Mohamady, Mahmoud Galal, Wagdy M. Eldehna, David C. Gutierrez, Hany S. Ibrahim, Mohey M. Elmazar, <span class="NLM_string-name hlFld-ContribAuthor">Hamed I. Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (30)
                                     , 18872-18886. <a href="https://doi.org/10.1021/acsomega.0c02038" title="DOI URL">https://doi.org/10.1021/acsomega.0c02038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c02038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c02038%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDual%252BTargeting%252Bof%252BVEGFR2%252Band%252BC-Met%252BKinases%252Bvia%252Bthe%252BDesign%252Band%252BSynthesis%252Bof%252BSubstituted%252B3-%252528Triazolo-thiadiazin-3-yl%252529indolin-2-one%252BDerivatives%252Bas%252BAngiogenesis%252BInhibitors%26aulast%3DMohamady%26aufirst%3DSamy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D03072020%26date%3D24072020%26volume%3D5%26issue%3D30%26spage%3D18872%26epage%3D18886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nenad Manevski, Lloyd King, William R. Pitt, Fabien Lecomte, <span class="NLM_string-name hlFld-ContribAuthor">Francesca Toselli</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10955-10994. <a href="https://doi.org/10.1021/acs.jmedchem.9b00875" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00875%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolism%252Bby%252BAldehyde%252BOxidase%25253A%252BDrug%252BDesign%252Band%252BComplementary%252BApproaches%252Bto%252BChallenges%252Bin%252BDrug%252BDiscovery%26aulast%3DManevski%26aufirst%3DNenad%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30052019%26date%3D20082019%26date%3D06082019%26volume%3D62%26issue%3D24%26spage%3D10955%26epage%3D10994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhengsheng Zhan, Xia Peng, Yiming Sun, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2018,</strong> <em>31 </em>
                                    (11)
                                     , 1213-1218. <a href="https://doi.org/10.1021/acs.chemrestox.8b00191" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.8b00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.8b00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.8b00191%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DEvaluation%252Bof%252BDeuterium-Labeled%252BJNJ38877605%25253A%252BPharmacokinetic%25252C%252BMetabolic%25252C%252Band%252Bin%252BVivo%252BAntitumor%252BProfiles%26aulast%3DZhan%26aufirst%3DZhengsheng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18072018%26date%3D16102018%26date%3D04102018%26volume%3D31%26issue%3D11%26spage%3D1213%26epage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Dengyou  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Gao</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Chen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (5)
                                     , 507-512. <a href="https://doi.org/10.1021/ml5004876" title="DOI URL">https://doi.org/10.1021/ml5004876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml5004876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml5004876%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BImidazo%25255B1%25252C2-a%25255Dpyridine%252BDerivatives%252Bas%252BPotent%252Bc-Met%252BInhibitors%26aulast%3DLi%26aufirst%3DChunpu%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D25112014%26date%3D01032015%26date%3D03042015%26date%3D14052015%26date%3D02032015%26volume%3D6%26issue%3D5%26spage%3D507%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Jia</span>, <span class="hlFld-ContribAuthor ">Guangxiu  Dai</span>, <span class="hlFld-ContribAuthor ">Jianyang  Weng</span>, <span class="hlFld-ContribAuthor ">Zhulin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Longxian  Jiao</span>, <span class="hlFld-ContribAuthor ">Yumin  Cui</span>, <span class="hlFld-ContribAuthor ">Yongxin  Ren</span>, <span class="hlFld-ContribAuthor ">Shiming  Fan</span>, <span class="hlFld-ContribAuthor ">Jinghong  Zhou</span>, <span class="hlFld-ContribAuthor ">Weiguo  Qing</span>, <span class="hlFld-ContribAuthor ">Yi  Gu</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Sai</span>, and <span class="hlFld-ContribAuthor ">Weiguo  Su</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (18)
                                     , 7577-7589. <a href="https://doi.org/10.1021/jm500510f" title="DOI URL">https://doi.org/10.1021/jm500510f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500510f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500510f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-1-%2525281-%252528Imidazo%25255B1%25252C2-a%25255Dpyridin-6-yl%252529ethyl%252529-6-%2525281-methyl-1H-pyrazol-4-yl%252529-1H-%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-b%25255Dpyrazine%252B%252528Volitinib%252529%252Bas%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BMesenchymal%2525E2%252580%252593Epithelial%252BTransition%252BFactor%252B%252528c-Met%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%252Bfor%252BTreatment%252Bof%252BCancer%26aulast%3DJia%26aufirst%3DHong%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D31032014%26date%3D15092014%26date%3D25092014%26date%3D22082014%26volume%3D57%26issue%3D18%26spage%3D7577%26epage%3D7589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Jin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Huifang  Li</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Yaning  Hu</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, and <span class="hlFld-ContribAuthor ">Tao  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (9)
                                     , 2544-2554. <a href="https://doi.org/10.1021/ci500268s" title="DOI URL">https://doi.org/10.1021/ci500268s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500268s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500268s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMolecular%252BModeling%252Bof%252BExquisitely%252BSelective%252Bc-Met%252BInhibitors%252Bthrough%252B3D-QSAR%252Band%252BMolecular%252BDynamics%252BSimulations%26aulast%3DYuan%26aufirst%3DHaoliang%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D05052014%26date%3D09092014%26date%3D22092014%26date%3D02092014%26volume%3D54%26issue%3D9%26spage%3D2544%26epage%3D2554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4427-4453. <a href="https://doi.org/10.1021/jm401427c" title="DOI URL">https://doi.org/10.1021/jm401427c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401427c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BReceptor%252BTyrosine%252BKinase%252BMET%252Bin%252BCancer%25253A%252BSmall%252BMolecule%252BInhibitors%252Band%252BClinical%252BProgress%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D16092013%26date%3D18122013%26date%3D12062014%26date%3D09122013%26volume%3D57%26issue%3D11%26spage%3D4427%26epage%3D4453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Michelle  Tran-Dubé</span>, <span class="hlFld-ContribAuthor ">Mitchell  Nambu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Neil  Grodsky</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Shirley  Aguirre</span>, <span class="hlFld-ContribAuthor ">Max  Parker</span>, <span class="hlFld-ContribAuthor ">Qiuhua  Li</span>, <span class="hlFld-ContribAuthor ">Helen  Zou</span>, and <span class="hlFld-ContribAuthor ">James  Christensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 6651-6665. <a href="https://doi.org/10.1021/jm400926x" title="DOI URL">https://doi.org/10.1021/jm400926x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400926x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400926x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLessons%252Bfrom%252B%252528S%252529-6-%2525281-%2525286-%2525281-Methyl-1H-pyrazol-4-yl%252529-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-b%25255Dpyridazin-3-yl%252529ethyl%252529quinoline%252B%252528PF-04254644%252529%25252C%252Ban%252BInhibitor%252Bof%252BReceptor%252BTyrosine%252BKinase%252Bc-Met%252Bwith%252BHigh%252BProtein%252BKinase%252BSelectivity%252Bbut%252BBroad%252BPhosphodiesterase%252BFamily%252BInhibition%252BLeading%252Bto%252BMyocardial%252BDegeneration%252Bin%252BRats%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D20032013%26date%3D29082013%26date%3D12092013%26date%3D14082013%26volume%3D56%26issue%3D17%26spage%3D6651%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingrong  Li</span>, <span class="hlFld-ContribAuthor ">Nan  Wu</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Tian</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, and <span class="hlFld-ContribAuthor ">Shuguang  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Aminopyridyl/Pyrazinyl Spiro[indoline-3,4′-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (8)
                                     , 806-810. <a href="https://doi.org/10.1021/ml400203d" title="DOI URL">https://doi.org/10.1021/ml400203d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400203d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400203d%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAminopyridyl%25252FPyrazinyl%252BSpiro%25255Bindoline-3%25252C4%2525E2%252580%2525B2-piperidine%25255D-2-ones%252BAs%252BHighly%252BSelective%252Band%252BEfficacious%252Bc-Met%25252FALK%252BInhibitors%26aulast%3DLi%26aufirst%3DJingrong%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D24052013%26date%3D12072013%26date%3D16072013%26date%3D08082013%26date%3D12072013%26volume%3D4%26issue%3D8%26spage%3D806%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan B.  Northrup</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Katcher</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Melissa  Chenard</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Daniels</span>, <span class="hlFld-ContribAuthor ">Sujal V.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Danielle  Falcone</span>, <span class="hlFld-ContribAuthor ">David J.  Guerin</span>, <span class="hlFld-ContribAuthor ">Harold  Hatch</span>, <span class="hlFld-ContribAuthor ">Chaomin  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>, <span class="hlFld-ContribAuthor ">Bart  Lutterbach</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Allison</span>, <span class="hlFld-ContribAuthor ">Sangita B.  Patel</span>, <span class="hlFld-ContribAuthor ">John F.  Reilly</span>, <span class="hlFld-ContribAuthor ">Michael  Reutershan</span>, <span class="hlFld-ContribAuthor ">Keith W.  Rickert</span>, <span class="hlFld-ContribAuthor ">Craig  Rosenstein</span>, <span class="hlFld-ContribAuthor ">Stephen M.  Soisson</span>, <span class="hlFld-ContribAuthor ">Alexander A.  Szewczak</span>, <span class="hlFld-ContribAuthor ">Deborah  Walker</span>, <span class="hlFld-ContribAuthor ">Kevin  Wilson</span>, <span class="hlFld-ContribAuthor ">Jonathan R.  Young</span>, <span class="hlFld-ContribAuthor ">Bo-Sheng  Pan</span>, and <span class="hlFld-ContribAuthor ">Christopher J.  Dinsmore</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (6)
                                     , 2294-2310. <a href="https://doi.org/10.1021/jm301619u" title="DOI URL">https://doi.org/10.1021/jm301619u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301619u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301619u%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25255B3-%2525281-Methyl-1H-pyrazol-4-yl%252529-5-oxo-5H-benzo%25255B4%25252C5%25255Dcyclohepta%25255B1%25252C2-b%25255Dpyridin-7-yl%25255D-N-%252528pyridin-2-ylmethyl%252529methanesulfonamide%252B%252528MK-8033%252529%25253A%252BA%252BSpecific%252Bc-Met%25252FRon%252BDual%252BKinase%252BInhibitor%252Bwith%252BPreferential%252BAffinity%252Bfor%252Bthe%252BActivated%252BState%252Bof%252Bc-Met%26aulast%3DNorthrup%26aufirst%3DAlan%2BB.%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D02112012%26date%3D18032013%26date%3D28032013%26date%3D04022013%26volume%3D56%26issue%3D6%26spage%3D2294%26epage%3D2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vrushabendra  Basavanna</span>, <span class="hlFld-ContribAuthor ">Srikantamurthy  Ningaiah</span>, <span class="hlFld-ContribAuthor ">Manasa  Chandramouli</span>, <span class="hlFld-ContribAuthor ">Anjali  Sobha</span>, <span class="hlFld-ContribAuthor ">Shridevi  Doddamani</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolinyl-pyrazoles: synthesis and pharmacological evolution in the recent decennial. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Iranian Chemical Society</span><span> <strong>2021,</strong> <em>18 </em>
                                    (7)
                                     , 1479-1522. <a href="https://doi.org/10.1007/s13738-020-02152-1" title="DOI URL">https://doi.org/10.1007/s13738-020-02152-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13738-020-02152-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13738-020-02152-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Iranian%2520Chemical%2520Society%26atitle%3DQuinolinyl-pyrazoles%25253A%252Bsynthesis%252Band%252Bpharmacological%252Bevolution%252Bin%252Bthe%252Brecent%252Bdecennial%26aulast%3DBasavanna%26aufirst%3DVrushabendra%26date%3D2021%26date%3D2021%26volume%3D18%26issue%3D7%26spage%3D1479%26epage%3D1522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Guo</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yitong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of triazolotriazine derivatives as c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (2)
                                     , 839-846. <a href="https://doi.org/10.1007/s11030-020-10067-5" title="DOI URL">https://doi.org/10.1007/s11030-020-10067-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10067-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10067-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Btriazolotriazine%252Bderivatives%252Bas%252Bc-Met%252Binhibitors%26aulast%3DGuo%26aufirst%3DYuting%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalini</span>, <span class="hlFld-ContribAuthor ">Vipan  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 335-363. <a href="https://doi.org/10.1080/17460441.2021.1850686" title="DOI URL">https://doi.org/10.1080/17460441.2021.1850686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1850686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1850686%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DHave%252Bmolecular%252Bhybrids%252Bdelivered%252Beffective%252Banti-cancer%252Btreatments%252Band%252Bwhat%252Bshould%252Bfuture%252Bdrug%252Bdiscovery%252Bfocus%252Bon%25253F%26aulast%3DShalini%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D335%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatemeh  Moosavi</span>, <span class="hlFld-ContribAuthor ">Ahmad  Ebadi</span>, <span class="hlFld-ContribAuthor ">Maryam  Mohabbati</span>, <span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Motahareh  Mortazavi</span>, <span class="hlFld-ContribAuthor ">Ramin  Miri</span>, <span class="hlFld-ContribAuthor ">Omidreza  Firuzi</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>894 </em>, 173850. <a href="https://doi.org/10.1016/j.ejphar.2021.173850" title="DOI URL">https://doi.org/10.1016/j.ejphar.2021.173850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2021.173850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2021.173850%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DAntiproliferative%252Beffect%25252C%252Balteration%252Bof%252Bcancer%252Bcell%252Bcycle%252Bprogression%252Band%252Bpotential%252BMET%252Bkinase%252Binhibition%252Binduced%252Bby%252B3%25252C4-dihydropyrimidin-2%2525281H%252529-one%252BC5%252Bamide%252Bderivatives%26aulast%3DMoosavi%26aufirst%3DFatemeh%26date%3D2021%26volume%3D894%26spage%3D173850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vegard Torp  Lien</span>, <span class="hlFld-ContribAuthor ">Sofie  Celen</span>, <span class="hlFld-ContribAuthor ">Syed  Nuruddin</span>, <span class="hlFld-ContribAuthor ">Bala  Attili</span>, <span class="hlFld-ContribAuthor ">Gilles  Doumont</span>, <span class="hlFld-ContribAuthor ">Gaetan  Van Simaeys</span>, <span class="hlFld-ContribAuthor ">Guy  Bormans</span>, <span class="hlFld-ContribAuthor ">Jo  Klaveness</span>, <span class="hlFld-ContribAuthor ">Dag Erlend  Olberg</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2021,</strong> <em>93 </em>, 74-80. <a href="https://doi.org/10.1016/j.nucmedbio.2020.12.002" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2020.12.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2020.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2020.12.002%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DPreclinical%252Bevaluation%252Bof%252B%25255B18F%25255Dcabozantinib%252Bas%252Ba%252BPET%252Bimaging%252Bagent%252Bin%252Ba%252Bprostate%252Bcancer%252Bmouse%252Bmodel%26aulast%3DLien%26aufirst%3DVegard%2BTorp%26date%3D2021%26volume%3D93%26spage%3D74%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Miriam  Holzhäuser-Rein</span>, <span class="hlFld-ContribAuthor ">Stefanie  Mueller-Wilke</span>, <span class="hlFld-ContribAuthor ">Florian  Lordick</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 82. <a href="https://doi.org/10.3390/ijms22010082" title="DOI URL">https://doi.org/10.3390/ijms22010082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22010082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22010082%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSATB1-Mediated%252BUpregulation%252Bof%252Bthe%252BOncogenic%252BReceptor%252BTyrosine%252BKinase%252BHER3%252BAntagonizes%252BMET%252BInhibition%252Bin%252BGastric%252BCancer%252BCells%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolay S.  Zimnitskiy</span>, <span class="hlFld-ContribAuthor ">Alexey Yu.  Barkov</span>, <span class="hlFld-ContribAuthor ">Maria V.  Ulitko</span>, <span class="hlFld-ContribAuthor ">Igor B.  Kutyashev</span>, <span class="hlFld-ContribAuthor ">Vladislav Yu.  Korotaev</span>, <span class="hlFld-ContribAuthor ">Vyacheslav Ya.  Sosnovskikh</span>. </span><span class="cited-content_cbyCitation_article-title">An expedient synthesis of novel spiro[indenoquinoxaline-pyrrolizidine]-pyrazole conjugates with anticancer activity from 1,5-diarylpent-4-ene-1,3-diones through the 1,3-dipolar cycloaddition/cyclocondensation sequence. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (37)
                                     , 16185-16199. <a href="https://doi.org/10.1039/D0NJ02817G" title="DOI URL">https://doi.org/10.1039/D0NJ02817G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ02817G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ02817G%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DAn%252Bexpedient%252Bsynthesis%252Bof%252Bnovel%252Bspiro%25255Bindenoquinoxaline-pyrrolizidine%25255D-pyrazole%252Bconjugates%252Bwith%252Banticancer%252Bactivity%252Bfrom%252B1%25252C5-diarylpent-4-ene-1%25252C3-diones%252Bthrough%252Bthe%252B1%25252C3-dipolar%252Bcycloaddition%25252Fcyclocondensation%252Bsequence%26aulast%3DZimnitskiy%26aufirst%3DNikolay%2BS.%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D37%26spage%3D16185%26epage%3D16199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annamaria  Martorana</span>, <span class="hlFld-ContribAuthor ">Gabriele  La Monica</span>, <span class="hlFld-ContribAuthor ">Antonino  Lauria</span>. </span><span class="cited-content_cbyCitation_article-title">Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4279. <a href="https://doi.org/10.3390/molecules25184279" title="DOI URL">https://doi.org/10.3390/molecules25184279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184279%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DQuinoline-Based%252BMolecules%252BTargeting%252Bc-Met%25252C%252BEGF%25252C%252Band%252BVEGF%252BReceptors%252Band%252Bthe%252BProteins%252BInvolved%252Bin%252BRelated%252BCarcinogenic%252BPathways%26aulast%3DMartorana%26aufirst%3DAnnamaria%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kartikey  Singh</span>, <span class="hlFld-ContribAuthor ">Rama Pati  Tripathi</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview on Glyco-Macrocycles: Potential New Lead and their Future in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (20)
                                     , 3386-3410. <a href="https://doi.org/10.2174/0929867326666190227232721" title="DOI URL">https://doi.org/10.2174/0929867326666190227232721</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190227232721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190227232721%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DAn%252BOverview%252Bon%252BGlyco-Macrocycles%25253A%252BPotential%252BNew%252BLead%252Band%252Btheir%252BFuture%252Bin%252BMedicinal%252BChemistry%26aulast%3DSingh%26aufirst%3DKartikey%26date%3D2020%26volume%3D27%26issue%3D20%26spage%3D3386%26epage%3D3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima Ezzahra  Bennani</span>, <span class="hlFld-ContribAuthor ">Latifa  Doudach</span>, <span class="hlFld-ContribAuthor ">Yahia  Cherrah</span>, <span class="hlFld-ContribAuthor ">Youssef  Ramli</span>, <span class="hlFld-ContribAuthor ">Khalid  Karrouchi</span>, <span class="hlFld-ContribAuthor ">M'hammed  Ansar</span>, <span class="hlFld-ContribAuthor ">My El Abbes  Faouzi</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103470. <a href="https://doi.org/10.1016/j.bioorg.2019.103470" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103470%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOverview%252Bof%252Brecent%252Bdevelopments%252Bof%252Bpyrazole%252Bderivatives%252Bas%252Ban%252Banticancer%252Bagent%252Bin%252Bdifferent%252Bcell%252Bline%26aulast%3DBennani%26aufirst%3DFatima%2BEzzahra%26date%3D2020%26volume%3D97%26spage%3D103470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sakineh  Dadashpour</span>, <span class="hlFld-ContribAuthor ">Tuba T.  Küçükkılınç</span>, <span class="hlFld-ContribAuthor ">Ayse  Ercan</span>, <span class="hlFld-ContribAuthor ">Seyed J.  Hosseinimehr</span>, <span class="hlFld-ContribAuthor ">Nima  Naderi</span>, <span class="hlFld-ContribAuthor ">Hamid  Irannejad</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Anticancer Activity of Benzimidazole/Benzoxazole Substituted Triazolotriazines in Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>19 </em>
                                    (17)
                                     , 2120-2129. <a href="https://doi.org/10.2174/1871520619666190808152051" title="DOI URL">https://doi.org/10.2174/1871520619666190808152051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190808152051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190808152051%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BAnticancer%252BActivity%252Bof%252BBenzimidazole%25252FBenzoxazole%252BSubstituted%252BTriazolotriazines%252Bin%252BHepatocellular%252BCarcinoma%26aulast%3DDadashpour%26aufirst%3DSakineh%26date%3D2020%26volume%3D19%26issue%3D17%26spage%3D2120%26epage%3D2129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in the Development of Small Molecule c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1276-1288. <a href="https://doi.org/10.2174/1568026619666190712205353" title="DOI URL">https://doi.org/10.2174/1568026619666190712205353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190712205353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190712205353%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecule%252Bc-Met%252BInhibitors%26aulast%3DLv%26aufirst%3DPeng-Cheng%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1276%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiaoling  Song</span>, <span class="hlFld-ContribAuthor ">Xueting  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Wei</span>, <span class="hlFld-ContribAuthor ">Rilei  Yu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual Screening Guided Design, Synthesis and Bioactivity Study of Benzisoselenazolones (BISAs) on Inhibition of c-Met and Its Downstream Signalling Pathways. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (10)
                                     , 2489. <a href="https://doi.org/10.3390/ijms20102489" title="DOI URL">https://doi.org/10.3390/ijms20102489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20102489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20102489%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DVirtual%252BScreening%252BGuided%252BDesign%25252C%252BSynthesis%252Band%252BBioactivity%252BStudy%252Bof%252BBenzisoselenazolones%252B%252528BISAs%252529%252Bon%252BInhibition%252Bof%252Bc-Met%252Band%252BIts%252BDownstream%252BSignalling%252BPathways%26aulast%3DZhang%26aufirst%3DSiqi%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D10%26spage%3D2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sakineh  Dadashpour</span>, <span class="hlFld-ContribAuthor ">Tuba Tüylü  Küçükkılınç</span>, <span class="hlFld-ContribAuthor ">Beyza  Ayazgök</span>, <span class="hlFld-ContribAuthor ">Seyed Jalal  Hosseinimehr</span>, <span class="hlFld-ContribAuthor ">Ann M  Chippindale</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>, <span class="hlFld-ContribAuthor ">Hamid  Irannejad</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (10)
                                     , 1119-1136. <a href="https://doi.org/10.4155/fmc-2018-0412" title="DOI URL">https://doi.org/10.4155/fmc-2018-0412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0412%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B1%25252C2%25252C4-triazolo-1%25252C2%25252C4-triazines%252Bwith%252Bthiomethylpyridine%252Bhinge%252Bbinders%252Bas%252Bpotent%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DDadashpour%26aufirst%3DSakineh%26date%3D2019%26volume%3D11%26issue%3D10%26spage%3D1119%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hany S.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Mohamed E.  Albakri</span>, <span class="hlFld-ContribAuthor ">Walaa R.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Heba Abdelrasheed  Allam</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Reda</span>, <span class="hlFld-ContribAuthor ">Hatem A.  Abdel-Aziz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>85 </em>, 337-348. <a href="https://doi.org/10.1016/j.bioorg.2019.01.006" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsome%252Bnovel%252Bthiobenzimidazole%252Bderivatives%252Bas%252Banti-renal%252Bcancer%252Bagents%252Bthrough%252Binhibition%252Bof%252Bc-MET%252Bkinase%26aulast%3DIbrahim%26aufirst%3DHany%2BS.%26date%3D2019%26volume%3D85%26spage%3D337%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor V.  Syakaev</span>, <span class="hlFld-ContribAuthor ">Julia E.  Morozova</span>, <span class="hlFld-ContribAuthor ">Andrei V.  Bogdanov</span>, <span class="hlFld-ContribAuthor ">Yana V.  Shalaeva</span>, <span class="hlFld-ContribAuthor ">Alina M.  Ermakova</span>, <span class="hlFld-ContribAuthor ">Alexandra D.  Voloshina</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zobov</span>, <span class="hlFld-ContribAuthor ">Irek R.  Nizameev</span>, <span class="hlFld-ContribAuthor ">Marsil K.  Kadirov</span>, <span class="hlFld-ContribAuthor ">Vladimir F.  Mironov</span>, <span class="hlFld-ContribAuthor ">Alexander I.  Konovalov</span>. </span><span class="cited-content_cbyCitation_article-title">Solubilization of azo-dye-modiﬁed isatin derivative by amphiphilic carboxyresorcinarenes: The effect of macrocycle structure on the supramolecular association. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces A: Physicochemical and Engineering Aspects</span><span> <strong>2018,</strong> <em>553 </em>, 368-377. <a href="https://doi.org/10.1016/j.colsurfa.2018.05.078" title="DOI URL">https://doi.org/10.1016/j.colsurfa.2018.05.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfa.2018.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfa.2018.05.078%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520A%253A%2520Physicochemical%2520and%2520Engineering%2520Aspects%26atitle%3DSolubilization%252Bof%252Bazo-dye-modi%2525EF%2525AC%252581ed%252Bisatin%252Bderivative%252Bby%252Bamphiphilic%252Bcarboxyresorcinarenes%25253A%252BThe%252Beffect%252Bof%252Bmacrocycle%252Bstructure%252Bon%252Bthe%252Bsupramolecular%252Bassociation%26aulast%3DSyakaev%26aufirst%3DVictor%2BV.%26date%3D2018%26volume%3D553%26spage%3D368%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Libo  Yan</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Bingren  Xiang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2018,</strong> <em>36 </em>
                                    (8)
                                     , 2015-2031. <a href="https://doi.org/10.1080/07391102.2017.1340852" title="DOI URL">https://doi.org/10.1080/07391102.2017.1340852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2017.1340852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2017.1340852%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DInsight%252Binto%252Bthe%252Bkey%252Bfeatures%252Bfor%252Bligand%252Bbinding%252Bin%252BY1230%252Bmutated%252Bc-Met%252Bkinase%252Bdomain%252Bby%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DYan%26aufirst%3DLibo%26date%3D2018%26date%3D2017%26volume%3D36%26issue%3D8%26spage%3D2015%26epage%3D2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. S.  Kopchuk</span>, <span class="hlFld-ContribAuthor ">A. P.  Krinochkin</span>, <span class="hlFld-ContribAuthor ">E. S.  Starnovskaya</span>, <span class="hlFld-ContribAuthor ">Ya. K.  Shtaitz</span>, <span class="hlFld-ContribAuthor ">I. S.  Kovalev</span>, <span class="hlFld-ContribAuthor ">G. V.  Zyryanov</span>, <span class="hlFld-ContribAuthor ">V. L.  Rusinov</span>, <span class="hlFld-ContribAuthor ">O. N.  Chupakhin</span>. </span><span class="cited-content_cbyCitation_article-title">Substitution of Cyano Group in Position 5 of 1,2,4-Triazines by Carboxylic Acid Hydrazide Residues under Solvent-Free Conditions. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>54 </em>
                                    (3)
                                     , 509-511. <a href="https://doi.org/10.1134/S1070428018030223" title="DOI URL">https://doi.org/10.1134/S1070428018030223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428018030223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428018030223%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSubstitution%252Bof%252BCyano%252BGroup%252Bin%252BPosition%252B5%252Bof%252B1%25252C2%25252C4-Triazines%252Bby%252BCarboxylic%252BAcid%252BHydrazide%252BResidues%252Bunder%252BSolvent-Free%252BConditions%26aulast%3DKopchuk%26aufirst%3DD.%2BS.%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D3%26spage%3D509%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riham F  George</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of simple 2-oxindole-based compounds with promising antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (3)
                                     , 269-282. <a href="https://doi.org/10.4155/fmc-2017-0148" title="DOI URL">https://doi.org/10.4155/fmc-2017-0148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0148%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DFacile%252Bsynthesis%252Bof%252Bsimple%252B2-oxindole-based%252Bcompounds%252Bwith%252Bpromising%252Bantiproliferative%252Bactivity%26aulast%3DGeorge%26aufirst%3DRiham%2BF%26date%3D2018%26volume%3D10%26issue%3D3%26spage%3D269%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Palak K.  Parikh</span>, <span class="hlFld-ContribAuthor ">Manjunath D.  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the discovery of small molecule c-Met Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1103-1138. <a href="https://doi.org/10.1016/j.ejmech.2017.08.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252Bc-Met%252BKinase%252Binhibitors%26aulast%3DParikh%26aufirst%3DPalak%2BK.%26date%3D2018%26volume%3D143%26spage%3D1103%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. V.  Bogdanov</span>, <span class="hlFld-ContribAuthor ">I. F.  Zaripova</span>, <span class="hlFld-ContribAuthor ">A. D.  Voloshina</span>, <span class="hlFld-ContribAuthor ">A. S.  Strobykina</span>, <span class="hlFld-ContribAuthor ">N. V.  Kulik</span>, <span class="hlFld-ContribAuthor ">S. V.  Bukharov</span>, <span class="hlFld-ContribAuthor ">V. F.  Mironov</span>. </span><span class="cited-content_cbyCitation_article-title">Isatin Derivatives Containing Sterically Hindered Phenolic Fragment and Water-Soluble Acyl Hydrazones on Their Basis: Synthesis and Antimicrobial Activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2018,</strong> <em>88 </em>
                                    (1)
                                     , 57-67. <a href="https://doi.org/10.1134/S1070363218010097" title="DOI URL">https://doi.org/10.1134/S1070363218010097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363218010097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363218010097%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DIsatin%252BDerivatives%252BContaining%252BSterically%252BHindered%252BPhenolic%252BFragment%252Band%252BWater-Soluble%252BAcyl%252BHydrazones%252Bon%252BTheir%252BBasis%25253A%252BSynthesis%252Band%252BAntimicrobial%252BActivity%26aulast%3DBogdanov%26aufirst%3DA.%2BV.%26date%3D2018%26date%3D2018%26volume%3D88%26issue%3D1%26spage%3D57%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khalid  Karrouchi</span>, <span class="hlFld-ContribAuthor ">Smaail  Radi</span>, <span class="hlFld-ContribAuthor ">Youssef  Ramli</span>, <span class="hlFld-ContribAuthor ">Jamal  Taoufik</span>, <span class="hlFld-ContribAuthor ">Yahia  Mabkhot</span>, <span class="hlFld-ContribAuthor ">Faiz  Al-aizari</span>, <span class="hlFld-ContribAuthor ">M’hammed  Ansar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (1)
                                     , 134. <a href="https://doi.org/10.3390/molecules23010134" title="DOI URL">https://doi.org/10.3390/molecules23010134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23010134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23010134%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BPharmacological%252BActivities%252Bof%252BPyrazole%252BDerivatives%25253A%252BA%252BReview%26aulast%3DKarrouchi%26aufirst%3DKhalid%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D1%26spage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuka  Nozaki</span>, <span class="hlFld-ContribAuthor ">Shoma  Tamori</span>, <span class="hlFld-ContribAuthor ">Masahiro  Inada</span>, <span class="hlFld-ContribAuthor ">Reika  Katayama</span>, <span class="hlFld-ContribAuthor ">Hiromi  Nakane</span>, <span class="hlFld-ContribAuthor ">Osamu  Minamishima</span>, <span class="hlFld-ContribAuthor ">Yuka  Onodera</span>, <span class="hlFld-ContribAuthor ">Makoto  Abe</span>, <span class="hlFld-ContribAuthor ">Shota  Shiina</span>, <span class="hlFld-ContribAuthor ">Kei  Tamura</span>, <span class="hlFld-ContribAuthor ">Daichi  Kodama</span>, <span class="hlFld-ContribAuthor ">Keiko  Sato</span>, <span class="hlFld-ContribAuthor ">Yasushi  Hara</span>, <span class="hlFld-ContribAuthor ">Ryo  Abe</span>, <span class="hlFld-ContribAuthor ">Ryoko  Takasawa</span>, <span class="hlFld-ContribAuthor ">Atsushi  Yoshimori</span>, <span class="hlFld-ContribAuthor ">Nariyoshi  Shinomiya</span>, <span class="hlFld-ContribAuthor ">Sei-ichi  Tanuma</span>, <span class="hlFld-ContribAuthor ">Kazunori  Akimoto</span>. </span><span class="cited-content_cbyCitation_article-title">Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Genes & Cancer</span><span> <strong>2017,</strong> <em>8 </em>
                                    (7-8)
                                     , 628-639. <a href="https://doi.org/10.18632/genesandcancer.148" title="DOI URL">https://doi.org/10.18632/genesandcancer.148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/genesandcancer.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Fgenesandcancer.148%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%2520%2526%2520Cancer%26atitle%3DCorrelation%252Bbetween%252Bc-Met%252Band%252BALDH1%252Bcontributes%252Bto%252Bthe%252Bsurvival%252Band%252Btumor-sphere%252Bformation%252Bof%252BALDH1%252Bpositive%252Bbreast%252Bcancer%252Bstem%252Bcells%252Band%252Bpredicts%252Bpoor%252Bclinical%252Boutcome%252Bin%252Bbreast%252Bcancer%26aulast%3DNozaki%26aufirst%3DYuka%26date%3D2017%26volume%3D8%26issue%3D7-8%26spage%3D628%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Jing  Li</span>, <span class="hlFld-ContribAuthor ">Guan-Zhao  Wu</span>, <span class="hlFld-ContribAuthor ">Quentin  Kaas</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Ri-Lei  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2017,</strong> <em>75 </em>, 241-249. <a href="https://doi.org/10.1016/j.jmgm.2017.04.004" title="DOI URL">https://doi.org/10.1016/j.jmgm.2017.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2017.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDevelopment%252Bof%252Befficient%252Bdocking%252Bstrategies%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Bthe%252Bc-Met%252Btype%252BII%252Binhibitors%26aulast%3DLi%26aufirst%3DMing-Jing%26date%3D2017%26volume%3D75%26spage%3D241%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parag  Sahasrabudhe</span>, <span class="hlFld-ContribAuthor ">Veerabahu  Shanmugasundaram</span>, <span class="hlFld-ContribAuthor ">Mark  Flanagan</span>, <span class="hlFld-ContribAuthor ">Kris A.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Holly  Heaslet</span>, <span class="hlFld-ContribAuthor ">Anil  Rane</span>, <span class="hlFld-ContribAuthor ">Alex  McColl</span>, <span class="hlFld-ContribAuthor ">Tim  Subashi</span>, <span class="hlFld-ContribAuthor ">George  Karam</span>, <span class="hlFld-ContribAuthor ">Ron  Sarver</span>, <span class="hlFld-ContribAuthor ">Melissa  Harris</span>, <span class="hlFld-ContribAuthor ">Boris A.  Chrunyk</span>, <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Thomas V.  Magee</span>, <span class="hlFld-ContribAuthor ">Kelly  Fahnoe</span>, <span class="hlFld-ContribAuthor ">Brian  Lacey</span>, <span class="hlFld-ContribAuthor ">Henry  Putz</span>, <span class="hlFld-ContribAuthor ">J. Richard  Miller</span>, <span class="hlFld-ContribAuthor ">Jaehyun  Cho</span>, <span class="hlFld-ContribAuthor ">Arthur  Palmer</span>, <span class="hlFld-ContribAuthor ">Jane M.  Withka</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Drug Discovery with Biophysical Information. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 241-261. <a href="https://doi.org/10.1002/9781119099512.ch13" title="DOI URL">https://doi.org/10.1002/9781119099512.ch13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119099512.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119099512.ch13%26sid%3Dliteratum%253Aachs%26atitle%3DDriving%252BDrug%252BDiscovery%252Bwith%252BBiophysical%252BInformation%26aulast%3DSahasrabudhe%26aufirst%3DParag%26date%3D2017%26date%3D2017%26spage%3D241%26epage%3D261%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DApplied%252BBiophysics%252Bfor%252BDrug%252BDiscovery%26aulast%3DHuddler%26aufirst%3DDonald%26date%3D2017%26volume%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhao</span>, <span class="hlFld-ContribAuthor ">Le-Duo  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Hao</span>, <span class="hlFld-ContribAuthor ">Na  Chen</span>, <span class="hlFld-ContribAuthor ">Rui  Bai</span>, <span class="hlFld-ContribAuthor ">Yu-Ji  Wang</span>, <span class="hlFld-ContribAuthor ">Chun-Chun  Zhang</span>, <span class="hlFld-ContribAuthor ">Gong-Sheng  Li</span>, <span class="hlFld-ContribAuthor ">Li-Jun  Hao</span>, <span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Mao</span>, <span class="hlFld-ContribAuthor ">Yi  Fan</span>, <span class="hlFld-ContribAuthor ">Guang-Xin  Xia</span>, <span class="hlFld-ContribAuthor ">Jian-Xin  Yu</span>, <span class="hlFld-ContribAuthor ">Yan-Jun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 3-substituted-6-(1-(1 H -[1,2,3]triazolo[4,5- b ]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>134 </em>, 147-158. <a href="https://doi.org/10.1016/j.ejmech.2017.03.085" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.085%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B3-substituted-6-%2525281-%2525281%252BH%252B-%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-%252Bb%252B%25255Dpyrazin-1-yl%252529ethyl%252529quinoline%252Bderivatives%252Bas%252Bhighly%252Bpotent%252Band%252Bselective%252Bmesenchymal-epithelial%252Btransition%252Bfactor%252B%252528c-Met%252529%252Binhibitors%252Bvia%252Bmetabolite%252Bprofiling-based%252Bstructural%252Boptimization%26aulast%3DZhao%26aufirst%3DFei%26date%3D2017%26volume%3D134%26spage%3D147%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquib  Alam</span>, <span class="hlFld-ContribAuthor ">Md. Aftab  Alam</span>, <span class="hlFld-ContribAuthor ">Amulya K.  Panda</span>, <span class="hlFld-ContribAuthor ">Rahisuddin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Cytotoxicity Evaluation of 3‐(5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐1‐phenyl‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)pyridine and 5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐3‐(pyridin‐3‐yl)‐4,5‐dihydropyrazole‐1‐carbaldehyde Derivatives as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2017,</strong> <em>54 </em>
                                    (3)
                                     , 1812-1821. <a href="https://doi.org/10.1002/jhet.2768" title="DOI URL">https://doi.org/10.1002/jhet.2768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2768%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BCytotoxicity%252BEvaluation%252Bof%252B3%2525E2%252580%252590%2525285%2525E2%252580%252590%2525283%2525E2%252580%252590%252528aryl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525904%2525E2%252580%252590yl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525904%25252C5%2525E2%252580%252590dihydro%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525903%2525E2%252580%252590yl%252529pyridine%252Band%252B5%2525E2%252580%252590%2525283%2525E2%252580%252590%252528aryl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525904%2525E2%252580%252590yl%252529%2525E2%252580%2525903%2525E2%252580%252590%252528pyridin%2525E2%252580%2525903%2525E2%252580%252590yl%252529%2525E2%252580%2525904%25252C5%2525E2%252580%252590dihydropyrazole%2525E2%252580%2525901%2525E2%252580%252590carbaldehyde%252BDerivatives%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DAlam%26aufirst%3DRaquib%26date%3D2017%26date%3D2016%26volume%3D54%26issue%3D3%26spage%3D1812%26epage%3D1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">O.  Schadt</span>, <span class="hlFld-ContribAuthor ">A.  Blaukat</span>. </span><span class="cited-content_cbyCitation_article-title">Tepotinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 178-203. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12468-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12468-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12468-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12468-0%26sid%3Dliteratum%253Aachs%26atitle%3DTepotinib%26aulast%3DSchadt%26aufirst%3DO.%26date%3D2017%26spage%3D178%26epage%3D203%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Heejung  Jung</span>, <span class="hlFld-ContribAuthor ">Hyung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">In-Young  Jang</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Un  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells. </span><span class="cited-content_cbyCitation_journal-name">BMC Cancer</span><span> <strong>2016,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12885-016-2058-y" title="DOI URL">https://doi.org/10.1186/s12885-016-2058-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12885-016-2058-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12885-016-2058-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Cancer%26atitle%3DNovel%252Bc-Met%252Binhibitor%252Bsuppresses%252Bthe%252Bgrowth%252Bof%252Bc-Met-addicted%252Bgastric%252Bcancer%252Bcells%26aulast%3DPark%26aufirst%3DChi%2BHoon%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia M.  Stella</span>, <span class="hlFld-ContribAuthor ">Alessandra  Gentile</span>, <span class="hlFld-ContribAuthor ">Alice  Balderacchi</span>, <span class="hlFld-ContribAuthor ">Federica  Meloni</span>, <span class="hlFld-ContribAuthor ">Melissa  Milan</span>, <span class="hlFld-ContribAuthor ">Silvia  Benvenuti</span>. </span><span class="cited-content_cbyCitation_article-title">Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Translational Medicine</span><span> <strong>2016,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12967-016-1008-4" title="DOI URL">https://doi.org/10.1186/s12967-016-1008-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12967-016-1008-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12967-016-1008-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Translational%2520Medicine%26atitle%3DOckham%2525E2%252580%252599s%252Brazor%252Bfor%252Bthe%252BMET-driven%252Binvasive%252Bgrowth%252Blinking%252Bidiopathic%252Bpulmonary%252Bfibrosis%252Band%252Bcancer%26aulast%3DStella%26aufirst%3DGiulia%2BM.%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquib  Alam</span>, <span class="hlFld-ContribAuthor ">Divya  Wahi</span>, <span class="hlFld-ContribAuthor ">Raja  Singh</span>, <span class="hlFld-ContribAuthor ">Devapriya  Sinha</span>, <span class="hlFld-ContribAuthor ">Vibha  Tandon</span>, <span class="hlFld-ContribAuthor ">Abhinav  Grover</span>, <span class="hlFld-ContribAuthor ">Rahisuddin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2016,</strong> <em>69 </em>, 77-90. <a href="https://doi.org/10.1016/j.bioorg.2016.10.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2016.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2016.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bcytotoxicity%25252C%252BHuTopoII%2525CE%2525B1%252Binhibitory%252Bactivity%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bpyrazole%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DAlam%26aufirst%3DRaquib%26date%3D2016%26volume%3D69%26spage%3D77%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hany S.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Sahar M.  Abou-Seri</span>, <span class="hlFld-ContribAuthor ">Hatem A.  Abdel-Aziz</span>. </span><span class="cited-content_cbyCitation_article-title">3-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>122 </em>, 366-381. <a href="https://doi.org/10.1016/j.ejmech.2016.06.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.06.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.06.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D3-Hydrazinoindolin-2-one%252Bderivatives%25253A%252BChemical%252Bclassification%252Band%252Binvestigation%252Bof%252Btheir%252Btargets%252Bas%252Banticancer%252Bagents%26aulast%3DIbrahim%26aufirst%3DHany%2BS.%26date%3D2016%26volume%3D122%26spage%3D366%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Hao</span>, <span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Guangxin  Xia</span>, <span class="hlFld-ContribAuthor ">Jianxin  Yu</span>, <span class="hlFld-ContribAuthor ">Yanjun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal–epithelial transition factor (c-Met) protein kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (18)
                                     , 4281-4290. <a href="https://doi.org/10.1016/j.bmc.2016.07.019" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.07.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.07.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Ba%252Bseries%252Bof%252Bimidazo%25255B4%25252C5-b%25255Dpyrazine%252Bderivatives%252Bas%252Bhighly%252Bpotent%252Band%252Bexquisitely%252Bselective%252Binhibitors%252Bof%252Bthe%252Bmesenchymal%2525E2%252580%252593epithelial%252Btransition%252Bfactor%252B%252528c-Met%252529%252Bprotein%252Bkinase%26aulast%3DZhao%26aufirst%3DFei%26date%3D2016%26volume%3D24%26issue%3D18%26spage%3D4281%26epage%3D4290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Garima  Verma</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic voyage of pyrazole and its analogs: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>120 </em>, 170-201. <a href="https://doi.org/10.1016/j.ejmech.2016.04.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Btherapeutic%252Bvoyage%252Bof%252Bpyrazole%252Band%252Bits%252Banalogs%25253A%252BA%252Breview%26aulast%3DKhan%26aufirst%3DMohemmed%2BFaraz%26date%3D2016%26volume%3D120%26spage%3D170%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kishna Ram  Senwar</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Dinesh  Thummuri</span>, <span class="hlFld-ContribAuthor ">Pankaj  Sharma</span>, <span class="hlFld-ContribAuthor ">V.G.M.  Naidu</span>, <span class="hlFld-ContribAuthor ">Gannoju  Srinivasulu</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>118 </em>, 34-46. <a href="https://doi.org/10.1016/j.ejmech.2016.04.025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bapoptosis%252Binducing%252Beffect%252Bof%252Bnovel%252B%252528Z%252529-3-%2525283%2525E2%252580%2525B2-methoxy-4%2525E2%252580%2525B2-%2525282-amino-2-oxoethoxy%252529-benzylidene%252529indolin-2-ones%252Bas%252Bpotential%252Bantitumour%252Bagents%26aulast%3DSenwar%26aufirst%3DKishna%2BRam%26date%3D2016%26volume%3D118%26spage%3D34%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Xu</span>, <span class="hlFld-ContribAuthor ">Zhen-zhen  Yang</span>, <span class="hlFld-ContribAuthor ">Jun-rong  Jiang</span>, <span class="hlFld-ContribAuthor ">Wan-gui  Pan</span>, <span class="hlFld-ContribAuthor ">Xiao-le  Yang</span>, <span class="hlFld-ContribAuthor ">Jian-yong  Wu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhu</span>, <span class="hlFld-ContribAuthor ">John  Wang</span>, <span class="hlFld-ContribAuthor ">Qi-Yang  Shou</span>, <span class="hlFld-ContribAuthor ">Han-gui  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3- b ][1,2,4,5]tetrazine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (13)
                                     , 3042-3047. <a href="https://doi.org/10.1016/j.bmcl.2016.05.007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.05.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.05.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%25252C%252Bantitumor%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252B%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-%252Bb%252B%25255D%25255B1%25252C2%25252C4%25252C5%25255Dtetrazine%252Bderivatives%26aulast%3DXu%26aufirst%3DFeng%26date%3D2016%26volume%3D26%26issue%3D13%26spage%3D3042%26epage%3D3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Shiyu  Jin</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Limin  Zeng</span>, <span class="hlFld-ContribAuthor ">Yiming  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>108 </em>, 322-333. <a href="https://doi.org/10.1016/j.ejmech.2015.11.042" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.11.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.11.042%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyridazinone%252Bderivatives%252Bdisplaying%252Bhighly%252Bpotent%252Band%252Bselective%252Binhibitory%252Bactivities%252Bagainst%252Bc-Met%252Btyrosine%252Bkinase%26aulast%3DLiu%26aufirst%3DYang%26date%3D2016%26volume%3D108%26spage%3D322%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Palak  Parikh</span>, <span class="hlFld-ContribAuthor ">Manjunath  Ghate</span>, <span class="hlFld-ContribAuthor ">Vivek K.  Vyas</span>. </span><span class="cited-content_cbyCitation_article-title">CoMFA and CoMSIA studies on 6,7-disubstituted-4-phenoxyquinoline derivatives as c-Met kinase inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2015,</strong> <em>24 </em>
                                    (12)
                                     , 4078-4092. <a href="https://doi.org/10.1007/s00044-015-1450-5" title="DOI URL">https://doi.org/10.1007/s00044-015-1450-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-015-1450-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-015-1450-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DCoMFA%252Band%252BCoMSIA%252Bstudies%252Bon%252B6%25252C7-disubstituted-4-phenoxyquinoline%252Bderivatives%252Bas%252Bc-Met%252Bkinase%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DParikh%26aufirst%3DPalak%26date%3D2015%26date%3D2015%26volume%3D24%26issue%3D12%26spage%3D4078%26epage%3D4092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dario  Presutti</span>, <span class="hlFld-ContribAuthor ">Simonetta  Santini</span>, <span class="hlFld-ContribAuthor ">Beatrice  Cardinali</span>, <span class="hlFld-ContribAuthor ">Giuliana  Papoff</span>, <span class="hlFld-ContribAuthor ">Cristiana  Lalli</span>, <span class="hlFld-ContribAuthor ">Simone  Samperna</span>, <span class="hlFld-ContribAuthor ">Valentina  Fustaino</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Giannini</span>, <span class="hlFld-ContribAuthor ">Giovina  Ruberti</span>, . </span><span class="cited-content_cbyCitation_article-title">MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (11)
                                     , e0143333. <a href="https://doi.org/10.1371/journal.pone.0143333" title="DOI URL">https://doi.org/10.1371/journal.pone.0143333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0143333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0143333%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DMET%252BGene%252BAmplification%252Band%252BMET%252BReceptor%252BActivation%252BAre%252BNot%252BSufficient%252Bto%252BPredict%252BEfficacy%252Bof%252BCombined%252BMET%252Band%252BEGFR%252BInhibitors%252Bin%252BEGFR%252BTKI-Resistant%252BNSCLC%252BCells%26aulast%3DPresutti%26aufirst%3DDario%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D11%26spage%3De0143333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iwei  Yeh</span>, <span class="hlFld-ContribAuthor ">Thomas  Botton</span>, <span class="hlFld-ContribAuthor ">Eric  Talevich</span>, <span class="hlFld-ContribAuthor ">A. Hunter  Shain</span>, <span class="hlFld-ContribAuthor ">Alyssa J.  Sparatta</span>, <span class="hlFld-ContribAuthor ">Arnaud  de la Fouchardiere</span>, <span class="hlFld-ContribAuthor ">Thaddeus W.  Mully</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  North</span>, <span class="hlFld-ContribAuthor ">Maria C.  Garrido</span>, <span class="hlFld-ContribAuthor ">Alexander  Gagnon</span>, <span class="hlFld-ContribAuthor ">Swapna S.  Vemula</span>, <span class="hlFld-ContribAuthor ">Timothy H.  McCalmont</span>, <span class="hlFld-ContribAuthor ">Philip E.  LeBoit</span>, <span class="hlFld-ContribAuthor ">Boris C.  Bastian</span>. </span><span class="cited-content_cbyCitation_article-title">Activating MET kinase rearrangements in melanoma and Spitz tumours. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2015,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms8174" title="DOI URL">https://doi.org/10.1038/ncomms8174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms8174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms8174%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DActivating%252BMET%252Bkinase%252Brearrangements%252Bin%252Bmelanoma%252Band%252BSpitz%252Btumours%26aulast%3DYeh%26aufirst%3DIwei%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minghui  Dong</span>, <span class="hlFld-ContribAuthor ">Yujie  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure–activity relationships and molecular docking simulations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (19)
                                     , 4118-4126. <a href="https://doi.org/10.1016/j.bmcl.2015.08.025" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Btriazolo%25255B4%25252C5-b%25255Dpyrazine%252Bderivatives%252Bas%252Bhepatocyte%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bthrough%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Band%252Bmolecular%252Bdocking%252Bsimulations%26aulast%3DDong%26aufirst%3DMinghui%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4118%26epage%3D4126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbao  Ye</span>, <span class="hlFld-ContribAuthor ">Jie  Wu</span>, <span class="hlFld-ContribAuthor ">Jiebo  Yang</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Luo</span>, <span class="hlFld-ContribAuthor ">Yanmei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and molecular docking analysis of some novel 7-[(quinolin-6-yl)methyl] purines as potential c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2015,</strong> <em>24 </em>
                                    (8)
                                     , 3327-3333. <a href="https://doi.org/10.1007/s00044-015-1383-z" title="DOI URL">https://doi.org/10.1007/s00044-015-1383-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-015-1383-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-015-1383-z%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bmolecular%252Bdocking%252Banalysis%252Bof%252Bsome%252Bnovel%252B7-%25255B%252528quinolin-6-yl%252529methyl%25255D%252Bpurines%252Bas%252Bpotential%252Bc-Met%252Binhibitors%26aulast%3DYe%26aufirst%3DLianbao%26date%3D2015%26date%3D2015%26volume%3D24%26issue%3D8%26spage%3D3327%26epage%3D3333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shipeng  Tao</span>, <span class="hlFld-ContribAuthor ">Qinquan  Hu</span>, <span class="hlFld-ContribAuthor ">Huan  Li</span>, <span class="hlFld-ContribAuthor ">Shan  Ma</span>, <span class="hlFld-ContribAuthor ">Yunfeng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of [1,2,3]Triazolo[5,1-
              
                a
              
              ]isoquinoline Derivatives via a Selective Cascade Cyclization Sequence of 1,2-bis(Phenylethynyl)benzene Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2015,</strong> <em>45 </em>
                                    (11)
                                     , 1354-1361. <a href="https://doi.org/10.1080/00397911.2015.1020952" title="DOI URL">https://doi.org/10.1080/00397911.2015.1020952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2015.1020952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2015.1020952%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthesis%252Bof%252B%25255B1%25252C2%25252C3%25255DTriazolo%25255B5%25252C1-%252Ba%252B%25255Disoquinoline%252BDerivatives%252Bvia%252Ba%252BSelective%252BCascade%252BCyclization%252BSequence%252Bof%252B1%25252C2-bis%252528Phenylethynyl%252529benzene%252BDerivatives%26aulast%3DTao%26aufirst%3DShipeng%26date%3D2015%26date%3D2015%26volume%3D45%26issue%3D11%26spage%3D1354%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Obaid  Afzal</span>, <span class="hlFld-ContribAuthor ">Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Md Rafi  Haider</span>, <span class="hlFld-ContribAuthor ">Md Rahmat  Ali</span>, <span class="hlFld-ContribAuthor ">Rajiv  Kumar</span>, <span class="hlFld-ContribAuthor ">Manu  Jaggi</span>, <span class="hlFld-ContribAuthor ">Sandhya  Bawa</span>. </span><span class="cited-content_cbyCitation_article-title">A review on anticancer potential of bioactive heterocycle quinoline. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>97 </em>, 871-910. <a href="https://doi.org/10.1016/j.ejmech.2014.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Banticancer%252Bpotential%252Bof%252Bbioactive%252Bheterocycle%252Bquinoline%26aulast%3DAfzal%26aufirst%3DObaid%26date%3D2015%26volume%3D97%26spage%3D871%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Ding</span>, <span class="hlFld-ContribAuthor ">Wen  Wen</span>, <span class="hlFld-ContribAuthor ">Daimin  Xiang</span>, <span class="hlFld-ContribAuthor ">Peipei  Yin</span>, <span class="hlFld-ContribAuthor ">Yanfang  Liu</span>, <span class="hlFld-ContribAuthor ">Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Guoping  He</span>, <span class="hlFld-ContribAuthor ">Zhuo  Cheng</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Yin</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Fajun  Nan</span>, <span class="hlFld-ContribAuthor ">Wencai  Ye</span>, <span class="hlFld-ContribAuthor ">Xiuli  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongyang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (13)
                                     , 11627-11639. <a href="https://doi.org/10.18632/oncotarget.3435" title="DOI URL">https://doi.org/10.18632/oncotarget.3435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.3435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.3435%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3D%2525CF%252588-Bufarenogin%25252C%252Ba%252Bnovel%252Banti-tumor%252Bcompound%25252C%252Bsuppresses%252Bliver%252Bcancer%252Bgrowth%252Bby%252Binhibiting%252Breceptor%252Btyrosine%252Bkinase-mediated%252Bsignaling%26aulast%3DDing%26aufirst%3DJin%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D13%26spage%3D11627%26epage%3D11639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dieter  Dorsch</span>, <span class="hlFld-ContribAuthor ">Oliver  Schadt</span>, <span class="hlFld-ContribAuthor ">Frank  Stieber</span>, <span class="hlFld-ContribAuthor ">Michael  Meyring</span>, <span class="hlFld-ContribAuthor ">Ulrich  Grädler</span>, <span class="hlFld-ContribAuthor ">Friedhelm  Bladt</span>, <span class="hlFld-ContribAuthor ">Manja  Friese-Hamim</span>, <span class="hlFld-ContribAuthor ">Christine  Knühl</span>, <span class="hlFld-ContribAuthor ">Ulrich  Pehl</span>, <span class="hlFld-ContribAuthor ">Andree  Blaukat</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (7)
                                     , 1597-1602. <a href="https://doi.org/10.1016/j.bmcl.2015.02.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Band%252Boptimization%252Bof%252Bpyridazinones%252Bas%252Bpotent%252Band%252Bselective%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DDorsch%26aufirst%3DDieter%26date%3D2015%26volume%3D25%26issue%3D7%26spage%3D1597%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik  Díaz-Cervantes</span>, <span class="hlFld-ContribAuthor ">Alejandro  Islas-Jácome</span>, <span class="hlFld-ContribAuthor ">Angel  Rentería-Gómez</span>, <span class="hlFld-ContribAuthor ">Juvencio  Robles</span>, <span class="hlFld-ContribAuthor ">Rocío  Gámez-Montaño</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro and in silico evaluation of twelve newly-synthesized 1-acetamide-5-methoxy-2-oxindoles as 5-Ht7 receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (7)
                                     , 1580-1585. <a href="https://doi.org/10.1016/j.bmcl.2015.02.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.02.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.02.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIn%252Bvitro%252Band%252Bin%252Bsilico%252Bevaluation%252Bof%252Btwelve%252Bnewly-synthesized%252B1-acetamide-5-methoxy-2-oxindoles%252Bas%252B5-Ht7%252Breceptor%252Bligands%26aulast%3DD%25C3%25ADaz-Cervantes%26aufirst%3DErik%26date%3D2015%26volume%3D25%26issue%3D7%26spage%3D1580%26epage%3D1585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul R.  Gavine</span>, <span class="hlFld-ContribAuthor ">Yongxin  Ren</span>, <span class="hlFld-ContribAuthor ">Lu  Han</span>, <span class="hlFld-ContribAuthor ">Jing  Lv</span>, <span class="hlFld-ContribAuthor ">Shiming  Fan</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen  Xu</span>, <span class="hlFld-ContribAuthor ">Yuan Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Tianwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Haihua  Fu</span>, <span class="hlFld-ContribAuthor ">Yongjuan  Yu</span>, <span class="hlFld-ContribAuthor ">Huiying  Wang</span>, <span class="hlFld-ContribAuthor ">Shirlian  Xu</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xinying  Su</span>, <span class="hlFld-ContribAuthor ">XiaoLu  Yin</span>, <span class="hlFld-ContribAuthor ">Liang  Xie</span>, <span class="hlFld-ContribAuthor ">Linfang  Wang</span>, <span class="hlFld-ContribAuthor ">Weiguo  Qing</span>, <span class="hlFld-ContribAuthor ">Longxian  Jiao</span>, <span class="hlFld-ContribAuthor ">Weiguo  Su</span>, <span class="hlFld-ContribAuthor ">Q. May  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2015,</strong> <em>9 </em>
                                    (1)
                                     , 323-333. <a href="https://doi.org/10.1016/j.molonc.2014.08.015" title="DOI URL">https://doi.org/10.1016/j.molonc.2014.08.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molonc.2014.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molonc.2014.08.015%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DVolitinib%25252C%252Ba%252Bpotent%252Band%252Bhighly%252Bselective%252Bc-Met%252Binhibitor%25252C%252Beffectively%252Bblocks%252Bc-Met%252Bsignaling%252Band%252Bgrowth%252Bin%252Bc-MET%252Bamplified%252Bgastric%252Bcancer%252Bpatient-derived%252Btumor%252Bxenograft%252Bmodels%26aulast%3DGavine%26aufirst%3DPaul%2BR.%26date%3D2015%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3D323%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel  Rentería-Gómez</span>, <span class="hlFld-ContribAuthor ">Alejandro  Islas-Jácome</span>, <span class="hlFld-ContribAuthor ">J. Oscar C.  Jiménez-Halla</span>, <span class="hlFld-ContribAuthor ">Rocío  Gámez-Montaño</span>. </span><span class="cited-content_cbyCitation_article-title">Regiospecific synthesis of 1-acetamide-5-methoxy-2-oxindoles in two steps: (Ugi-SN2)/xanthate mediated free radical cyclization. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (48)
                                     , 6567-6570. <a href="https://doi.org/10.1016/j.tetlet.2014.10.026" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.10.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.10.026%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DRegiospecific%252Bsynthesis%252Bof%252B1-acetamide-5-methoxy-2-oxindoles%252Bin%252Btwo%252Bsteps%25253A%252B%252528Ugi-SN2%252529%25252Fxanthate%252Bmediated%252Bfree%252Bradical%252Bcyclization%26aulast%3DRenter%25C3%25ADa-G%25C3%25B3mez%26aufirst%3DAngel%26date%3D2014%26volume%3D55%26issue%3D48%26spage%3D6567%26epage%3D6570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Li  Zhao</span>, <span class="hlFld-ContribAuthor ">Tong  Zhang</span>, <span class="hlFld-ContribAuthor ">Li-Wei  Zhuang</span>, <span class="hlFld-ContribAuthor ">Bing-Zhu  Yan</span>, <span class="hlFld-ContribAuthor ">Rui-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Bing-Rong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">RETRACTED ARTICLE: Uncovering the pathogenesis and identifying novel targets of pancreatic cancer using bioinformatics approach. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2014,</strong> <em>41 </em>
                                    (7)
                                     , 4697-4704. <a href="https://doi.org/10.1007/s11033-014-3340-1" title="DOI URL">https://doi.org/10.1007/s11033-014-3340-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-014-3340-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-014-3340-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DRETRACTED%252BARTICLE%25253A%252BUncovering%252Bthe%252Bpathogenesis%252Band%252Bidentifying%252Bnovel%252Btargets%252Bof%252Bpancreatic%252Bcancer%252Busing%252Bbioinformatics%252Bapproach%26aulast%3DZhao%26aufirst%3DLi-Li%26date%3D2014%26date%3D2014%26volume%3D41%26issue%3D7%26spage%3D4697%26epage%3D4704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simpal  Kumari</span>, <span class="hlFld-ContribAuthor ">Sarvesh  Paliwal</span>, <span class="hlFld-ContribAuthor ">Rajani  Chauhan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrazole Derivatives Possessing Anticancer Activity: Current Status. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2014,</strong> <em>44 </em>
                                    (11)
                                     , 1521-1578. <a href="https://doi.org/10.1080/00397911.2013.828757" title="DOI URL">https://doi.org/10.1080/00397911.2013.828757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2013.828757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2013.828757%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthesis%252Bof%252BPyrazole%252BDerivatives%252BPossessing%252BAnticancer%252BActivity%25253A%252BCurrent%252BStatus%26aulast%3DKumari%26aufirst%3DSimpal%26date%3D2014%26date%3D2014%26volume%3D44%26issue%3D11%26spage%3D1521%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>, <span class="hlFld-ContribAuthor ">Vangala Santhosh  Reddy</span>, <span class="hlFld-ContribAuthor ">Santosh  Karnewar</span>, <span class="hlFld-ContribAuthor ">Sumit S.  Chourasiya</span>, <span class="hlFld-ContribAuthor ">Anver Basha  Shaik</span>, <span class="hlFld-ContribAuthor ">G. Bharath  Kumar</span>, <span class="hlFld-ContribAuthor ">Chandan  Kishor</span>, <span class="hlFld-ContribAuthor ">M. Kashi  Reddy</span>, <span class="hlFld-ContribAuthor ">M. P.  Narasimha Rao</span>, <span class="hlFld-ContribAuthor ">Ananthamurthy  Nagabhushana</span>, <span class="hlFld-ContribAuthor ">Kallaganti V. S.  Ramakrishna</span>, <span class="hlFld-ContribAuthor ">Anthony  Addlagatta</span>, <span class="hlFld-ContribAuthor ">Srigiridhar  Kotamraju</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Imidazopyridine-Oxindole Conjugates as Microtubule-Targeting Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2013,</strong> <em>8 </em>
                                    (12)
                                     , 2015-2025. <a href="https://doi.org/10.1002/cmdc.201300308" title="DOI URL">https://doi.org/10.1002/cmdc.201300308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300308%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BImidazopyridine-Oxindole%252BConjugates%252Bas%252BMicrotubule-Targeting%252BAgents%26aulast%3DKamal%26aufirst%3DAhmed%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D12%26spage%3D2015%26epage%3D2025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen P.H.  Alexander</span>, <span class="hlFld-ContribAuthor ">Helen E.  Benson</span>, <span class="hlFld-ContribAuthor ">Elena  Faccenda</span>, <span class="hlFld-ContribAuthor ">Adam J.  Pawson</span>, <span class="hlFld-ContribAuthor ">Joanna L.  Sharman</span>, <span class="hlFld-ContribAuthor ">Michael  Spedding</span>, <span class="hlFld-ContribAuthor ">John A.  Peters</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Harmar</span>, . </span><span class="cited-content_cbyCitation_article-title">The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2013,</strong> <em>170 </em>
                                    (8)
                                     , 1676-1705. <a href="https://doi.org/10.1111/bph.12449" title="DOI URL">https://doi.org/10.1111/bph.12449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.12449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.12449%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DThe%252BConcise%252BGuide%252Bto%252BPHARMACOLOGY%252B2013%25252F14%25253A%252BCatalytic%252BReceptors%26aulast%3DAlexander%26aufirst%3DStephen%2BP.H.%26date%3D2013%26date%3D2013%26volume%3D170%26issue%3D8%26spage%3D1676%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dengyou  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Yun  Zhai</span>, <span class="hlFld-ContribAuthor ">Zhongjie  Liang</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Zhao</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (21)
                                     , 6804-6820. <a href="https://doi.org/10.1016/j.bmc.2013.07.032" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.07.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.07.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-amino-5-aryl-3-benzylthiopyridine%252Bscaffold%252Bbased%252Bpotent%252Bc-Met%252Binhibitors%26aulast%3DZhang%26aufirst%3DDengyou%26date%3D2013%26volume%3D21%26issue%3D21%26spage%3D6804%26epage%3D6820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kapil  Upadhyaya</span>, <span class="hlFld-ContribAuthor ">Arya  Ajay</span>, <span class="hlFld-ContribAuthor ">Rohit  Mahar</span>, <span class="hlFld-ContribAuthor ">Renu  Pandey</span>, <span class="hlFld-ContribAuthor ">Brijesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanjeev K.  Shukla</span>, <span class="hlFld-ContribAuthor ">Rama Pati  Tripathi</span>. </span><span class="cited-content_cbyCitation_article-title">A strategy to access fused triazoloquinoline and related nucleoside analogues. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2013,</strong> <em>69 </em>
                                    (40)
                                     , 8547-8558. <a href="https://doi.org/10.1016/j.tet.2013.07.088" title="DOI URL">https://doi.org/10.1016/j.tet.2013.07.088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2013.07.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2013.07.088%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bstrategy%252Bto%252Baccess%252Bfused%252Btriazoloquinoline%252Band%252Brelated%252Bnucleoside%252Banalogues%26aulast%3DUpadhyaya%26aufirst%3DKapil%26date%3D2013%26volume%3D69%26issue%3D40%26spage%3D8547%26epage%3D8558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative c-MET Inhibitors in Clinical Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Structural Elucidation of an HTS Hit</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Structures of Oxindole-Based Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0004.jpeg" id="rightTab-GRAPHIC-d1592e596-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Compound <b>8</b> bound in CDK2 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FVT">1FVT</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (b) Overlay of <b>8</b> with the proposed binding orientation of <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>10</b> with the nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of c-MET protein structures from cocrystal structures with <b>10</b> (gray) and <b>9</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Efforts in the Replacement of the Chemically Unstable Oxindole Hydrazide Scaffold</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of cocrystal structures of <b>10</b> (gray) and <b>12</b> (purple) bound with the nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>24</b> and <b>12</b> with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0029.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Human liver microsomal clearance (HLM: CLint., app) vs cLogD; (b) Human hepatocyte clearance (HHEP: CLint., app) vs cLogD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0028.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of <b>2</b> with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0027.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Overlay of cocrystal structures of <b>2</b> (gray) and crizotinib (green) with nonphosphorylated c-MET.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0026.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Electronic property calculations of fragments <b>A</b>–<b>E</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0025.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Tumor growth inhibition of <b>2</b> in the GTL-16 xenograft tumor model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="schI" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0024.jpeg" id="rightTab-GRAPHIC-d1592e1966-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HOBT, EDC, NMP, ambient temperature, 1–2 h; (b) microwave at 170 °C, 0.5 h or longer.</p></p></figure><figure data-id="schII" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0023.jpeg" id="rightTab-GRAPHIC-d1592e2017-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-butanol, DIPEA, reflux, 48 h; (b) isoamyl nitrite, DMF, ambient temperature, overnight, 70 °C to the completion; (c) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 3.5 h.</p></p></figure><figure data-id="schIII" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0022.jpeg" id="rightTab-GRAPHIC-d1592e2075-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schIII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 16 h; (b) <i>i</i>-PrMgCl, THF, 0 °C to RT, 1 h; (c) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 16 h; (d) 4 N HCl/dioxane, CH<sub>2</sub>Cl<sub>2</sub>, RT.</p></p></figure><figure data-id="schIV" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0021.jpeg" id="rightTab-GRAPHIC-d1592e2129-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schIV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, overnight.</p></p></figure><figure data-id="schV" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/medium/jm-2012-00967g_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0020.jpeg" id="rightTab-GRAPHIC-d1592e2184-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm300967g/production/images/large/jm-2012-00967g_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300967g&amp;id=schV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) H<sub>2</sub>, Pd/C, MeOH/AcOH/EtOAc, 18 h; (b) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, 16 h; (c) concentrated ammonia–water solution, microwave at 100 °C, 1 h; (d) K<sub>2</sub>CO<sub>3</sub>, <i>i</i>-PrOH, microwave at 80 °C, 20 min; (e) Et<sub>3</sub>N, <i>n</i>-BuOH, microwave at 120 °C, 20 min.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccaccio, C.</span><span> </span><span class="NLM_article-title">Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1006%2Fexcr.1999.4684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=10579914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADyaK1MXnsF2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1999&pages=88-99&author=P.+M.+Comoglioauthor=L.+Tamagnoneauthor=C.+Boccaccio&title=Plasminogen-related+growth+factor+and+semaphorin+receptors%3A+a+gene+superfamily+controlling+invasive+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen-Related Growth Factor and Semaphorin Receptors: A Gene Superfamily Controlling Invasive Growth</span></div><div class="casAuthors">Comoglio, Paolo M.; Tamagnone, Luca; Boccaccio, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review, with 131 refs.  Plasminogen-related growth factors (PRGFs), also known as "scatter factors", trigger a unique biol. program leading to "invasive growth".  This is a result of the integration of apparently independent biol. responses including cell proliferation, cell survival, cell motility, invasion of extracellular matrixes, and induction of cell polarity.  Under physiol. conditions, the coordinated execution of the underlying genetic programs leads to the formation of tubular structures by epithelial organs (the so-called branching morphogenesis).  PRGF receptors are tyrosine kinases, encoded by a family of oncogenes: MET and RON.  They feature unique signal transduction properties as their cytoplasmic tails contain a two-tyrosine multifunctional docking site that binds multiple SH2-contg. intracellular signal transducers.  Invasive growth results from the concomitant activation of Ras (growth), phosphatidylinositol 3-kinase ("scattering"), and signal transducer and activator of transcription (cell polarity and morphogenesis).  We recently identified a new human gene family, encoding large transmembrane proteins, sex/plexins, sharing homologies with Met.  These mols. are receptors for semaphorins, involved in axon guidance and cell-cell repulsion, a process reminiscent of scattering and invasive growth.  Deregulated activation of PRGF or semaphorin ligands or receptors, by mutation or overexpression, confers to cancer cells invasive and metastatic properties.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoexoQs4NR1hrVg90H21EOLACvtfcHk0lg9UbCPR9Xmcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnsF2it74%253D&md5=c177cf4d120afa68c3c9e108306b4a14</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1999.4684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1999.4684%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DBoccaccio%26aufirst%3DC.%26atitle%3DPlasminogen-related%2520growth%2520factor%2520and%2520semaphorin%2520receptors%253A%2520a%2520gene%2520superfamily%2520controlling%2520invasive%2520growth%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1999%26volume%3D253%26spage%3D88%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Invasive growth: from development to metastasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=857-862&author=P.+M.+Comoglioauthor=L.+Trusolino&title=Invasive+growth%3A+from+development+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInvasive%2520growth%253A%2520from%2520development%2520to%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D857%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0lhHtc420Nd2JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520c-MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET: structure, functions and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1023%2FA%3A1023768811842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=12884908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=309-325&author=P.+C.+Maauthor=G.+Maulikauthor=J.+Christensenauthor=R.+Salgia&title=c-MET%3A+structure%2C+functions+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met: Structure, functions and potential for therapeutic inhibition</span></div><div class="casAuthors">Ma, Patrick C.; Maulik, Gautam; Christensen, James; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Studies on signal transduction pathways have generated various promising mol. targets for therapeutic inhibition in cancer therapy.  Receptor tyrosine kinases represent an important class of such therapeutic targets.  C-Met is a receptor tyrosine kinase that has been shown to be overexpressed and/or mutated in a variety of malignancies.  A no. of c-Met activating mutations, many of which are located in the tyrosine kinase domain, have been detected in various solid tumors and have been implicated in invasion and metastasis of tumor cells.  It is known that stimulation of c-Met via its natural ligand, hepatocyte growth factor (also known as scatter factor, HGF/SF) results in a plethora of biol. and biochem. effects in the cell.  Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  In this review, the role of c-Met dysregulation in tumor progression and metastasis is discussed in detail with particular emphasis on c-Met mutations.  Moreover, we summarize current knowledge on various pathways of c-Met signal transduction, highlighting the central role in the cytoskeletal functions.  In this summary is included recent data in our lab. indicating that phosphorylation of focal adhesion proteins, such as paxillin, p125FAK, and PYK2, occurs in response to c-Met stimulation in lung cancer cells.  Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rIdb5Ao4a7Vg90H21EOLACvtfcHk0lhHtc420Nd2JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiurY%253D&md5=7b7bf60da872071a39ce313efd32fd1f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023768811842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023768811842%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%253A%2520structure%252C%2520functions%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D309%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">c-MET as a target in human cancer and characterization of inhibitors for therapeutic intervention</span> <span class="citation_source-journal">Cancer Lett. (Amsterdam, Neth.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">225</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2Fj.canlet.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=15922853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2005&pages=1-26&author=J.+Christensenauthor=J.+Burrowsauthor=R.+Salgia&title=c-MET+as+a+target+in+human+cancer+and+characterization+of+inhibitors+for+therapeutic+intervention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention</span></div><div class="casAuthors">Christensen, James G.; Burrows, Jon; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-26</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, Imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.  A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clin. setting.  The proto-oncogene, c-Met, encodes the high-affinity receptor for hepatocyte growth factor (HGF) or scatter factor (SF).  C-Met and HGF are each required for normal mammalian development and have been shown to be particularly important in cell migration, morphogenic differentiation, and organization of three-dimensional tubular structures (e.g. renal tubular cells, gland formation, etc.) as well as cell growth and angiogenesis.  Both c-Met and HGF have been shown to be deregulated in and to correlate with poor prognosis in a no. of major human cancers.  New data describing the constitutive phosphorylation of c-Met in a no. of human tumors is presented here along with a variety of mechanisms by which c-Met can become activated, including mutation and gene amplification.  In support of the clin. data implicating c-Met activation in the pathogenesis of human cancers, introduction of c-Met and HGF (or mutant c-Met) into cells conferred the properties of motility, invasiveness, and tumorigenicity to the transformed cells.  Conversely, the inhibition of c-Met with a variety of receptor antagonists inhibited the motility, invasiveness, and tumorigenicity of human tumor cell lines.  Consistent with this observation, small-mol. inhibitors of c-Met were developed that antagonized c-Met/HGF-dependent phenotypes and tumor growth in mouse models.  This review will address the potential for development of c-Met inhibitors for treatment of human cancers with particular emphasis on recent findings with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTbSn0ouMILVg90H21EOLACvtfcHk0lg9IEBMo-MaQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ggs7c%253D&md5=106b145cbf442e9fec9667817697658d</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3Dc-MET%2520as%2520a%2520target%2520in%2520human%2520cancer%2520and%2520characterization%2520of%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DCancer%2520Lett.%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D2005%26volume%3D225%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The met receptor tyrosine kinase in invasion and metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+met+receptor+tyrosine+kinase+in+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0lg9IEBMo-MaQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520met%2520receptor%2520tyrosine%2520kinase%2520in%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lhooAlZnMsTCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1200%2FJCO.20.6.1544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=11896103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1544-1550&author=H.-L.+Chengauthor=B.+Trinkauthor=T.-S.+Tzaiauthor=H.-S.+Liuauthor=S.-H.+Chanauthor=C.-L.+Hoauthor=D.+Sidranskyauthor=N.-H.+Chow&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+transitional+cell+carcinoma+of+the+urinary+bladder%3A+a+comparison+with+p53+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation</span></div><div class="casAuthors">Cheng, Hong-Lin; Trink, Barry; Tzai, Tzong-Shin; Liu, Hsiao-Sheng; Chan, Shih-Huang; Ho, Chung-Liang; Sidransky, David; Chow, Nan-Haw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1550</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: The c-met proto-oncogene encodes a receptor tyrosine kinase (Met) and has been shown to play a role in oncogenesis.  Given that high titers of hepatocyte growth factor, the specific ligand for Met, are excreted in the urine and tend to reflect disease activity of bladder cancer, we performed this study to examine the clin. significance of Met in human bladder cancer.  Materials and Methods: We studied the mRNA expression and genomic alteration of c-met in five bladder cancer cell lines.  Significance of Met overexpression was then compared with p53 nuclear accumulation (TP53) in primary bladder cancer (n = 142 patients).  Results: Expression of c-met mRNA tended to pos. correlate with differentiation of cancer cell lines in the absence of point mutation.  High expression of Met was found in seven cases (4.9%), low expression in 32 cases (22.5%), and neg. expression in 103 cases (72.5%).  Expression of Met was pos. assocd. with histol. grade, stage classification, tumor size, and nodular tumor growth (P < .05, resp.); however, it was not related to TP53 status.  Factors that predicted disease progression were tumor stage, Met status, and TP53 accumulation (P < .05, resp.).  Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P = .0006, .01, and .04, resp.).  Conclusion: The c-met proto-oncogene plays a more important role in the progression of bladder carcinogenesis than p53.  Evaluation of Met expression could identify a subset of bladder cancer patients who may require a more intensive treatment strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfd5r45qOJLVg90H21EOLACvtfcHk0lhooAlZnMsTCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeitrw%253D&md5=2b9b03134c74318b533f82908304a28e</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1544%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DTrink%26aufirst%3DB.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DChan%26aufirst%3DS.-H.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520urinary%2520bladder%253A%2520a%2520comparison%2520with%2520p53%2520nuclear%2520accumulation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1544%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lengyel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resau, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindemann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harneck, N.</span><span> </span><span class="NLM_article-title">c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1002%2Fijc.20598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=15455388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Km" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2005&pages=678-682&author=E.+Lengyelauthor=D.+Prechtelauthor=J.+H.+Resauauthor=K.+Gaugerauthor=A.+Welkauthor=K.+Lindemannauthor=G.+Alantiauthor=T.+Richterauthor=B.+Knudsenauthor=G.+F.+Vande+Woudeauthor=N.+Harneck&title=c-MET+overexpression+in+node-positive+breast+cancer+identifies+patients+with+poor+clinical+outcome+independent+of+Her2%2Fneu"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu</span></div><div class="casAuthors">Lengyel, Ernst; Prechtel, Dieter; Resau, James H.; Gauger, Katja; Welk, Anita; Lindemann, Kristina; Salanti, Georgia; Richter, Thomas; Knudsen, Beatrice; Vande Woude, George F.; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-682</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis.  In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochem. and confocal immunofluorescence.  Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade.  Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression.  Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addn. to Her2/neu.  Median disease-free survival in patients with c-Met overexpressing tumors was 8 mo compared to 53 mo when c-Met expression was low (p = 0.037; RR = 3.0).  This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate anal.  In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further anal. in a larger cohort of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-vk_XMTZ6LVg90H21EOLACvtfcHk0ljDel0r3WTQtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Km&md5=d1d709a602edbff17ee9240e05cb8412</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1002%2Fijc.20598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20598%26sid%3Dliteratum%253Aachs%26aulast%3DLengyel%26aufirst%3DE.%26aulast%3DPrechtel%26aufirst%3DD.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DGauger%26aufirst%3DK.%26aulast%3DWelk%26aufirst%3DA.%26aulast%3DLindemann%26aufirst%3DK.%26aulast%3DAlanti%26aufirst%3DG.%26aulast%3DRichter%26aufirst%3DT.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DHarneck%26aufirst%3DN.%26atitle%3Dc-MET%2520overexpression%2520in%2520node-positive%2520breast%2520cancer%2520identifies%2520patients%2520with%2520poor%2520clinical%2520outcome%2520independent%2520of%2520Her2%252Fneu%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D113%26spage%3D678%26epage%3D682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lo Muzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coccia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capogreco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campisi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carinci, F.</span><span> </span><span class="NLM_article-title">Effect of c-MET expression on survival in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1159%2F000092716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=116-121&author=L.+Lo+Muzioauthor=A.+Farinaauthor=C.+Rubiniauthor=E.+Cocciaauthor=M.+Capogrecoauthor=G.+Colellaauthor=R.+Leonardiauthor=G.+Campisiauthor=F.+Carinci&title=Effect+of+c-MET+expression+on+survival+in+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1159%2F000092716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000092716%26sid%3Dliteratum%253Aachs%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26aulast%3DFarina%26aufirst%3DA.%26aulast%3DRubini%26aufirst%3DC.%26aulast%3DCoccia%26aufirst%3DE.%26aulast%3DCapogreco%26aufirst%3DM.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DLeonardi%26aufirst%3DR.%26aulast%3DCampisi%26aufirst%3DG.%26aulast%3DCarinci%26aufirst%3DF.%26atitle%3DEffect%2520of%2520c-MET%2520expression%2520on%2520survival%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2006%26volume%3D27%26spage%3D116%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sawada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radjabi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kistner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkyilmaz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, E.</span><span> </span><span class="NLM_article-title">c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">–</span> <span class="NLM_lpage">1679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1670-1679&author=K.+Sawadaauthor=A.+E.+Radjabiauthor=N.+Shinomiyaauthor=E.+Kistnerauthor=H.+Kennyauthor=A.+R.+Beckerauthor=M.+A.+Turkyilmazauthor=R.+Salgiaauthor=S.+D.+Yamadaauthor=G.+F.+Vande+Woudeauthor=M.+S.+Tretiakovaauthor=E.+Lengyel&title=c-MET+overexpression+is+a+prognostic+factor+in+ovarian+cancer+and+an+effective+target+for+inhibition+of+peritoneal+dissemination+and+invasion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawada%26aufirst%3DK.%26aulast%3DRadjabi%26aufirst%3DA.%2BE.%26aulast%3DShinomiya%26aufirst%3DN.%26aulast%3DKistner%26aufirst%3DE.%26aulast%3DKenny%26aufirst%3DH.%26aulast%3DBecker%26aufirst%3DA.%2BR.%26aulast%3DTurkyilmaz%26aufirst%3DM.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DYamada%26aufirst%3DS.%2BD.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DLengyel%26aufirst%3DE.%26atitle%3Dc-MET%2520overexpression%2520is%2520a%2520prognostic%2520factor%2520in%2520ovarian%2520cancer%2520and%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520peritoneal%2520dissemination%2520and%2520invasion%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1670%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Drebber, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollschweiler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienes, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hölscher, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mönig, S. P.</span><span> </span><span class="NLM_article-title">Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=18497953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3e&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1477-1483&author=U.+Drebberauthor=S.+E.+Baldusauthor=B.+Noldenauthor=G.+Grassauthor=E.+Bollschweilerauthor=H.+P.+Dienesauthor=A.+H.+H%C3%B6lscherauthor=S.+P.+M%C3%B6nig&title=Overexpression+of+c-MET+as+a+prognostic+indicator+for+gastric+carcinoma+compared+to+p53+and+p21+nuclear+accumulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3eR"><div class="casContent"><span class="casTitleNuber">3e</span><div class="casTitle"><span class="NLM_cas:atitle">The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation</span></div><div class="casAuthors">Drebber Uta; Baldus Stephan E; Nolden Britt; Grass Guido; Bollschweiler Elfriede; Dienes Hans P; Holscher Arnulf H; Monig Stefan P</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1477-83</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas.  We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy.  Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Lauren, Ming and Goseki classifications.  Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21.  The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters.  The c-met staining pattern was positive in 73.7%.  P53 and p21 were positive in 86.8 and 67.5%, respectively.  No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen.  A significant increase of p53 expression was observed in stage pT3 and -4.  The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis.  In the multivariate analysis this impact was maintained for c-met.  P21 proved to be a significant prognostic factor in the multivariate analysis.  Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcwNSw0zEj49-cVm4E2RlLfW6udTcc2ebjRWgwAyJeKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjsV2ntg%253D%253D&md5=5f503921226de1902468d1526a7322e7</span></div><a href="/servlet/linkout?suffix=cit3e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrebber%26aufirst%3DU.%26aulast%3DBaldus%26aufirst%3DS.%2BE.%26aulast%3DNolden%26aufirst%3DB.%26aulast%3DGrass%26aufirst%3DG.%26aulast%3DBollschweiler%26aufirst%3DE.%26aulast%3DDienes%26aufirst%3DH.%2BP.%26aulast%3DH%25C3%25B6lscher%26aufirst%3DA.%2BH.%26aulast%3DM%25C3%25B6nig%26aufirst%3DS.%2BP.%26atitle%3DOverexpression%2520of%2520c-MET%2520as%2520a%2520prognostic%2520indicator%2520for%2520gastric%2520carcinoma%2520compared%2520to%2520p53%2520and%2520p21%2520nuclear%2520accumulation%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D1477%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Mechanism and significance of bifunctional NK4 in cancer treatment</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2005&pages=316-327&author=K.+Matsumotoauthor=T.+Nakamura&title=Mechanism+and+significance+of+bifunctional+NK4+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DMechanism%2520and%2520significance%2520of%2520bifunctional%2520NK4%2520in%2520cancer%2520treatment%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2005%26volume%3D333%26spage%3D316%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Otsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubczak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breckenridge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larochelle, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, G.</span><span> </span><span class="NLM_article-title">Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2055</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1128%2FMCB.20.6.2055-2065.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=10688652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVKmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2055-2065&author=T.+Otsukaauthor=J.+Jakubczakauthor=W.+Vieiraauthor=D.+P.+Bottaroauthor=D.+Breckenridgeauthor=W.+J.+Larochelleauthor=G.+Merlino&title=Disassociation+of+met-mediated+biological+responses+in+vivo%3A+the+natural+hepatocyte+growth+factor%2Fscatter+factor+splice+variant+NK2+antagonizes+growth+but+facilitates+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis</span></div><div class="casAuthors">Otsuka, Toshiyuki; Jakubczak, John; Vieira, Wilfred; Bottaro, Donald P.; Breckenridge, Diane; Larochelle, William J.; Merlino, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2055-2065</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) stimulates numerous cellular activities capable of contributing to the metastatic phenotype, including growth, motility, invasiveness, and morphogenetic transformation.  When inappropriately expressed in vivo, an HGF/SF transgene induces numerous hyperplastic and neoplastic lesions.  NK1 and NK2 are natural splice variants of HGF/SF; all interact with a common receptor, Met.  Although both agonistic and antagonistic properties have been ascribed to each isoform in vitro, NK1 retains the full spectrum of HGF/SF-like activities when expressed as a transgene in vivo.  Here the authors report that transgenic mice broadly expressing NK2 exhibit none of the phenotypes characteristic of HGF/SF or NK1 transgenic mice.  Instead, when coexpressed in NK2-HGF/SF bitransgenic mice, NK2 antagonizes the pathol. consequences of HGF/SF and discourages the s.c. growth of transplanted Met-contg. melanoma cells.  Remarkably, the metastatic efficiency of these same melanoma cells is dramatically enhanced in NK2 transgenic host mice relative to wild-type recipients, rivaling levels achieved in HGF/SF and NK1 transgenic hosts.  Considered in conjunction with reports that in vitro NK2 induces scatter, but not other activities, these data strongly suggest that cellular motility is a crit. determinant of metastasis.  Moreover, the authors' results demonstrate how alternatively structured ligands can be exploited in vivo to functionally dissoc. Met-mediated activities and their downstream pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp01dLjR6oTS7Vg90H21EOLACvtfcHk0liPbVZymdpSPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVKmsb0%253D&md5=9313466d62905b39955631301907861d</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.6.2055-2065.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.6.2055-2065.2000%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DT.%26aulast%3DJakubczak%26aufirst%3DJ.%26aulast%3DVieira%26aufirst%3DW.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DBreckenridge%26aufirst%3DD.%26aulast%3DLarochelle%26aufirst%3DW.%2BJ.%26aulast%3DMerlino%26aufirst%3DG.%26atitle%3DDisassociation%2520of%2520met-mediated%2520biological%2520responses%2520in%2520vivo%253A%2520the%2520natural%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520splice%2520variant%2520NK2%2520antagonizes%2520growth%2520but%2520facilitates%2520metastasis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2055%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Matsumoto, K</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor and Met in tumor biology and therapeutic applications with NK4</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3360</span><span class="NLM_x">–</span> <span class="NLM_lpage">3370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=3360-3370&author=K+Matsumotoauthor=T.+Nakamuraauthor=K.+Sakaiauthor=T.+Nakamura&title=Hepatocyte+growth+factor+and+Met+in+tumor+biology+and+therapeutic+applications+with+NK4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DK%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DHepatocyte%2520growth%2520factor%2520and%2520Met%2520in%2520tumor%2520biology%2520and%2520therapeutic%2520applications%2520with%2520NK4%26jtitle%3DProteomics%26date%3D2008%26volume%3D8%26spage%3D3360%26epage%3D3370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Burgess, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coxon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattley, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, X.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span> </span><span class="NLM_article-title">Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1721-1729&author=T.+Burgessauthor=A.+Coxonauthor=S.+Meyerauthor=J.+Sunauthor=K.+Rexauthor=T.+Tsurudaauthor=Q.+Chenauthor=S.-Y.+Hoauthor=L.+Liauthor=S.+Kaufmanauthor=K.+McDormanauthor=R.+C.+Cattleyauthor=J.+Sunauthor=G.+Elliottauthor=K.+Zhangauthor=X.+Fengauthor=X.-C.+Jiaauthor=L.+Greenauthor=R.+Radinskyauthor=R.+Kendall&title=Fully+human+monoclonal+antibodies+to+hepatocyte+growth+factor+with+therapeutic+potential+against+hepatocyte+growth+factor%2Fc-Met-dependent+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DHo%26aufirst%3DS.-Y.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DCattley%26aufirst%3DR.%2BC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DX.-C.%26aulast%3DGreen%26aufirst%3DL.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26atitle%3DFully%2520human%2520monoclonal%2520antibodies%2520to%2520hepatocyte%2520growth%2520factor%2520with%2520therapeutic%2520potential%2520against%2520hepatocyte%2520growth%2520factor%252Fc-Met-dependent%2520human%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1721%26epage%3D1729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Reslan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span> </span><span class="NLM_article-title">MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4360</span><span class="NLM_x">–</span> <span class="NLM_lpage">4368</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4360-4368&author=H.+Jinauthor=R.+Yangauthor=Z.+Zhengauthor=M.+Romeroauthor=J.+Rossauthor=H.+Bou-Reslanauthor=R.+A.D.+Caranoauthor=I.+Kasmanauthor=E.+Maiauthor=J.+Youngauthor=J.+Zhaauthor=Z.+Zhangauthor=S.+Rossauthor=R.+Schwallauthor=G.+Colbernauthor=M.+Merchant&title=MetMAb%2C+the+one-armed+5D5+anti-c-Met+antibody%2C+inhibits+orthotopic+pancreatic+tumor+growth+and+improves+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DRomero%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DBou-Reslan%26aufirst%3DH.%26aulast%3DCarano%26aufirst%3DR.%2BA.D.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSchwall%26aufirst%3DR.%26aulast%3DColbern%26aufirst%3DG.%26aulast%3DMerchant%26aufirst%3DM.%26atitle%3DMetMAb%252C%2520the%2520one-armed%25205D5%2520anti-c-Met%2520antibody%252C%2520inhibits%2520orthotopic%2520pancreatic%2520tumor%2520growth%2520and%2520improves%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4360%26epage%3D4368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van der Horst, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velilla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madrona, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, A. K.</span><span> </span><span class="NLM_article-title">Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models <i>in vivo</i></span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=355-364&author=E.+H.+van+der+Horstauthor=L.+Chinnauthor=M.+Wangauthor=T.+Velillaauthor=H.+Tranauthor=Y.+Madronaauthor=A.+Lamauthor=M.+Jiauthor=T.+C.+Hoeyauthor=A.+K.+Sato&title=Discovery+of+fully+human+anti-MET+monoclonal+antibodies+with+antitumor+activity+against+colon+cancer+tumor+models+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DE.%2BH.%26aulast%3DChinn%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DVelilla%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DMadrona%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DHoey%26aufirst%3DT.%2BC.%26aulast%3DSato%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%2520fully%2520human%2520anti-MET%2520monoclonal%2520antibodies%2520with%2520antitumor%2520activity%2520against%2520colon%2520cancer%2520tumor%2520models%2520in%2520vivo%26jtitle%3DNeoplasia%26date%3D2009%26volume%3D11%26spage%3D355%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">Development of c-MET pathway inhibitors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1225</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1225-1241&author=X.+Liuauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=Development+of+c-MET+pathway+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520c-MET%2520pathway%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1225%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">Novel antibody, rilotumumab (AMG 102) shows activity in metastatic colorectal cancer patients</span> <span class="citation_source-journal">Oncology Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=22-23&author=R.+S.+Tuma&title=Novel+antibody%2C+rilotumumab+%28AMG+102%29+shows+activity+in+metastatic+colorectal+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DNovel%2520antibody%252C%2520rilotumumab%2520%2528AMG%2520102%2529%2520shows%2520activity%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%26jtitle%3DOncology%2520Times%26date%3D2011%26volume%3D33%26spage%3D22%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Catenacci, D. V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=573-579&author=D.+V.+T.+Catenacciauthor=L.+Hendersonauthor=S.-Y.+Xiaoauthor=P.+Patelauthor=R.+L.+Yauchauthor=P.+Hegdeauthor=J.+Zhaauthor=A.+Panditaauthor=A.+Petersonauthor=R.+Salgia&title=Durable+complete+response+of+metastatic+gastric+cancer+with+anti-Met+therapy+followed+by+resistance+at+recurrence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%2BT.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DS.-Y.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDurable%2520complete%2520response%2520of%2520metastatic%2520gastric%2520cancer%2520with%2520anti-Met%2520therapy%2520followed%2520by%2520resistance%2520at%2520recurrence%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D573%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Surati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1517%2F14712598.2011.626762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22047509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1655-1662&author=M.+Suratiauthor=P.+Patelauthor=A.+Petersonauthor=R.+Salgia&title=Role+of+MetMAb+%28OA-5D5%29+in+c-MET+active+lung+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span></div><div class="casAuthors">Surati, Mosmi; Patel, Premal; Peterson, Amy; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase.  Though only in early clin. testing, this agent holds great promise in diseases thought to be driven by c-MET activation, as evidenced by the Phase II results in NSCLC where a benefit in overall survival was obsd. in patients with MET-diagnostic-pos. disease.  Thus far, both alone and in combination with other targeted agents, this drug has been well tolerated and no new significant safety signals have been identified.  Areas covered: This review summarizes the structure and function of the c-MET receptor and its ligand hepatic growth factor (HGF), provides an overview of select targeted monotherapies developed to interfere in the MET-HGF signaling pathway, discusses pre-clin. and clin. data surrounding MetMAb, and concludes with an expert opinion regarding this novel agent.  Expert opinion: MetMAb has been well tolerated and based on Phase II data testing it, in combination with erlotinib in advanced NSCLC, may have a role in improving survival in patients with disease driven by c-MET activation.  However, Phase III validation is underway and the results of these studies will help elucidate which patients will benefit most from this novel agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNaynTSW2ErVg90H21EOLACvtfcHk0ljzKZHEbGsicA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN&md5=78a25ac9a8b03aa9e3113776d40854e2</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.626762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.626762%26sid%3Dliteratum%253Aachs%26aulast%3DSurati%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520MetMAb%2520%2528OA-5D5%2529%2520in%2520c-MET%2520active%2520lung%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 7505.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Spigel%2C+D.+R.%3B+Ervin%2C+T.+J.%3B+Ramlau%2C+R.%3B+Daniel%2C+D.+B.%3B+Goldschmidt%2C+J.+H.%3B+Blumenschein%2C+G.+R.%3B+Krzakowski%2C+M.+J.%3B+Robinet%2C+G.%3B+Clement-Duchene%2C+C.%3B+Barlesi%2C+F.%3B+Govindan%2C+R.%3B+Patel%2C+T.%3B+Orlov%2C+S.+V.%3B+Wertheim%2C+M.+S.%3B+Zha%2C+J.%3B+Pandita%2C+A.%3B+Yu%2C+W.%3B+Yauch%2C+R.+L.%3B+Patel%2C+P.+H.%3B+Peterson%2C+A.+C.+Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+7505."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mroczkowski, B.; McTigue, M. A..; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu., J.</span><span> </span><span class="NLM_article-title">Catalytic domains of the human hepatocyte growth factor receptor kinase and material and methods for identification thereof</span>. USP 277968, EP1243596A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Mroczkowski&author=M.+A..+McTigue&author=J.+Sarup&author=B.+W.+Murray&author=M.+Hickey&author=H.+Parge&author=J.+Zhu.&title=Catalytic+domains+of+the+human+hepatocyte+growth+factor+receptor+kinase+and+material+and+methods+for+identification+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMroczkowski%26aufirst%3DB.%26atitle%3DCatalytic%2520domains%2520of%2520the%2520human%2520hepatocyte%2520growth%2520factor%2520receptor%2520kinase%2520and%2520material%2520and%2520methods%2520for%2520identification%2520thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0lijks7J_6m9uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Tracy+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DTracy%2BLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Srinivasan, R.; Choueiri, T. K.; Vaishampayan, U.; Rosenberg, J. E.; Stein, M. N.; Logan, T.; Bukowski, R. M.; Mueller, T.; Keer, H. N.; Linehan, W. M.</span><span> </span><span class="NLM_article-title">A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)</span>. Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30–June 3, 2008; Abstr. 5103.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Srinivasan%2C+R.%3B+Choueiri%2C+T.+K.%3B+Vaishampayan%2C+U.%3B+Rosenberg%2C+J.+E.%3B+Stein%2C+M.+N.%3B+Logan%2C+T.%3B+Bukowski%2C+R.+M.%3B+Mueller%2C+T.%3B+Keer%2C+H.+N.%3B+Linehan%2C+W.+M.+A+phase+II+study+of+the+dual+MET%2FVEGFR2+inhibitor+XL880+in+patients+%28pts%29+with+papillary+renal+carcinoma+%28PRC%29.+Presented+at+ASCO+2008+Annual+Meeting%2C+Chicago%2C+IL%2C+May+30%E2%80%93June+3%2C+2008%3B+Abstr.+5103."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DR.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520dual%2520MET%252FVEGFR2%2520inhibitor%2520XL880%2520in%2520patients%2520%2528pts%2529%2520with%2520papillary%2520renal%2520carcinoma%2520%2528PRC%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Jhawer, M. P.; Kindler, H. L.; Wainberg, Z. A.; Hecht, J. R.; Kerr, R. O.; Ford, J. M.; Henderson, C.; Mueller, T.; Keer, H. N.; Shah, M. A.</span><span> </span><span class="NLM_article-title">Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study</span>. Presented at ASCO 2008 Annual Meeting, Chicago, IL, May 30–June 3, 2008; Abstr. 4572.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jhawer%2C+M.+P.%3B+Kindler%2C+H.+L.%3B+Wainberg%2C+Z.+A.%3B+Hecht%2C+J.+R.%3B+Kerr%2C+R.+O.%3B+Ford%2C+J.+M.%3B+Henderson%2C+C.%3B+Mueller%2C+T.%3B+Keer%2C+H.+N.%3B+Shah%2C+M.+A.+Preliminary+activity+of+XL880%2C+a+dual+MET%2FVEGFR2+inhibitor%2C+in+MET+amplified+poorly+differentiated+gastric+cancer+%28PDGC%29%3A+Interim+results+of+a+multicenter+phase+II+study.+Presented+at+ASCO+2008+Annual+Meeting%2C+Chicago%2C+IL%2C+May+30%E2%80%93June+3%2C+2008%3B+Abstr.+4572."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJhawer%26aufirst%3DM.%2BP.%26atitle%3DPreliminary%2520activity%2520of%2520XL880%252C%2520a%2520dual%2520MET%252FVEGFR2%2520inhibitor%252C%2520in%2520MET%2520amplified%2520poorly%2520differentiated%2520gastric%2520cancer%2520%2528PDGC%2529%253A%2520Interim%2520results%2520of%2520a%2520multicenter%2520phase%2520II%2520study" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span> </span><span class="NLM_article-title">Structural basis for selective small molecule kinase inhibition of activated c-Met</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">11218</span><span class="NLM_x">–</span> <span class="NLM_lpage">11225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=11218-11225&author=K.+W.+Rickertauthor=S.+B.+Patelauthor=T.+J.+Allisonauthor=N.+J.+Byrneauthor=P.+L.+Darkeauthor=R.+E.+Fordauthor=D.+J.+Guerinauthor=D.+L.+Hallauthor=M.+Kornienkoauthor=J.+Luauthor=S.+K.+Munshiauthor=J.+C.+Reidauthor=J.+M.+Shipmanauthor=E.+F.+Stantonauthor=K.+J.+Wilsonauthor=J.+R.+Youngauthor=S.+M.+Soissonauthor=K.+J.+Lumb&title=Structural+basis+for+selective+small+molecule+kinase+inhibition+of+activated+c-Met"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAllison%26aufirst%3DT.%2BJ.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DStanton%26aufirst%3DE.%2BF.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520selective%2520small%2520molecule%2520kinase%2520inhibition%2520of%2520activated%2520c-Met%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D11218%26epage%3D11225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lh7DuBT0TTdmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell-lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.-J.+Bangauthor=R.+Camidgeauthor=A.+T.+Shawauthor=B+Solomonauthor=R.+G.+Makiauthor=S.-H.+I.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.-H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell-lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0liw4wtJ88slbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DCamidge%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.-H.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell-lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2ebMYOx6b5ZvRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Chi, A. S.; Kwak, E. L.; Clark, J. W.; Wang, D. L.; Louis, D. N.; Iafrate, A. J.; Batchelor, T.</span><span> </span><span class="NLM_article-title">Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 2072.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chi%2C+A.+S.%3B+Kwak%2C+E.+L.%3B+Clark%2C+J.+W.%3B+Wang%2C+D.+L.%3B+Louis%2C+D.+N.%3B+Iafrate%2C+A.+J.%3B+Batchelor%2C+T.+Clinical+improvement+and+rapid+radiographic+regression+induced+by+a+MET+inhibitor+in+a+patient+with+MET-amplified+glioblastoma.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+2072."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26atitle%3DClinical%2520improvement%2520and%2520rapid%2520radiographic%2520regression%2520induced%2520by%2520a%2520MET%2520inhibitor%2520in%2520a%2520patient%2520with%2520MET-amplified%2520glioblastoma" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lennerz, J. K.; Kwak, E. L.; Michael, M.; Fox, S. B.; Ackerman, A.; Bergethon, K.; Lauwers, G. Y.; Christensen, J. G.; Wilner, K. D.; Haber, D. A.; Salgia, R.; Bang, Y.; Clark, J. W.; Solomon, B. J.; Iafrate, A., J.</span><span> </span><span class="NLM_article-title">Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7, 2011; Abstr. 4130.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lennerz%2C+J.+K.%3B+Kwak%2C+E.+L.%3B+Michael%2C+M.%3B+Fox%2C+S.+B.%3B+Ackerman%2C+A.%3B+Bergethon%2C+K.%3B+Lauwers%2C+G.+Y.%3B+Christensen%2C+J.+G.%3B+Wilner%2C+K.+D.%3B+Haber%2C+D.+A.%3B+Salgia%2C+R.%3B+Bang%2C+Y.%3B+Clark%2C+J.+W.%3B+Solomon%2C+B.+J.%3B+Iafrate%2C+A.%2C+J.+Identification+of+a+small+and+lethal+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib+by+MET+amplification.+Presented+at+ASCO+2011+Annual+Meeting%2C+Chicago%2C+IL%2C+June+3%E2%80%937%2C+2011%3B+Abstr.+4130."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26atitle%3DIdentification%2520of%2520a%2520small%2520and%2520lethal%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%2520by%2520MET%2520amplification" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0liw4wtJ88slbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garmey, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerley, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramlau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbachevsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span> </span><span class="NLM_article-title">Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3307</span><span class="NLM_x">–</span> <span class="NLM_lpage">3315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1200%2FJCO.2010.34.0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=21768463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3307-3315&author=L.+V.+Sequistauthor=J.+von+Pawelauthor=E.+G.+Garmeyauthor=W.+L.+Akerleyauthor=W.+Bruggerauthor=D.+Ferrariauthor=Y.+Chenauthor=D.+B.+Costaauthor=D.+E.+Gerberauthor=S.+Orlovauthor=R.+Ramlauauthor=S.+Arthurauthor=I.+Gorbachevskyauthor=B.+Schwartzauthor=J.+H.+Schiller&title=Randomized+phase+II+study+of+erlotinib+plus+tivantinib+versus+erlotinib+plus+placebo+in+previously+treated+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ramdomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; von Pawel, Joachim; Garmey, Edward G.; Akerley, Wallace L.; Brugger, Wolfram; Ferrari, Dora; Chen, Yinpu; Costa, Daniel B.; Gerber, David E.; Orlov, Sergey; Ramlau, Rodryg; Arthur, Susan; Gorbachevsky, Igor; Schwartz, Brian; Schiller, Joan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3307-3315</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: c-MET (MET) receptor activation is assocd. with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell lung cancer (NSCLC).  This global, randomized phase II trial examd. erlotinib plus tivantinib (ARQ 197; ArQule, Woburn, MA), a novel MET inhibitor.  Methods: Previously treated patients with EGFR TKI-naive advanced NSCLC were randomly assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or erlotinib plus placebo (EP).  The primary end point was progression-free survival (PFS).  At the time of progression, cross-over from EP to erlotinib plus tivantinib (ET) was permitted.  Archival tumor tissue specimens were required.  Results: One hundred sixty-seven patients were randomly assigned to ET (n = 84) and to EP (n = 83).  Median PFS was 3.8 mo for ET and 2.3 mo for EP (hazard ratio [HR], 0.81; 95% CI, 0.57 to 1.16; P = .24).  Exploratory anal. revealed that the small cohort with KRAS mutations achieved a PFS HR of 0.18 (95% CI, 0.05 to 0.70; interaction P = .006).  Objective responses were seen in 10% of patients on ET, 7% of patients on EP, and in two patients who crossed over from EP to ET, including one with EGFR mutation and MET gene copy no. greater than 5.  There were no significant differences in adverse events between study arms.  Conclusion: The combination of the MET inhibitor tivantinib and erlotinib is well-tolerated.  Although the study did not meet its primary end point, evidence of activity was demonstrated, esp. among patients with KRAS mutations.  Addnl. study of tivantinib and erlotinib in patients with NSCLC is planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk9Ba8OADqqrVg90H21EOLACvtfcHk0liNBOQrmM5nAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsrnL&md5=a74b99021191c96e18b79ba11ac5075c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.34.0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.34.0570%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGarmey%26aufirst%3DE.%2BG.%26aulast%3DAkerley%26aufirst%3DW.%2BL.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DArthur%26aufirst%3DS.%26aulast%3DGorbachevsky%26aufirst%3DI.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520erlotinib%2520plus%2520tivantinib%2520versus%2520erlotinib%2520plus%2520placebo%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3307%26epage%3D3315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span> </span><span class="NLM_article-title">Cho, Tang. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Wei&title=Cho%2C+Tang.+Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26atitle%3DCho%252C%2520Tang.%2520Discovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bramson, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corona, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gampe, R. T.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montana, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuyper, L. F.</span><span> </span><span class="NLM_article-title">Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and x-ray crystallographic analysis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4339</span><span class="NLM_x">–</span> <span class="NLM_lpage">4358</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010117d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4339-4358&author=H.+N.+Bramsonauthor=J.+Coronaauthor=S.+T.+Davisauthor=S.+H.+Dickersonauthor=M.+Edelsteinauthor=S.+V.+Fryeauthor=R.+T.+Gampeauthor=P.+A.+Harrisauthor=A.+Hassellauthor=W.+D.+Holmesauthor=R.+N.+Hunterauthor=K.+E.+Lackeyauthor=B.+Lovejoyauthor=M.+J.+Luzzioauthor=V.+Montanaauthor=W.+J.+Rocqueauthor=D.+Rusnakauthor=L.+Shewchukauthor=J.+M.+Vealauthor=D.+H.+Walkerauthor=L.+F.+Kuyper&title=Oxindole-based+inhibitors+of+cyclin-dependent+kinase+2+%28CDK2%29%3A+design%2C+synthesis%2C+enzymatic+activities%2C+and+x-ray+crystallographic+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span></div><div class="casAuthors">Bramson, H. Neal; Corona, John; Davis, Stephen T.; Dickerson, Scott H.; Edelstein, Mark; Frye, Stephen V.; Gampe, Robert T., Jr.; Harris, Phil A.; Hassell, Anne; Holmes, William D.; Hunter, Robert N.; Lackey, Karen E.; Lovejoy, Brett; Luzzio, Michael J.; Montana, Val; Rocque, Warren J.; Rusnak, David; Shewchuk, Lisa; Veal, James M.; Walker, Duncan H.; Kuyper, Lee F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4339-4358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related classes of oxindole-based compds., 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).  The initial lead compd. was prepd. as a homolog of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor.  Crystallog. anal. of the lead compd. bound to CDK2 provided the basis for analog design.  A semiautomated method of ligand docking was used to select compds. for synthesis, and a no. of compds. with low nanomolar inhibitory activity vs. CDK2 were identified.  Enzyme binding determinants for several analogs were evaluated by X-ray crystallog.  Compds. in this series inhibited CDK2 with a potency ∼10-fold greater than that for CDK1.  Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOmtXxUWKlrVg90H21EOLACvtfcHk0ljBDwncMnZQ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D&md5=d628549913ca46f9edf6b4692c82419d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm010117d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010117d%26sid%3Dliteratum%253Aachs%26aulast%3DBramson%26aufirst%3DH.%2BN.%26aulast%3DCorona%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DS.%2BT.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DLovejoy%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMontana%26aufirst%3DV.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DKuyper%26aufirst%3DL.%2BF.%26atitle%3DOxindole-based%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202%2520%2528CDK2%2529%253A%2520design%252C%2520synthesis%252C%2520enzymatic%2520activities%252C%2520and%2520x-ray%2520crystallographic%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4339%26epage%3D4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of c-MET kinase inhibits c-MET-dependent phenotypes <i>in vitro</i> and exhibits cytoreductive antimutor activity <i>in vivo</i></span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">–</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+c-MET+kinase+inhibits+c-MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520c-MET%2520kinase%2520inhibits%2520c-MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm">2wkm</a> for the PHA-665752/c-MET complex.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone hydrazides as c-met inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+hydrazides+as+c-met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520hydrazides%2520as%2520c-met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic compounds as c-Met inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+compounds+as+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520compounds%2520as%2520c-Met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of triazolotriazines as c-Met modulators for treating cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+triazolotriazines+as+c-Met+modulators+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520triazolotriazines%2520as%2520c-Met%2520modulators%2520for%2520treating%2520cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl triazolo and imidazopyrazines as c-MET inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+triazolo+and+imidazopyrazines+as+c-MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520triazolo%2520and%2520imidazopyrazines%2520as%2520c-MET%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F1535-7163.MCT-11-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22389468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1036-1047&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=K.+Burgessauthor=M.+Qiuauthor=L.+Engstromauthor=S.+Yamazakiauthor=M.+Parkerauthor=S.+Timofeevskiauthor=J.+J.+Cuiauthor=M.+McTigueauthor=M.+G.+Losauthor=S.+Benderauthor=T.+Smealauthor=J.+G.+Christensen&title=Sensitivity+of+Selected+Human+Tumor+Models+to+PF-04217903%2C+a+Novel+Selective+c-Met+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; Burgess, Kristina; Qiu, Ming; Engstrom, Lars D.; Yamazaki, Shinji; Parker, Max; Timofeevski, Sergei; Cui, Jingrong Jean; McTigue, Michele; Los, Gerrit; Bender, Steven L.; Smeal, Tod; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1036-1047</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met pathway has been implicated in a variety of human cancers for its crit. role in tumor growth, invasion, and metastasis.  PF-04217903 is a novel ATP-competitive small-mol. inhibitor of c-Met kinase.  PF-04217903 showed more than 1,000-fold selectivity for c-Met compared with more than 150 kinases, making it one of the most selective c-Met inhibitors described to date.  PF-04217903 inhibited tumor cell proliferation, survival, migration/invasion in MET-amplified cell lines in vitro, and showed marked antitumor activity in tumor models harboring either MET gene amplification or a hepatocyte growth factor (HGF)/c-Met autocrine loop at well-tolerated dose levels in vivo.  Antitumor efficacy of PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and tumor cell proliferation/survival.  In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by PF-04217903 only led to partial tumor growth inhibition (38%-46%) in vivo.  The combination of PF-04217903 with Recepteur d'origine nantais (RON) short hairpin RNA (shRNA) knockdown in the HT29 model that also expresses activated RON kinase-induced tumor cell apoptosis and resulted in enhanced antitumor efficacy (77%) compared with either PF-04217903 (38%) or RON shRNA alone (56%).  PF-04217903 also showed potent antiangiogenic properties in vitro and in vivo.  Furthermore, PF-04217903 strongly induced phospho-PDGFRβ (platelet-derived growth factor receptor) levels in U87MG xenograft tumors, indicating a possible oncogene switching mechanism in tumor cell signaling as a potential resistance mechanism that might compromise tumor responses to c-Met inhibitors.  Collectively, these results show the use of highly selective inhibition of c-Met and provide insight toward targeting tumors exhibiting different mechanisms of c-Met dysregulation.  Mol Cancer Ther; 11(4); 1036-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrrZdx_x0SrVg90H21EOLACvtfcHk0li9AGPG7A0Pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D&md5=bd5d2896768e7ae6a65b9c5e2ec3ce15</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0839%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DBurgess%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DEngstrom%26aufirst%3DL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DM.%2BG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DSensitivity%2520of%2520Selected%2520Human%2520Tumor%2520Models%2520to%2520PF-04217903%252C%2520a%2520Novel%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1036%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaptason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span> </span><span class="NLM_article-title">Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically-based pharmacokinetic modeling versus traditional one-compartment model</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=383-393&author=S.+Yamazakiauthor=J.+Skaptasonauthor=D.+Romeroauthor=S.+Vekichauthor=H.+M.+Jonesauthor=W.+Tanauthor=K.+Wilnerauthor=T.+Koudriakova&title=Prediction+of+oral+pharmacokinetics+of+cMet+kinase+inhibitors+in+humans%3A+physiologically-based+pharmacokinetic+modeling+versus+traditional+one-compartment+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DVekich%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DKoudriakova%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520oral%2520pharmacokinetics%2520of%2520cMet%2520kinase%2520inhibitors%2520in%2520humans%253A%2520physiologically-based%2520pharmacokinetic%2520modeling%2520versus%2520traditional%2520one-compartment%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D383%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Trust, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albright, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">N. A. Perkinson, N. A.</span><span> </span><span class="NLM_article-title">6- and 7-aryl-1,2,4-triazolo[4,3-<i>b</i>]-1,2,4-triazines. Synthesis and characterization</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1979&pages=1393-1403&author=R.+I.+Trustauthor=J.+D.+Albrightauthor=F.+M.+Lovellauthor=N.+A.+N.+A.+Perkinson&title=6-+and+7-aryl-1%2C2%2C4-triazolo%5B4%2C3-b%5D-1%2C2%2C4-triazines.+Synthesis+and+characterization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrust%26aufirst%3DR.%2BI.%26aulast%3DAlbright%26aufirst%3DJ.%2BD.%26aulast%3DLovell%26aufirst%3DF.%2BM.%26aulast%3DN.%2BA.%2BPerkinson%26aufirst%3DN.%2BA.%26atitle%3D6-%2520and%25207-aryl-1%252C2%252C4-triazolo%255B4%252C3-b%255D-1%252C2%252C4-triazines.%2520Synthesis%2520and%2520characterization%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1979%26volume%3D16%26spage%3D1393%26epage%3D1403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marusyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanessa Almendro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">Intra-tumour heterogeneity: a looking glass for cancer? </span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=323-334&author=A.+Marusykauthor=V.+Vanessa+Almendroauthor=K.+Polyak&title=Intra-tumour+heterogeneity%3A+a+looking+glass+for+cancer%3F+"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarusyk%26aufirst%3DA.%26aulast%3DVanessa%2BAlmendro%26aufirst%3DV.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DIntra-tumour%2520heterogeneity%253A%2520a%2520looking%2520glass%2520for%2520cancer%253F%2520%26jtitle%3DCancer%26date%3D2012%26volume%3D12%26spage%3D323%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Szerlipa, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazab, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravartyb, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuirec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fangd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollande, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hused, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanward, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levershac, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikkelseni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C. W.</span><span> </span><span class="NLM_article-title">Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3041-3046&author=N.+J.+Szerlipaauthor=A.+Pedrazabauthor=D.+Chakravartybauthor=M.+Azimcauthor=J.+McGuirecauthor=Y.+Fangdauthor=T.+Ozawaeauthor=E.+C.+Hollandeauthor=J.+T.+Husedauthor=S.+Jhanwardauthor=M.+A.+Levershacauthor=T.+Mikkelseniauthor=C.+W.+Brennan&title=Intratumoral+heterogeneity+of+receptor+tyrosine+kinases+EGFR+and+PDGFRA+amplification+in+glioblastoma+defines+subpopulations+with+distinct+growth+factor+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzerlipa%26aufirst%3DN.%2BJ.%26aulast%3DPedrazab%26aufirst%3DA.%26aulast%3DChakravartyb%26aufirst%3DD.%26aulast%3DAzimc%26aufirst%3DM.%26aulast%3DMcGuirec%26aufirst%3DJ.%26aulast%3DFangd%26aufirst%3DY.%26aulast%3DOzawae%26aufirst%3DT.%26aulast%3DHollande%26aufirst%3DE.%2BC.%26aulast%3DHused%26aufirst%3DJ.%2BT.%26aulast%3DJhanward%26aufirst%3DS.%26aulast%3DLevershac%26aufirst%3DM.%2BA.%26aulast%3DMikkelseni%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26atitle%3DIntratumoral%2520heterogeneity%2520of%2520receptor%2520tyrosine%2520kinases%2520EGFR%2520and%2520PDGFRA%2520amplification%2520in%2520glioblastoma%2520defines%2520subpopulations%2520with%2520distinct%2520growth%2520factor%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2012%26volume%3D109%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gerlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David Endesfelder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronroos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillimore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nohadani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eklund, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Dene, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szallasi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1056%2FNEJMoa1113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=22397650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=883-892&author=M.+Gerlingerauthor=A.+J.+Rowanauthor=S.+Horswellauthor=J.+Larkinauthor=D.+David+Endesfelderauthor=E.+Gronroosauthor=P.+Martinezauthor=N.+Matthewsauthor=A.+Stewartauthor=P.+Tarpeyauthor=I.+Varelaauthor=B.+Phillimoreauthor=S.+Begumauthor=N.+Q.+McDonaldauthor=A.+Butlerauthor=D.+Jonesauthor=K.+Raineauthor=C.+Latimerauthor=C.+R.+Santosauthor=M.+Nohadaniauthor=A.+C.+Eklundauthor=B.+Spencer-Deneauthor=G+Clarkauthor=L.+Pickeringauthor=G.+Stampauthor=M.+Goreauthor=Z.+Szallasiauthor=J.+Downwardauthor=P.+A.+Futrealauthor=C.+Swanton&title=Intratumor+heterogeneity+and+branched+evolution+revealed+by+multiregion+sequencing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span></div><div class="casAuthors">Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Donward, Julian; Futreal, P. Andrew; Swanton, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.  Methods: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration anal., and ploidy profiling on multiple spatially sepd. samples obtained from primary renal carcinomas and assocd. metastatic sites.  We characterized the consequences of intratumor heterogeneity using immunohistochem. anal., mutation functional anal., and profiling of mRNA expression.  Results: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region.  Intratumor heterogeneity was obsd. for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro.  Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially sepd. inactivating mutations within a single tumor, suggesting convergent phenotypic evolution.  Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor.  Allelic compn. and ploidy profiling anal. revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors.  Conclusions: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.  Intratumor heterogeneity, assocd. with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5FKqZ_4ThTLVg90H21EOLACvtfcHk0lhQD5S8Rfr0GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D&md5=2ab2e658d1218935e12cc934b09e1b95</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113205%26sid%3Dliteratum%253Aachs%26aulast%3DGerlinger%26aufirst%3DM.%26aulast%3DRowan%26aufirst%3DA.%2BJ.%26aulast%3DHorswell%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDavid%2BEndesfelder%26aufirst%3DD.%26aulast%3DGronroos%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DTarpey%26aufirst%3DP.%26aulast%3DVarela%26aufirst%3DI.%26aulast%3DPhillimore%26aufirst%3DB.%26aulast%3DBegum%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DButler%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DLatimer%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DNohadani%26aufirst%3DM.%26aulast%3DEklund%26aufirst%3DA.%2BC.%26aulast%3DSpencer-Dene%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DG%26aulast%3DPickering%26aufirst%3DL.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DSzallasi%26aufirst%3DZ.%26aulast%3DDownward%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DIntratumor%2520heterogeneity%2520and%2520branched%2520evolution%2520revealed%2520by%2520multiregion%2520sequencing%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D883%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatiana B. Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300967g&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300967g&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300967g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Tatiana+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=B.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lhTpPsOHbSEcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DTatiana%2BB.%2BKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DB.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FVT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1FVT','PDB','1FVT'); return false;">PDB: 1FVT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wkm','PDB','2wkm'); return false;">PDB: 2wkm</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2wgj','PDB','2wgj'); return false;">PDB: 2wgj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz','PDB','3zxz'); return false;">PDB: 3zxz</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze','PDB','3zze'); return false;">PDB: 3zze</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ap7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ap7','PDB','4ap7'); return false;">PDB: 4ap7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4aoi" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4aoi','PDB','4aoi'); return false;">PDB: 4aoi</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i75"><a href="/doi/suppl/10.1021/jm300967g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18246"></div></div></div></div></div><hr /></hr><p class="last">Kinase selectivity screening data for <b>12</b> against a total of 98 protein kinases. This material is available free of charge via the internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300967g/suppl_file/jm300967g_si_001.pdf">jm300967g_si_001.pdf (170.3 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates of the c-MET crystal structures have been deposited in the Protein Data Bank for compounds <b>2</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>), <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze">3zze</a>), <b>12</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ap7">4ap7</a>), and <b>24</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4aoi">4aoi</a>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300967g&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-18%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm300967g%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300967g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ad123a8583d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
